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ABSTRACT 
Understanding of p53 family protein (p53, p63 and p73) networks in head and 
neck squamous cell carcinoma (HNSCC), can positively influence in cancer 
screening, diagnosis, treatment and prevention. P53 family proteins are 
regulating diverse cell signalling pathways at diverse conditions to determine 
cell fate. At each condition of cells state, how these proteins are controlling cell 
fate is more complexed due to the presense of several isoforms for each p53 
family proteins and their multifaceted interactions. Like other solid tumours, 
the p53 pathway is disabled by several mechanisms in HNSCC. Despite of the 
convincing evidence of a high frequency of p53 mutations in HNSCC, a subset 
of cancers arise in the absence of mutations. The molecular mechaninsms 
through which p53 lacking mutations subvert its tumor supressor functions in 
HNSCC still remain uncertain. In fact, some cancers and established cancer cell 
lines are over-expressing wild type p53 protein makes questionable of p53 role 
as only a tumor suppressor or it has some other additional functions, even in 
cancer cells. For an answer of this hypothesis, we have performed detailed 
molecular characterization, in an invitro model of head and neck cancer, in a 
broad panel of 12 newly established HNSCC cell lines. In our studies, we 
found that some head and neck cancer cell lines are accumulating wild p53 
protein hyperphosphorylated at serine15 and 392 and it leads to the over 
expression of ∆Np73, the mechanism already reported from our laboratory in 
HPV38 immortalized keratinocytes. To better understand the functions of 
accumulated wild p53 role in HPV positive and negative cancer cell lines, we 
have performed p53 knock down by siRNA and the results have showed that 
p53 knock down inhibited cell proliferation in both HPV positive and negative 
cancer cells. Moreover, p53 knock down induced significant morphological 
changes and senescence associated beta galactosidase activity in these cells. 
Our results pinpoint, wild-type p53 protein accumulated in transformed cell 
lines has an additional role in cell proliferation other than its well known tumor 
supressor activity. Moreover, the key role of p53 family network in modulating 
epidermal growth factor receptor (EGFR) expression and in controlling cell 
proliferation and apoptosis arises the question of whether p53 family proteins 
status influences the efficacy of EGFR inhibitors, investigating its ability to 
reduce cell growth, to induce apoptosis and to modulate cell cycle and various 
EGFR pathwayrelated targets in head and neck cancer. Because, recently 
improved understanding of the pathogenesis of human head and neck 
squamous cell carcinoma has led to the development of new, molecular based 
therapeutic strategies, one of the most promising is the utilization of tyrosine 
kinase (TK) inhibitors, targeting EGFR. The comparison between the targets 
analysed and gefitinib effectiveness evidenced the absence of a clear 
relationship, exluding them as predictive factors for gefitinib efficacy. Our 
results confirmed the in vitro efficacy of an anti-EGFR approach, but other 
targets than those analysed here should be characterized in order to identify 
valid predictive factors for gefitinib utilization in head and neck cancer. We 
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have also performed chemoresistance analysis in our invitro model of HNSCC 
cell lilnes and found that p53 family network has less predictive role in 
HNSCC chemoresistance but ABCG2, a multidrug resistance protein, has over-
expressed in HNSCC. 
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1. BACKGROUND 
 
1.1 Cancer    
It is widely known that cancer is one of the most frequent causes of death, 
especially in the developed countries of the world, where the most common 
lethal diseases have now been  practically eradicated. For cancer to reach a 
stage at which it causes serious damage and, potentially, death, it must follow a 
well-known pre-determined course. It emerges locally at cellular level, spreads 
and infects neighboring tissues, perhaps re-instantiates at a remote location 
using natural transport means and, if no action is taken to remove it or halt its 
growth, grows to a degree where the functionality of vital organs is irreversibly 
compromised. In the last few decades understanding of the molecular events at 
cell level, which are necessary for development of cancer, has greatly 
increased. According to a theory of carcinogenesis, a complex and multi-step 
process is likely involved in the development of cancer.  
A number of factors are attributed to the development of cancer. The factors 
include diet, toxins, smoking, alcohol, obesity and infections, which usually 
help in the process of carcinogenesis by inducing variation in epigenetic code 
or cause aberrations in tumor suppressor genes, and oncogenes and genes 
involved in repair machinery. This usually leads to uncontrolled growth by 
recessive loss of tumor suppressor genes or dominant gain of oncogens and/or 
aneuploidy. Causative factors may vary among different cancers but the basic 
hypothesis that a normal human cell has to acquire at least six essential 
alterations to become a malignant cancerous cell in case of solid tumours. 
These six alterations include: the ability to sustain autonomous growth; the 
ability to avoid growth inhibitory signals; the evasion of apoptosis; the 
potential to replicate infinitely; sustained angiogenesis; and finally, for the 
malignant tissue to be invasive and metastatic (Hanahan and Weinberg 2000). 
Cancer cells contain many altered and/or mutated genes. These almost always 
include: mutations in genes that are involved in mitosis; that is, in genes that 
control the cell cycle. Their mutated or over-expressed products stimulate 
mitosis even though normal growth signals are absent. Example: many tyrosine 
kinase receptors including epidermal growth factor receptor (EGFR), the gene 
encoding the receptor for epidermal growth factor (EGF) (EGFR is also known 
as HER1.) Moreover, for altering cell homeostasis in favor of cellular 
immortality cell has to by bass cell signals, which inhibit uncontrolled cell 
proliferation, they are tumor suppressor genes, and these genes normally inhibit 
mitosis. Example: the p53 gene product normally senses DNA damage and 
either halts the cell cycle until it can be repaired or, if the damage is too 
massive; triggers apoptosis. During the course of  cellular immortalization 
different cell signaling pathways are altered in favor of tumorogenesis and 
understanding of these altered cell signaling pathways in detail helps to design 
anticancer therapies. 
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1.2 p53 
p53, (53KD) also known as tumour protein 53 (TP53), is a transcription factor 
that regulates the cell cycle and apoptosis, in case of cellular insults, and hence 
functions as a tumor suppressor. p53 has been described as "the guardian of the 
genome", "the guardian angel gene", or the "master watchman", referring to its 
role in conserving stability by preventing genome mutation.  Briefly, p53 was 
first identified in 1979 as a cellular protein that bound to the simian virus 
(SV40) large T antigen and accumulated in the nuclei of cancer cells. The gene 
encoding p53 (TP53) was cloned from neoplastic rodent and human cells, and 
found to have weak oncogenic activity when expressed in rodent cells. In the 
late 1980s, however, researchers discovered that they were studying missense 
mutants of the TP53 gene instead of the wild-type gene. The missense 
mutations found in the original TP53 cDNA clones proved to be the key to 
understanding the pathobiological activity of p53. The ability of p53 to form 
tetramers allows this protein to behave in a dominant-negative fashion, where 
the allele-producing mutant p53 suppresses the activity of wild-type p53. Later 
its character as a tumor suppressor transcription factor was finally revealed in 
1989 by Bert Vogelstein working at Johns Hopkins School of Medicine. 
Warren Maltzman, of the Waksman Institute of Rutgers University first 
demonstrated that TP53 was responsive to DNA damage in the form of 
ultraviolet radiation (Maltzman et al. 1984).  
 
The transcription factor p53 responds to diverse cellular stresses to regulate 
target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or 
changes in metabolism. In addition, p53 appears to induce apoptosis through 
nontranscriptional cytoplasmic processes. In unstressed cells, p53 is kept 
inactive essentially through the actions of the ubiquitin ligase MDM2, which 
inhibits p53 transcriptional activity and ubiquitinates p53 to promote its 
degradation. Numerous posttranslational modifications modulate p53 activity, 
most notably phosphorylation and acetylation. Several less abundant p53 
isoforms also modulate p53 activity. Activity of p53 is ubiquitously lost in 
human cancer either by mutation of the p53 gene itself or by loss of cell 
signaling upstream or downstream of p53 
 
1.3 p63 and p73; members of p53 family  
The identification of the two p53-related genes, p63 and p73, initially provoked 
speculation that all three genes might play an analogous role in human tumors 
(Yang and McKeon 2000; Melino et al. 2003; Moll and Slade 2004). In 
particular, the striking homology among the family members within both their 
DNA binding domain (DBD) and oligomerization domain (OD) suggested that 
these genes might regulate transcription of a common subset of target genes, by 
binding to common promoters as either homo- or heterotetrameric complexes. 
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Work from year to year, however, has revealed a much more complex picture 
of the contribution of p63 and p73 to human cancer. The p53-related genes p63 
and p73 exhibit significant structural homology to p53; however, they do not 
function as classical tumor suppressors and are rarely mutated in human 
cancers. Both p63 and p73 exhibit tissue-specific roles in normal development 
and a complex contribution to tumorigenesis that is due to their expression as 
multiple protein isoforms. The predominant p63/p73 isoforms expressed both 
in normal development and in many tumors lack the conserved transactivation 
(TA) domain; these isoforms instead exhibit a truncated N-terminus (DN) and 
function at least in part as transcriptional repressors. p63 and p73 isoforms are 
regulated through both transcriptional and post-translational mechanisms, and 
they in turn regulate diverse cellular functions including proliferation, survival 
and differentiation. The net effect of p63/p73 expression in a given context 
depends on the ratio of TA/DN isoforms expressed, on physical interaction 
between p63 and p73 isoforms, and on functional interactions with p53 at the 
promoters of specific downstream target genes. These multifaceted interactions 
occur in diverse ways in tumor-specific contexts, demonstrating a functional 
‘p53 family network’ in human tumorigenesis. Understanding the regulation 
and mechanistic contributions of p63 and p73 in human cancers may ultimately 
provide new therapeutic opportunities for a variety of these diseases. 
 
1.3.1 Gene structure of the p53 family transcription factors  
Although p63 and p73 are the most recently identified p53 family members, a 
p63/p73-like gene is considered to be the ancestral gene of the family (Yang et 
al. 2002). The proteins encoded by these two genes are more structurally 
similar to each other than to p53; however, all three family members possess 
several conserved protein domains (Figure 1a and 1b). These include an N-
terminal transactivation (TA) domain, a central DNA binding domain (DBD), 
and an oligomerization domain (OD) (Yang and McKeon 2000). The highest 
degree of homology among the three members is observed within the DBD 
(>60% amino-acid identity between p53 and both p63 and p73, and 85% 
amino-acid identity between p63 and p73), including conservation of all 
essential DNA contact residues (De Laurenzi and Melino 2000). This structural 
similarities allows p53 family proteins to interact physically and functionally 
make relevant in human cancer research. 
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Figure 1 
 
 
Figure 1. Structure and expression of p53 family members. (a) Structure of p53, p63 and p73 
transcription units. Numbered boxes indicate exons, and black shading denotes untranslated 
sequences. The approximate regions encoding the transactivation (TA) domain (light blue), 
DN-specific region (green), DNA-binding domain (red), oligomerization domain (yellow), 
sterile alpha motif (SAM, grey), and transactivational inhibitory domain (TID, orange) are 
indicated. Distinct transcription start sites are indicated by arrows. N-terminal alternative 
splicing for p53 and p73 are indicated by dotted lines, and C-terminal splicing events for all 
p53 family members are indicated by solid lines and Greek letter designation.( b) Protein 
domains of p53 family members. All three family members share a homologous DNA-binding 
domain and oligomerization domain (oligo). The TA domain is shared by p53, TAp63, and 
TAp73 isoforms.TAp63 g/TAp73g isoforms most closely resemble p53.N-terminally truncated 
DN isoforms possess unique N-terminal sequences. Alpha isoforms of p63 and p73 possess a 
C-terminal SAM domain followed by a transactivational inhibitory domain (TID). Other 
isoforms of p53, p63 and p73 are not shown. 
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1.4 Role of p53; normal versus cancer cells 
p53 is an intensively studied protein, its fame stemming mainly from its clear 
role as a tumour suppressor in humans and other mammals (Royds et al. 2006). 
Loss or mutation of p53 is strongly associated with an increased susceptibility 
to cancer, and most functions of p53 have been considered in the light of how 
p53 might protect from malignant progression (Vogelstein et al. 2000). Some 
p53-null mice can develop normally (Donehower 1996), an observation that 
has been taken to rule out major functions for p53 in normal physiology. But 
recent studies are questioning whether p53 is truly such a single-minded 
protein, and other functions of p53 that might be profoundly important during 
normal life are being uncovered. These include roles for p53 in regulating 
longevity and ageing, glycolytic pathways that might determine endurance and 
overall fitness, and apoptotic responses during ischaemic and other types of 
stress. Evidence for genetic variations in the activity of the p53 pathway in 
humans gives these ideas extra relevance (Pietsh et al. 2006). One of the major 
mechanisms by which p53 functions is as a transcription factor that both 
positively and negatively regulates the expression of a large and disparate 
group of responsive genes (Lapenko et al. 2006). Although some of these p53-
responsive genes have an important role in mediating cell-cycle arrest, 
senescence and apoptosis (the best understood activities of p53), it is now 
evident that the ability of p53 to influence gene expression has wider reaching 
effects. Numerous studies, including the recently reported genome wide ChIP 
analyses (Cawley et al. 2004; Wei et al. 2006), have identified p53-regulated 
genes that could have a role in a number of different and sometimes unexpected 
responses. Although some of these still need to be fully validated, there is now 
clear evidence for a role of p53 in the regulation of glycolysis (Matoba et al. 
2006; Bensaad et al. 2006) and autophagy (Crighton et al. 2006), the repair of 
genotoxic damage (Gatz and Wiesmuller 2006), cell survival and regulation of 
oxidative stress (Bensaad and Vousden 2005), invasion and motility (Roger et 
al. 2006), cellular senescence (Kortleverm et al. 2006), angiogenesis (Toeodoro 
et al. 2006), differentiation (Murray-Zmijewski et al. 2006) and bone 
remodeling (Wang et al. 2006). The cellular pathways in which p53 is 
involved, are schematically represented in Figure 2.  In these aspects, its 
worthy to analyze there is any cancer cells are expressing wild type p53, and if 
they are expressing, its role in cancer cells has to be  studied before clinical use 
of p53 mediated gene therapy as a canticancer therapy. 
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Figure 2 
 
 
 
 
Figure 2. Activation and functions of p53. p53 has a key role in integrating the cellular 
responses (pink arrows) to different types of stress (blue arrows). Activation of p53 can result 
in a number of cellular responses, and it is possible that different responses are induced by 
different stress signals. There is evidence that p53 can play a part in determining which 
response is induced through differential activation of target-gene expression. Although the 
importance of these responses to tumour suppression is clear, previously unanticipated 
contributions of these responses to other aspects of human health and disease are being 
uncovered. The role of p53 in tumour suppression, development and ageing is likely to depend 
on which cellular response is activated and on the context in which the activation occurs. 
 
1.4.1 A positive role; p53 functions in normal cells  
Tumor suppressor function of human p53 protein has been well known but at 
what conditions and which state exerts its tumor suppressive property in 
genomic altered cells are unknown. It has become evident that despite the many 
levels of negative regulation that are in place to restrain p53, the everyday 
rigours of normal mammalian life can more systemically induce low levels of 
p53 activity. And, recent studies have revealed a hitherto unappreciated 
importance of p53 under conditions of apparently normal growth and 
development. Interestingly, induction of p53 through these mechanisms seems 
to have a role in responses beyond cell-cycle arrest and apoptosis, including an 
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intriguing role of p53 in promoting cell survival (Lassus et al. 1996) through 
regulation of glucose metabolism and antioxidant function as well as 
autophagy.  
 
1.4.1.1 Regulation of glucose metabolism 
Recent results have indicated a role for p53 in determining the response of cells 
to nutrient stress and in regulating pathways of glucose usage and energy 
metabolism. Metabolic stress that results in low glucose levels has been shown 
to activate p53 through a pathway that involves AMP kinase (AMPK), and has 
been proposed to contribute to the short-term survival of cells suffering, 
hopefully temporary, starvation (Jones et al. 2005). Such a starvation-induced 
activity of p53 is entirely consistent with the concept of p53 as a sentinel in the 
detection and response to potentially oncogenic stress, but could clearly have a 
much broader role in the response to metabolic stress. More surprisingly, roles 
for p53 in controlling different metabolic pathways under apparently normal 
growth conditions have also been recently described. For example, p53 has 
been shown to induce the expression of the copper transporter SCO2, which is 
required for the assembly of cytochrome c oxidase (Matoba et al. 2006). This 
allows p53 to enhance oxidative phosphorylation. Conversely, the loss of p53 
activity in cells results in a reduction in oxygen consumption. The resultant 
defect in respiration would affect tumor cells (which are all defective in some 
way for p53 activity) particularly strongly, because the abnormal and 
deregulated proliferation that is characteristic of cancer cells makes them 
particularly energy demanding. In cancers, a dramatic increase in glycolysis  
called the ‘Warburg effect’  might help solve this problem of sustained energy 
production. Interestingly, loss of p53 seems to be a root cause of the metabolic 
changes that characterize cancer cells, because restoration of SCO2 expression 
in p53- deficient cancer cell lines can restore mitochondrial respiration (Matoba 
et al. 2006). But what effect does this change in mitochondrial respiration have 
on the whole animal? Closer examination of p53-null mice led to the 
identification of an interesting, and hitherto undetected, defect in endurance. 
p53-null mice get exhausted very quickly during exercise presumably because 
they cannot efficiently generate energy through aerobic respiration (Matoba et 
al.2006) . This might be one of many cancer-independent phenotypes that result 
from the loss of p53 that have been overlooked owing to our extreme focus on 
tumor development.  
 
1.4.1.2. Antioxidant functions 
Another recently described p53-inducible gene with a role in glycolysis is 
TIGAR (Tp53-inducible glycolysis and apoptosis regulator) (Bensaad et al. 
2006), which encodes a protein that shows some structural similarity to the 
bisphosphatase domain of the bifunctional enzyme 6-phosphofructo-2-
kinase/fructose 2,6 bisphosphate (PFK2/FBPase-2), and can lower the 
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intracellular levels of fructose-2,6-bisphosphate. An effect of TIGAR 
expression is therefore to decrease the activity of 6-phospho-1-kinase, a key 
glycolytic enzyme, thereby diverting the major glycolytic pathway into the 
pentose phosphate pathway. The resultant increase in nucleotide and NADPH 
production might have a number of interesting consequences, including an 
increase in glutathione levels to promote scavenging of reactive oxygen species 
(ROS). Although the apoptotic activity of p53 is mediated at least in part  
through increasing ROS levels (Johnson et al. 1996; Polyak et al. 1997), a 
number of studies have shown a survival function for p53 in lowering 
intracellular ROS levels, involving the activity of p53-inducible genes such as 
TIGAR, sestrins (Velasco-Miguel et al. 1999), aldehyde dehydrogenase-4 
(ALDH4) (Yoon et al. 2004), and others (Gu et al. 2006). Most interestingly, 
this antioxidant function of p53 is important in the absence of acute stress and 
acts to prevent the accumulation of DNA damage during normal cell functions 
(Sablina et al. 2005). It is worth pointing out, however, that even among these 
low-stress p53-response genes, the sensitivity to p53 can differ. For example, 
SCO2 and sestrin levels are reduced by the removal of p53 even in unstressed 
cells, whereas basal TIGAR expression is not so clearly affected. It seems likely 
that rather than dividing into two discrete groups of genes that respond to high 
stress and low stress, p53-responsive genes will form a continuum that shows 
ever-increasing sensitivity to p53 and stress levels. Based on current evidence, 
we can propose a model in which p53 can have two important, but 
fundamentally opposing, roles in response to stress. The low levels of DNA 
damage that are encountered during normal life are dealt with, through p53, by 
lowering ROS levels (and so reducing damage) and by promoting the survival 
of the slightly damaged cell to allow repair (a process to which p53 can also 
contribute). In response to more severe, sustained stress such as oncogene 
activation or exposure to high doses of radiation  p53 switches from promoting 
survival and repair to the induction of apoptosis (Bensaad et al. 2005). Of 
course, both activities of p53 (survival and apoptosis) contribute to tumor 
suppression. The question that has not been fully explored yet is: are there 
other consequences of loss of p53, in cancer cell which are expressing wild 
type p53 protein? 
 
1.4.1.3 p53 in development 
 In vertebrates, the two other p53 family members, p63 and p73, illustrate a 
requirement for at least some p53-like function during development (Murray-
Zmijewski et al. 2006). Deletion of either p63 or p73 has severe effects on the 
normal development of mice, and a number of human developmental diseases 
have also been linked to mutations in p63 (Barbieri et al. 2006). Although loss 
of p63 and p73 can result in a predisposition to cancer development (Flores et 
al. 2005), neither protein has the profound tumor-suppressive activity that is 
shown by p53. In light of the importance of p63 and p73 to normal 
development in mice, it is perhaps not so surprising that a closer analysis of the 
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p53-null mice revealed that they also show developmental abnormalities (Chio 
et al. 1999). Although many of these mice are normal at birth, females of some 
strains show neural tube-closure defects (or exencephaly) that reveal a role for 
p53 in normal development, at least under certain circumstances (Armstrong et 
al. 1995; Sah et al. 1995). This phenotype is also seen in mice with defects in 
other components of mitochondrial death pathways, which indicates that the 
lack of p53 leads to a failure in progenitor cell apoptosis and so an 
overproduction of neural tissue. Furthermore, studies of developmental 
abnormalities induced by in utero exposure to ionizing radiation clearly show 
that p53 has a role in reducing the rate of birth defects (Armstrong et al. 1995; 
Hall and Lane 1997; Baatout et al. 2002). These findings imply that the normal 
p53 response constantly monitors the early developmental process, presumably 
eliminating the odd aberrant cell or killing the embryo when the defects 
become too extreme (Hall and Lane 1997). Interestingly, p53 has a clear anti-
teratogenic function (Nicol et al. 1995; Norimura et al. 1996), presenting a 
much more tangible evolutionary advantage than the more frequently studied 
anti-tumor activity and illustrating an interesting parallel with the germline 
functions of p53 in lower organisms. It would be interesting to know whether 
birth defects are more common in patients with Li–Fraumeni syndrome, who 
carry a germline mutation in one p53 allele and have an extremely high 
incidence of cancer (Varley 2003). 
 
1.4.2 Negative role of p53 in human cells (The darker side of p53) 
Although suppression of cancer or inhibitions of teratogenesis are clearly 
desirable features of p53, the induction of p53 is not without cost. Most clearly, 
p53 is strongly activated in response to acute genotoxic stress such as is 
encountered following irradiation or chemotherapy, and the ensuing apoptosis 
is responsible for the classic symptoms of radiation sickness and side effects of 
cancer therapy. It is also clear that other forms of stress or trauma, not 
necessarily associated with potential malignant progression, can also lead to the 
activation of p53. For example, induction of p53 during ischaemia has been 
shown to contribute to damage through the activation of apoptosis, and a 
temporary inhibition of p53 function under these conditions might be highly 
beneficial in the prevention and management of injury to the liver, brain and 
kidneys (Georgiev et al. 2006; Fiskum et al. 2004; Dagher 2004), or in 
treatment following myocardial infarction (Matsusaka et al. 2006). Equally 
tantalizing is the possibility that p53 plays a part in neurodegenerative 
syndromes such as Parkinson’s disease, Alzheimer’s disease and Huntington’s 
disease (Jacobs et al. 2006). In contrast to the positive role of p53 in protection 
from cancer, each of these examples reflects a more negative role for p53 in 
which induction of the p53 response causes, rather than solves, problems. The 
concept that p53 has a darker side becomes even more profound with the 
realization that despite its help in protecting from cancer, p53 might also 
contribute to many of the undesirable aspects of ageing. Taken together, it 
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seems possible that we pay a high price for the protection from tumor 
development that is provided by p53. 
 
1.4.2.1 p53 and ageing —the quest for eternal life 
How p53 might promote ageing is not yet clear, although a contribution of p53 
to cellular senescence and the limitation of the proliferative capacity of stem 
cells has been proposed (Sharpless and DePinho 2004). In Drosophila 
melanogaster, the extended lifespan that results from a reduction of p53 activity 
in neurons is not further enhanced by calorie restriction (Bauer et al. 2005), 
which increases longevity in a number of organisms from yeast to mice. These 
results indicate that p53 functions in the pathways that respond to caloric 
restriction such as those involving silent information regulator-2 (SIR2) and/or 
insulin signaling (Maier et al. 2004; Bauer and Helfand 2006). How these 
observations link to the function of p53 as a survival factor in response to 
glucose deprivation is not yet clear. Some of these results also hint at a possible 
role for the recently identified N- or C-terminally truncated isoforms of p53 
(Bourdon et al. 2005) in controlling ageing (Tyner et al. 2002; Maier et al. 
2004). Regulation of glycolysis by p53 can also affect cellular, and so 
potentially organismal, lifespan (Kondoh et al. 2005). However, despite the 
evidence that p53 can induce premature ageing, it seems that this might not be 
a function of properly regulated p53. Mice containing an extra copy of the p53 
gene, or with reduced expression of Mdm2, showed the expected protection 
from tumor development but no decrease in normal lifespan (Garcia-Cao et al. 
2002; Mendrysa et al. 2006). Although not fully resolved, one explanation for 
this apparent paradox is that the ageing phenotype observed in the earlier 
studies reflects an imbalance of p53 signalling, with the activation of some, but 
not all, p53 functions (Mendrysa and Perry 2006; Poyurovsky and Prives 
2006). Although some activities of p53 would be predicted to contribute to 
accelerated ageing, it seems equally possible that lack of p53, and the 
associated enhanced oxidative stress, would also have the same effect. Indeed, 
a deficiency of the p53-related protein p63 has been shown to result in 
premature ageing that correlates with an induction of senescence (Efeyan et al. 
2006). A recent study in the fruitfly has also indicated that p53 is required for 
compensatory growth after tissue damage and might contribute to tissue repair, 
cell renewal and survival in other animals (Wells et al. 2006). Indeed, mice 
expressing altered forms of p53 also show perturbed wound healing (Tyner et 
al. 2002).  
 
1.5.The role of p53 in human cancer 
In the two decades since its original discovery, p53 has found a singularly 
prominent place in our understanding of human cancer. Although the 
biochemistry of p53 has been worked out in some detail, our knowledge of the 
biologic consequences of p53 dysfunction is still quite rudimentary. P53 
 21
dysfunction in cancer cells are manly due to its mutation (50%), epigenetic 
modulation at expressional level and low persistence of p53 protein level due to 
its enhanced turnover. Most p53 mutations found in human cancers are not null 
mutations but rather encode mutant version of the p53 protein that may have 
unwanted activities such as a gain-of-function or be dominant negative 
inhibitors of wt p53 activity. In this regard, it will be important to determine 
how best to harness the complex properties of p53’s ability to induce cellular 
growth arrest and cell death to generate novel, effective approaches to cancer 
therapy. Furthermore, a clearer appreciation of the direct interaction of 
epigenetic factors with p53 will lead to development of strategies to inhibit 
tumor initiation and progression.  
 
1.5.1 p53; the guardian of the genome 
DNA damage was the first type of stress found to activate p53 and, based on 
this, p53 has been widely regarded as “the guardian of the genome” (Lane 
1992). Extensive characterization of the signaling routes that connect DNA 
damage with p53 have identified a cascade of Ser/Thr kinases that includes 
ATM, ATR, Chk1 and Chk2, which phosphorylate p53 (Siliciano et al. 1997; 
Chao et al. 2000; Saito et al. 2002; Kurz et al. 2004). This signaling cascade is 
permanently activated in human cancer, suggesting that the cancerous state is 
intrinsically associated to the generation of DNA damage (Bartkova et al. 2005; 
Gorgoulins et al. 2005). The constitutive DNA damage present in cancer cells 
is thought to emanate primarily from the strong generation of reactive oxygen 
species, (Jackson et al. 2001) as well as, from the aberrant firing of DNA 
replication origins (Bartkova et al. 2006; Di Micco et al. 2006). Recent 
characterization of mice genetically manipulated with a knocked-in p53 that 
cannot be phosphorylated at two of the main residues targeted by 
ATM/ATR/Chk1/Chk2, namely, Ser18 and Ser23 (Ser15 and Ser20 in human 
p53), indicates an important role of these phosphorylation sites in some, but not 
all, the DNA damage induced and p53-dependent responses (Chao et al. 2006). 
In agreement with this, mice carrying p53S18A/S23A alleles are tumor prone, 
(Chao et al. 2006) although this phenotype is considerably milder than in the 
case of p53-null mice (Donehower et al. 1992; Jacks et al. 1994). These data 
suggest that the activation of p53 in response to DNA damage occurs through 
multiple pathways, which in addition to the well-established kinase cascade of 
ATM/ATR/Chk1/Chk2, probably include other kinases such as p38, 
JNK/SAPK and c-Abl (Milne et al. 1995; Hu et al. 1997; Fuchs et al. 1998; 
Bulavin et al. 1999; Buschmann et al. 2001; Harris et al. 2005). Regarding 
human cancer, the available information gathered from the analysis of epi-
genetic aberrations indicates that the aforementioned DNA damage signaling 
kinases are not, in general, significant targets of genetic and epi-genetic 
inactivation (Ingvarsson et al. 2002; Bartek et al. 2003; Feng et al. 2003). The 
only exception to this is found in hematological malignancies, which present a 
high incidence of mutations in ATM (13–40% depending on the particular type 
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of malignancy) (Gumy-Pause et al. 2004). In line with this, a recent large-scale 
sequencing effort of 210 diverse human cancers has identified ATM among the 
three most frequently mutated kinases (5% incidence) (Greenman et al. 2007). 
Based on the above genetic evidence, it can be concluded that DNA damage is 
conveyed to p53 through multiple redundant pathways in which many 
transducers participate, but none of them plays a critical role and, therefore, 
alteration of a single component does not have a significant impact on p53 
function. 
 
1.5.1.1. p53; The policeman of the oncogenes 
Among the many and varied stimuli that have been reported to activate p53, 
oncogenic signaling (Serrano et al. 1997) has gained much attention because, as 
DNA damage, is also universally present in cancer. Therefore, analogous to the 
title of “guardian of the genome”, we can also assign to p53 the function of 
“policeman of the oncogenes”. Oncogenic signaling activates p53 through 
ARF, (Palmero et al. 1998; de Stanchina et al. 1998; Zindy et al. 1998) which, 
in turn, interacts with MDM2 inhibiting its p53-ubiquitin ligase activity. In this 
manner, ARF-dependent stabilization of p53 results in a dramatic increase in 
p53 activity. Many transcription factors activate ARF in response to oncogenic 
signaling, (Sharpless 2005; Gil 2006) most notably, Dentin matrix acidic 
phosphoprotein (DMP1) (Inoue et al. 1999; Inoue et al. 2000). Mice lacking 
ARF have a remarkable tumor-prone phenotype, (Kamijo et al. 1997; Kamijo et 
al. 1999) although not as severe as p53-deficient mice, (Donehower et al. 1992; 
Jacks et al. 1994) and there is good genetic evidence in mice supporting the 
relevance of the ARF/MDM2/p53 axis in tumor suppression (Moore et al. 
2003). Importantly, mice deficient in ARF present a normal DNA damage 
response, indistinguishable from ARF-proficient mice (Kamijo et al. 1999). 
Regarding human cancer, the analysis of (epi)genetic alterations indicate that 
ARF is indeed inactivated with an extraordinary high frequency (~30%) 
(Sharpless et al. 2005). However, inactivation of ARF almost invariably occurs 
in combination with the loss of p16INK4a, the cell cycle inhibitor, thus 
generating an ambiguity about which is the key targeted tumor suppressor. In 
this regard, it should be mentioned the existence of germline point mutations 
that inactivate ARF alone (i.e., sparing p16INK4a) in human kindreds 
predisposed to cancer (Randerson-Moor et al. 2001; Rizos et al. 2001). 
Nonetheless, the number of germline mutations that inactivate p16INK4a only 
(i.e., sparing ARF) outnumbers by a factor of ~20 those that inactivate ARF 
alone (Kim et al. 2006). Together, currently available evidence indicates that 
ARF is an important upstream regulator of p53, whose lack of activity has a 
significant impact on cancer. 
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1.5.2 Downstream events of the p53 pathway 
Once the p53 protein is activated, it initiates a transcriptional program that 
reflects the nature of the stress signal, the protein modifications and proteins 
associated with the p53 protein. The p53 protein binds to a specific DNA 
sequence, termed the p53- responsive element (RE) (EI-Deiry et al. 1992; 
Bourdon et al. 1997), and induces the expression of downstream genes. An 
algorithm that identifies p53-responsive genes in the human and mouse genome 
has been utilized to detect a number of new genes regulated by the p53 protein 
(Hoh et al. 2002). The genes in this p53 network mainly initiate one of three 
programs that result in cell cycle arrest, DNA repair or apoptosis. 
 
1.5.2.1 Growth arrest 
p21WAF1/CIP1 is known to be a p53-downstream gene, and has been 
suggested to mediate p53-induced growth arrest triggered by DNA damage. 
The p21 protein is a cycline-dependent kinase inhibitor that associates with a 
class of CDKs and inhibits their kinase activities. This will facilitate the 
accumulation of hypophosphorylated form of pRB that in turn associates with 
E2F inhibiting its transcriptional activity, leading to cell cycle arrest. As long 
as pRb is bound to E2F, the cell is prevented from entering into S phase. This 
G1 arrest affords the cell time to repair the DNA damage. Should repair be 
unsuccessful, P53 levels drop and CDK-cyclin protein kinase activity resumes, 
leading to entry into S phase. In the event that the DNA is not repair, p53 
triggers apoptosis (Makoto et al. 1999; Kim et al. 2005). 
 
1.5.2.2 DNA repair 
Soon after having established TP53 as the most frequently altered gene in 
human tumours in the 1990s, (Hollstein et al. 1991, deFromentel and Soussi 
1992) p53 was understood as a major component of the DNA damage response 
pathway (Lane 1992; Levine 1997). After the introduction of DNA injuries the 
level of p53 protein rises, which in turn induces a transient cell cycle arrest or 
apoptotic cell death. DNA damage activates p53 through post-translational 
modifications by specific kinases, such as the strand break sensor ataxia 
telangiectasia mutated protein (Atm), by acetyltransferases like CREB-binding 
protein (Cbp)/p300, and by the poly (ADPribose) polymerase 1 (Parp-1), which 
prevent proteolysis via the Arf-mouse double minute 2 (Mdm2) pathway and/or 
enhance binding of p53 to consensus sequences within the genome (Saito et al. 
2003; Vaziri et al. 1997; Wang et al. 1998). Initially, investigations on a direct 
participation of p53 in DNA repair were spurred by a number of biochemical 
observations. Thus, the C-terminal 30 amino acids of p53 were shown to 
recognize several DNA damage-related structures, such as DNA ends, gaps, 
and insertion/deletion mismatches (Bakalkin 1994; Jayaraman and Prives 1995; 
Lee et al. 1995; Reed et al. 1995). p53 was also demonstrated to catalyse 
reannealing of short stretches of single- and double-stranded DNA and to 
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promote strand exchange between them   (Bakalkin et al. 1994, Oberosler et al. 
1993, Jean et al. 1997). Further, p53 binds to three-stranded heteroduplex joints 
and four-stranded Holliday junction DNA structures with localization 
specifically at the junction, suggesting that p53 directly participates in 
recombinational repair (Lee et al. 1997; Dudenho¨ ffer et al. 1998; Janz et al. 
2002). Moreover, several groups demonstrated a Mg2þ-dependent 3’–5’ 
exonuclease activity intrinsic to p53 (Jean et al. 1997; Bakhanashvili 2001). 
Noticeably, the same central region within p53, where tumourigenic mutations 
are clustered, recognises DNA sequence specifically, is required for junction-
specific binding of heteroduplex joints and is necessary and sufficient for the 
3’–5’ exonuclease activity on DNA (Mummenbrauer et al. 1996; Janus et al. 
1999; Dudenho¨ ffer  et al. 1999). In addition to p53’s biochemical activities, 
numerous reports on physical and functional protein interactions further 
strengthened the proposal of a direct role of p53 in nucleotide excision repair 
(NER), base excision repair (BER), and double-strand break (DSB) repair 
(Albrechtsen et al. 1999; Bertrand et al. 2004; Sengupta and Harris 2005). 
 
1.5.2.3 Apoptosis 
Pivotal to the tumor-suppressor activity of p53 is its ability to activate 
apoptosis via multiple different pathways (Fridman et al. 2003). Since the 
most-studied function of p53 is its role as a transcription factor that can activate 
transcription of an ever-increasing number of target genes, its transcriptional 
activation of pro-apoptotic genes, as well as its transcriptional repression of 
anti-apoptotic genes, has been widely analyzed (Fridman et al. 2003 and 
Vousden et al. 2002). However, although a large number of genes regulated by 
p53 during induction of apoptosis are known (Fridman et al. 2003 and Vousden 
et al. 2002), no single target gene has been identified whose altered expression 
alone can sufficiently explain p53 mediated transcription dependent apoptosis, 
and whose genetic deficiency phenocopies p53 deficiency in vivo. As an 
additional mode of p53’s pro-apoptotic activity, recent studies have placed non-
transcriptional pro- apoptotic activities of p53 at the center of an active debate 
that aims to establish a comprehensive understanding of p53- mediated 
apoptosis. 
 
1.5.2.3.1 p53 role in transcription dependent apoptosis 
The past twenty-five years have seen intensive and varied investigations to 
better understand the functions that p53 uses to mediate apoptosis. The first 
indication of the role of p53 in apoptosis was obtained using the M1 mouse 
myeloid leukemia cell line lacking endogenous p53. Using M1 cells stably 
transfected with a temperature-sensitive mutant that acquires the conformation 
of wild-type p53 at permissive temperature (32˚C), it was observed that upon 
downshift to the permissive temperature, the transfectants underwent rapid loss 
of viability with the characteristics of apoptosis (Yonish-Rouach  et al. 1991 
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and Selvakumaran et al. 1994). Several mechanisms have been implicated in 
p53-mediated apoptosis. One is p53 activation to up-regulation of pro-apoptotic 
Bax and down-regulation of pro-survival Bcl-2 (Selvakumaran M et al. 1994, 
Miyashita T et al. 1994). More recently its determined that p53-mediated 
apoptosis of M1 cells involves rapid activation of the pro-apoptotic Fas/CD95 
death pathway-via up-regulation of membrane bound Fas (Vesely et al. 2006) 
and the intrinsic mitochondrial pathway, which results in activation of caspases 
8, 9 and 10. Either Fas blocking antibody or inhibition of the apical caspases 8 
and 10, were each almost as effective as IL-6 in abrogating p53 mediated 
apoptosis. These observations argue that p53 regulation of the bcl-2 members 
Bax and BcI-2, associated with the intrinsic mitochondrial apoptotic pathway, 
is ancillary to the extrinsic Fas/CD95 apoptotic pathway in mediating p53 
induced apoptosis of M1 myeloid leukemia cells (Bennett et al. 1998). In other 
cell types up-regulation IGF-BP3, (Buckbinder et al. 1995) which sequesters 
the cell survival factor insulin-like growth factor-1 has been associated with 
p53 mediated apoptosis (Baserga et al. 1994). The gene encoding for the 
cathepsin-D protease, (Wu et al. 1998) PAG608 which encodes a nuclear zinc 
finger protein (Israeli et al. 1997) and the human homolog of the Drosophila 
sina gene (Nemani et al. 1996) have also been implicated as mediators of p53 
induced apoptosis in various cell types. Furthermore, a series of p53-induced 
genes (PIG genes) were documented to encode proteins that respond to 
oxidative stress, suggesting that p53-mediated apoptosis involves activation of 
redox- controlling targets followed by increase in ROS, oxidative damage to 
mitochondria and caspase activation (Polyak et al. 1997). Along this research 
line it was recently observed that p53 suppresses Nrf2-dependent transcription 
of antioxidant response genes, presumably to prevent the generation of 
antioxidants that could hinder induction of apoptosis (Faraonio et al. 2006) 
Clearly established is p53’s role as a nuclear transcription factor with the 
ability to activate, or repress, the expression of many genes. A number of p53 
transcriptional targets, such as the p53-induced genes BAX, PUMA, NOXA, 
and the p53-repressed genes BCL2 and SURVIVIN, represent genes with the 
potential to promote or inhibit apoptosis, respectively, in stressed cells. Puma 
and Noxa are thought to indirectly induce mitochondrial outer membrane 
permeabilization (MOMP), known to be induced by the activation of Bax and 
Bak, via interfering with Bax and Bac interaction with prosurvival Bcl-2 family 
members (Moll et al. 2006). Interestingly, it was observed that Puma and Noxa 
differentially contribute to the regulation of p53-mediated apoptotic pathways. 
In normal cells, Puma was found to induce mitochondrial outer membrane 
permeabilization via an ER-dependent pathway; however, upon E1A 
oncoprotein expression, cells also became susceptible to mitochondrial outer 
membrane permeabilization induction by Noxa via an ER-independent pathway 
(Tsukasa Shibue1 et al. 2006). In several instances, transcriptional activation by 
p53 was observed to be dispensable for p53-dependent apoptosis, since mutants 
p53 which fail to activate transcription could still induce apoptosis (Chen et al. 
1996 and  Haupt et al. 1995). In addition, p53-dependent apoptosis could occur 
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in the presence of inhibitors of transcription and translation (Caelles et al. 
1994). In recent years it has become clear that p53 also harbors a direct pro-
apoptotic function at the mitochondria via engaging in protein-protein 
interactions with anti- and pro-apoptotic Bcl2 family members, including 
BclXL and Bak (Moll et al. 2006).  
 
1.5.2.3.2 p53 role in mitochondrial mediated apoptosis 
It has been reported, certain transcriptionally inactive mutants of p53 can still 
induce apoptosis when over expressed in tumor cells (Haupt et al. 1995; Chen 
et al. 1996). Also, in response to some stresses, such as hypoxia, p53 induces 
apoptosis but does not function as a transactivator (Koumenis et al. 2001). 
Intriguingly, Moll and colleagues demonstrated that during p53-dependent 
apoptosis a fraction cellular p53 protein localizes to mitochondria and induces 
cytochrome c release; however, this is not observed during p53-mediated cell  
cycle arrest (Marchenko et al. 2000). Additional support for the concept that 
p53 has a cytoplasmic role in apoptosis induction resulted from functional 
analysis of polymorphic variants of p53 (Dumont  et al. 2003). Within exon 4 
of the p53 gene, a common single-nucleotide polymorphism (SNP) at codon 72 
leads to the incorporation of either an arginine (R72) or a proline (P72) at this 
position of the protein. Further investigation revealed that the R72 form of p53 
induces apoptosis markedly better than the P72 variant (Dumont  et al. 2003). 
When explored the potential mechanisms underlying the observed functional 
difference between the two p53 variants, made the initially surprising discovery 
that the greater apoptotic potential of the R72 form correlated with its much 
better ability to traffic to mitochondria. Based on these data, therefore 
concluded that the enhanced apoptosis-inducing activity of the R72 protein 
related, at least in part, to its greater mitochondrial localization. An analysis of 
whole cell or mitochondrial extracts by immunoprecipitation-western blot 
analysis, demonstrated the R72 form of p53 binds better to the mitochondrial 
death-effector protein BAK than does the P72 variant, correlating with the 
difference in apoptotic potential of the two p53 variants. In healthy cells, Bak 
resides at mitochondria as an inactive monomer. In response to various death 
stimuli, it undergoes an activating allosteric conformational change that 
promotes homo-oligomerization. This leads to formation of a pore in the outer 
mitochondrial membrane, and allows the release of cytochrome c and other 
pro-apoptogenic factors from the mitochondria resulting in the activation of a 
caspase cascade (Fig 3) (Griffiths et al. 1999; Wei et al. 2000). Recently, like 
BAK, the BCL2 family members BAX and BCL-XL have also been implicated 
in mitochondrial apoptosis induction by p53(Fig 3) (Mihara et al. 2003; Chipuk 
et al. 2004).  
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Figure 3 
 
 
Figure 3. The mitochondrial pro-apoptotic activities of p53. In healthy cells (left), the pro-
apoptotic BH3-only and effector BH123 proteins (ovals) exist either in complex with anti-
apoptotic proteins Bcl2 family proteins such as BclXL, Bcl2 and Mcl-1 (rectangles). Death 
stimulus induced mitochondrial p53 (triangle) forms a complex with BclXL and Bcl2, 
liberating pro-apoptotic BH3-only proteins (derepression by inhibiting their survival function) 
and BH123 proteins, resulting in Bax and Bak homo-oligomerization, activation and 
mitochondrial membrane permeabilization (MMP) to release a host of apoptotic activators. 
Moreover, translocated p53 can bind to Bak by disrupting the inhibitory Bak/Mcl1 complex, 
enabling Bak to ultimately undergo homo-oligomerization and MMP. In addition, in cells with 
a cytosolic BclXL fraction, p53 might activate cytoplasmic Bax through a ‘hit and run’ 
mechanism involving an intermediate cytosolic p53/BclXL complex that is disrupted by 
cytosolic Puma, which results in Bax conformational change, mitochondrial translocation, 
oligomerization and MMP. 
 
1.6 Modes of p53 alteration during tumorigenesis 
Alterations in the gene encoding the cellular p53 protein are perhaps the most 
frequent type of genetic lesions in human cancer. At the heart of these 
alterations is the abrogation of the tumor suppressor activity of the normal p53. 
In many cases this is achieved through polymorphisms, and point mutations in 
p53, which often result in pronounced conformational changes. Such mutant 
polypeptides, which tend to accumulate to high levels in cancer cells, are 
believed to exert a dominant negative effect over co-expressed normal p53. 
Other than polymorphisms and mutation mediated inactivation, cellular 
signaling pathways are involved to inactivate expressed wild type p53 through 
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enhanced MDM2 mediated degradation pathway, over-expression of dominant 
negative regulators of p53 family isoforms, e.g. detlaNp73 and other post-
translational modifications. 
 
1.6.1 Polymorphisms in Tp53: the codon 72 polymorphism 
The cDNA for p53 was first cloned in 1984; (Matlashewski et al. 1984; Wolf et 
al. 1985; Harlow et al. 1985) approximately 2 years later, a mobility shift in 
p53 protein was identified as a sequence polymorphism at amino acid 72, 
changing proline to arginine (Matlashewski et al. 1987; Buchman et al. 1988; 
Ara et al. 1990). Unfortunately, at the time of its discovery, researchers were 
inadvertently studying a tumor-derived mutant form of p53, with the belief that 
TRP53 was an oncogene. Therefore, the only functional analysis performed for 
these polymorphic variants was for their transforming potential, which did not 
differ, so the polymorphism was deemed functionally insignificant. Only in 
1994, when analyzing the allele frequencies of the proline 72 and arginine 72 
variants (P72 and R72, respectively) in human populations did Beckman and 
co-workers note statistically significant differences in allele frequency between 
different ethnic groups. For example, the P72 allele frequency is approximately 
60% in African Americans, but only 30–35% in Caucasian Americans. 
Interestingly, Beckman noted that the P72 allele frequency increases in a linear 
manner in multiple populations as they near the equator (Beckman et al. 1994). 
This led him to hypothesize that the codon 72 polymorphism might have an 
impact on p53 function, and that the high exposure to UV light in populations 
near the equator led to selection for the P72 allele. The first comparison of the 
biological activity of endogenous P72 and R72 proteins was performed by 
Bonafe et al. in 2002; in that study, blood leukocytes homozygous for R72 
were found to undergo significantly increased apoptosis in response to the 
cytotoxic drug cytosine arabinoside, compared to P72 (Bonafe et al. 2002). 
Further analysis, however, revealed that the R72 variant demonstrated greatly 
increased trafficking to mitochondria, where Moll and co-workers had reported 
in 2000 that p53 had direct ability to induce cytochrome c release and 
programmed cell death (Marchenko et al. 2000). A number of studies have 
attempted to determine if there is an association between codon 72 
polymorphic variants of TP53 and risk for particular cancer types. These 
studies have come to very varied conclusions, with some studies reporting 
increased risk associated with the P72 allele for certain cancer types (Sjalander 
et al. 1996; Wu et al. 2002; Granja et al. 2004) and others failing to reach such 
conclusions (Weston et al. 1994; Birgander et al. 1995; Rosenthal et al. 1998). 
The reasons for these discrepancies are not clear, but it can be safely said that if 
such associations exist, they may not be particularly strong, or they can be 
influenced by unknown variables that presently are not controlled for in such 
studies. 
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1.6.1.1 The codon 47 polymorphism 
A second exonic polymorphism at codon 47 changing a proline to serine has 
also been described (Felley- Bosco et al. 1993). The frequency is very low, 
ranging from 0.5% to 5% in various studies. This polymorphism is close to 
serine 46, phosphorylation of which is a key event for the apoptotic function of 
p53. In vitro studies have shown that the S47 variant is a poorer substrate for 
S46 phosphorylation and has an impaired proapoptotic ability (Li et al. 2005). 
The clinical significance of this p53 variant is not known. 
 
1.6.2 p53 mutations in cancer 
The p53 tumor suppressor gene is mutated in about half (50%) of all cancer 
types arising in a variety of tissues, and it manifests a high frequency of 
missense mutations (substitution of an amino acid in the encoded protein) 
(Hollstein et al. 1991; Levine et al. 1991; Aguilar et al. 1994). Non-missense 
mutations, e.g., deletions and insertions, are also found in the p53 gene but at a 
lower frequency—when compared with to other tumor suppressor genes, such 
as APC, BRCA and ATM. In the distribution of missense mutations, these 
types of mutations occur more frequently in exons 2–4 (54%) and 9–11 (77%) 
rather than in exons 5–8  (20%). The N-terminus of the p53 protein _encoded 
by exons 2–4 (Liu et al. 1993; Vogelstein et al. 1992; Thut et al. 1995; Lu et al. 
1995), has an abundance of acidic amino acids that are involved in the 
transcriptional function of p53 (Raycroft et al. 1990; Fields et al. 1990), and 
binds to transcription factors such as TBP in TFIID (Liu et al. 1993; Seto et al. 
1992; Truant et al. 1993; Martin et al. 1993; Mack et al. 1993). Experimental 
studies have shown that multiple point mutations in this domain are required to 
inactivate its transcriptional transactivation function (Lin et al. 1994). The 
carboxy-terminus _encoded by exons 9–11 of the p53 protein is enriched in 
basic amino acids that are important in: the oligomerization and nuclear 
localization of the p53 protein (Clore et al. 1994; Jeffrey et al. 1995; Hupp et 
al. 1995), the recognition of DNA damage (Jayaraman et al. 1995; Bakalkin et 
al. 1994), the negative regulation of p53 binding to promoter sequences of 
genes regulated by p53, the transcription of p53-transactivated genes 
(Horikoshi et al. 1995), and the induction of apoptosis (Wang et al. 1996). 
Laboratory studies have shown that at least 2-point mutations in the N-terminus 
of p53 are required to inhibit its transcriptional transactivity (Lin et al. 1994); 
therefore, deletions and insertions are more detrimental mutagenic mechanisms 
than single-point mutations for disrupting these N-terminal and C-terminal 
functional domains. More intensive studies on p53 mutation analysis find that 
some carcinogens are able to cause specific mutations. 
1.6.2.1 Aflatoxin B exposure and p53 codon 249 ser 1 (AGGªAGT)mutation 
In liver tumors from persons living in geographic areas where aflatoxin B and 
hepatitis B virus (HBV 1) are cancer risk factors, the majority of p53 mutations 
are at the third nucleotide pair of codon 249 (Bressac et al. 1991; Scorsone et 
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al. 1992; Li et al. 1993). A dose-dependent relationship between dietary 
aflatoxin B1 intake and codon 249ser p53 mutations is observed in 
hepatocellular carcinoma from Asia, Africa and North America _reviewed in 
Refs.(Harris et al. 1996 and Montesano et al. 1997). In addition, the mutation 
load of 249ser mutant cells in non tumorous liver is positively correlated with 
dietary aflatoxin B exposure (Hussain et al. 1998).  Exposure of aflatoxin B to 
human liver cells in vitro 1 produces 249ser_AGG to AGT) p53 mutants 
(Aguilar et al. 1993 and Mace et al. 1997). These results indicate that the 
expression of the 249ser mutant p53 protein provides a specific growth and/or 
survival advantage to liver cells (Puisieux et al. 1995), and are consistent with 
the hypothesis that p53 mutations can occur early in liver carcinogenesis.  
1.6.2.2 Sunlight exposure and p53 CCªTT tandem double mutation 
Sunlight exposure is a well known risk factor for skin cancer. Tandem CC to 
TT transition mutations are frequently found in squamous and basal cell skin 
carcinoma (Brash et al. 1991) while they are rarely reported in other types of 
cancers (Greenblatt et al. 1994). In vitro studies have shown the induction of 
the characteristic CC to TT mutations by ultraviolet exposure (Bredberg et al. 
1986; Brash et al. 1988; Kress et al. 1992). Sunlight- exposed normal and 
precancerous skin contain CC to TT tandem mutations (Nakazawa et al. 1994 
and Ziegler et al. 1994). These results indicate that CC to TT mutations induced 
by sunlight exposure may play a role in the occurrence of skin cancer. 
1.6.2.3 Benzo[a]pyrene exposure and p53 mutations at hotspot codons 157, 
248 and 273 
Cigarette smoking has been established as a major risk factor for the incidence 
of lung cancer. Codons 157, 248 and 273 of the p53 gene have been designated 
as mutational hotspots in lung cancer. The majority of mutations found at these 
codons are G to T transversions. Furthermore, in addition to lung cancer, codon 
157 also constitutes one of the hotspots for G to T transversions in breast, and 
head and neck cancers. In smoking-associated lung cancer, the occurrence of G 
to T transversions has been linked to the presence of benzo(a)pyrene (BP) in 
cigarette smoke. Interestingly, codon 157 (GTC to TTC) mutations are not 
found in lung cancer from never smokers (Greenblatt et al. 1994; Hainaut et al. 
1998). A dose-dependent increase in p53 G to T transversion mutations with 
cigarette smoking has been reported in lung cancer (Takeshima et al. 1993). 
Recently, it is shown that BP diol epoxide, the metabolically activated form of 
BP, binds to guanosine residues in codons 157, 248 and 273 which are 
mutational hotspots in lung cancer (Denissenko et al. 1996). Cigarette smoke 
condensate or BP also neoplastically transforms human bronchial epithelial 
cells in vitro (Klein-Szanto et al. 1992). The occurrence of characteristic p53 
mutation spectra upon exposure to a particular carcinogen can add to the 
‘weight of the evidence’ for implicating an environmental pollutant-
contaminant in the etiology of human cancer (Aguilar et al. 1994). 
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1.6.3 Co-operation and competition occur among p53 family isoforms  
 A complex picture emerges when we try to define the precise contribution of 
either p63 and/or p73 of ‘p53 family network’ to tumor development. A major 
part of this complexity stems from the expression of both DN and TA isoforms 
of p63 and p73 in many human tumors. Studies support the view that 
TAp63/TAp73 isoforms, like p53, exhibit tumor suppressive properties, and 
that up regulation of ∆Np63/ ∆Np73 isoforms is a common mechanism of their 
inactivation during tumorigenesis. Indeed, important physical and functional 
interactions among family members have now been demonstrated in tumor-
specific contexts. These diverse interactions are mediated through two general 
mechanisms. First, cooperation and competition at the conserved p53 family 
binding sites within promoters of particular shared target genes are likely to 
regulate interactions among all three family members (Flores et al. 2002; 
Stiewe et al. 2002; Yang et al. 2006). Second, direct physical interaction of 
isoforms is known to alter the function of the tetrameric complex required for 
DNA-binding and transcriptional regulation (Chan et al. 2004). In ectopic 
expression studies, heteromeric complexes have been demonstrated between 
different isoforms of the same gene, between TAp63 and ∆Np73 isoforms, and 
between TAp73 and ∆Np63 isoforms (Chan et al. 2004). In each case, the 
respective DN isoforms function as potent inhibitors of transactivation by the 
respective TA isoforms. Consistent with these findings, endogenous complexes 
have also been demonstrated between different p73 isoforms, and between 
∆Np63 and TAp73 (Deyoung et al. 2006; Rocco et al. 2006). Wild-type p53 
binds p63 and p73 with much lower affinity than p63 and p73 bind one another 
(Davison et al. 1999). Despite the absence of a strong physical interaction, 
however, it seems highly plausible that in some tumor contexts both ∆Np63 
and ∆Np73 serve to inhibit the function of p53 through promoter competition 
or other indirect mechanisms (Stiewe et al. 2002). 
 
1.7 p53 post translational modifications 
The well-studied post-translational modification of a single protein to date is 
human p53 protein. Therefore, several reports state its post-translational 
modifications role in determining its tumor-suppressor activity. And any 
alterations in it post-translational modifications can positively or negatively 
regulate cell fate determination and tumorigenesis. 
 
1.7.1 Phosphorylation of serines and threonines 
Human p53 has 23 different phosphorylation and dephosphorylation sites 
(Figure 4a). The regulation of p53 function by phosphorylation and 
dephosphorylation could, therefore, occur through many sites, most of which 
are outside the DNA binding domain (DBD). Most residues are phosphorylated 
by many different kinases in response to many stresses and are associated with 
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p53 activation (Bode et al. 2004). This defines two levels of potential 
redundancy, as a specific residue can be phosphorylated by several kinases (for 
example, serine 15 is phosphorylated by at least 8 kinases), and a specific 
kinase can phosphorylate several residues (for example, CHK2 phosphorylates 
7 different residues). Such redundancy might provide a fail-safe mechanism to 
enable diverse stresses to activate p53 (Bode et al. 2004). As some residues 
seem to be phosphorylated by a single kinase, unique phosphorylation patterns 
might determine a subset of cellular responses. Alternatively, this could reflect 
incomplete knowledge of the relevant kinases and their targets. For example, 
serine 378 was thought to be phosphorylated by a single kinase just 2 years ago 
(Bode et al. 2004), but recent data indicate that three different kinases are 
involved (Ou et al. 2005). Additionally, the dephosphorylation of some 
residues has been correlated with activation; therefore serine 376 is 
phosphorylated in unstressed cells and dephosphorylated after ionizing 
irradiation, correlating with the interaction of p53 with 14-3-3 proteins 
(Stavridi et al. 2001). Conversely, the phosphorylation of serine 215 by Aurora 
kinase A reportedly inhibits the binding of p53 to DNA and overrides stress 
responses induced by cisplatin and χ-irradiation (Liu et al. 2004). 
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Figure 4 
 
 
 
Figure 4. Comparative maps from in vitro human p53 and in vivo mouse p53 studies. a | Post-
translational modifications of human p53. Specific residues are modified as shown, with 
phosphorylation (P) in orange, acetylation (A) in green, ubiquitylation (Ub) in purple, 
neddylation (N) in pink, methylation (M) in blue and sumoylation (SU) in brown. Proteins 
responsible for these modifications are shown in matching colours. b | Targeted mutations at 
the mouse p53 locus. Mouse p53 shares a strong homology with human p53, but a few 
differences can be noted, including: mouse p53 is comprised of 390 amino acids; the N-
terminal part of mouse p53 is longer by 3 residues, so that the numbering is higher in the 
murine transactivation domain (TAD) than in the human TAD; the p53 proline-rich domain 
(PRD) is loosely conserved in evolution (the murine PRD is shorter, and contains 2 PXXPs 
motifs and 2 putative PIN1 sites instead of 5 PXXPs and 1 PIN1 site in the human PRD); in the 
DNA-binding domain and the C-terminal part of the protein, numbering is lower by 3 amino 
acids in murine compared with human (mouse serine 389 is functionally equivalent to human 
serine 392); the C-terminal regulatory domain (CTD) of mouse p53 contains 7 lysines, instead 
of the 6 in human p53. Residues that are subject to stress-induced modifications and that have 
been targeted at the mouse p53 locus are shown. Below the protein are shown other targeted 
mutations, which provided valuable information on p53 function, but did not precisely target 
residues modified by stress. For several point mutations, abbreviated names are mentioned (for 
example, QS instead of L25Q,W26S). AMPK, adenosine monophosphate-activated protein 
kinase; ATM, ataxia telangectasia mutated; ATR, ataxia telangectasia and Rad3-related 
protein; AurK, Aurora kinase A; CAK, CDK-activating kinase; CDK, cyclin-dependent kinase; 
CHK, checkpoint kinase; CK, casein kinase; CSNK, cop-9 signalosome associated kinase 
complex; DNAPK, DNA-dependent protein kinase; ERK, extracellular signal-regulated kinase; 
GSK3, glycogen synthase kinase 3; HIPK2, homeodomain-interacting protein kinase 2; JNK, 
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c-Jun NH2-terminal kinase; MAPKAPK2, mitogenactivated protein kinase-activated protein 
kinase 2; p38, p38 kinase; PCAF, p300/CBP associated factor; PKC, protein kinase C; PKR, 
double stranded RNA-activated kinase; PLK3, pol-like kinase 3; RSK2, ribosomal S6 kinase 2; 
SET9, SET9 methyltransferase; SMYD2, SET/MYND domain-containing methyltransferase 2; 
SUMO, small ubiquitin-like modifier 1; TAF1, TATA-binding protein– associated factor 1; 
VRK1, vaccinia-related kinase 1.  
 
1.7.2 Lysine modification 
 p53 C-terminal lysines are modified by ubiquitylation, acetylation, 
sumoylation, neddylation and methylation (FIG. 4a). Neddylation seems to 
inhibit transactivation, whereas sumoylation can positively or negatively affect 
p53 function (Bode et al. 2004). Recently, p53 sumoylation was proposed to 
induce senescence in normal human fibroblasts but apoptosis in RB 
(retinoblastoma 1)-deficient cells (Bischof et al.2006). Modifications of lysine 
320 were proposed to promote cell-cycle arrest, rather than apoptosis (Di 
Stefano et al. 2005; Knights et al. 2006; LeCam et al. 2007). Unlike lysines 
372, 373, 381 and 382, which are acetylated by p300 and ubiquitylated by 
MDM2 (Bode et al. 2004), lysine 320 is acetylated by the p300 and CBP 
associated factor (PCAF) (Di Stefano et al. 2005; Knights et al. 2006; 
Sakaguchi et al. 1998) and ubiquitylated by E4F1 (LeCam et al. 2007)). The 
E4F1-mediated lysine 48-like oligo-ubiquitylation has been proposed to induce 
cell-cycle arrest rather than promote p53 degradation (LeCam et al. 2007). 
Methylation at nearby lysines might also have dramatically different effects: 
lysine 372 methylation by SET9 stabilizes p53 (Chuikov et al. 2004), whereas 
the methylation of lysine 370 by SMYD2 destabilizes it. One interpretation of 
the increasing variety and complexity of p53 modifications at serines, 
threonines and lysines (FIG. 4a, b) is that the elegant model of p53 regulation.  
 
1.8 Head and Neck Cancer  
Head and neck cancer (HNC) accounts for about 5% of all cancers with >500 
000 cases diagnosed worldwide and >100 000 in Europe each year. The 
majority of HNC in the Western world is of squamous cell origin (90% head 
and neck squamous cell carcinoma, HNSCC) and present with locally or 
regionally advanced disease (Rogers et al. 2005). HNSCC represents a group of 
treatment-refractory malignancies derived from cells within the basal epithelia 
of the aerodigestive mucosa (Forastiere et al. 2001). The most important risk 
factors are tobacco and alcohol (Decker et al. 1982; Jacobs et al. 1990; Winn et 
al. 1991; Falk et al. 1989; Nam et al. 1992). Alcohol potentiates tobacco-related 
carcinogenesis and is also an independent risk factor. Epidemiologic studies 
suggest a strong association between smokeless tobacco and oral 
carcinogenesis (Winn et al. 1981; Winn 1992). The use of marijuana is also of 
concern (Jacobs et al. 1990). Occupational risk factors include nickel refining, 
woodworking, and exposure to textile fibers (Decker et al. 1982; Jacobs et al. 
1990; Brown et al. 1988; Muscat et al. 1992). An association of laryngeal 
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cancer with exposure to asbestos remains controversial (Jacobs et al. 1990; 
Muscat et al. 1992). Dietary factors may also play a part (Jacobs et al. 1990; 
Franceschi et al. 1990). Epidemiologic data suggest a protective role of dietary 
carotenoids (Peto et al. 1981) and an inverse association between the 
consumption of fruits and vegetables and the incidence of head and neck cancer 
(Peto et al. 1981; McLaughlin et al. 1988). The specific protective components 
in these foods remain to be identified.  Increasing evidence suggests that viruses 
contribute to the cause of head and neck cancer (Shillitoe et al. 1984; Watts et 
al. 1991; Henle et al. 1976). DNA from human papillomavirus has been 
detected in cancerous tissue from the head and neck, (Watts et al. 1991), and 
infection with the Epstein-Barr virus is associated with nasopharyngeal cancer, 
a rare form of cancer in the United States but a common form in some North 
African and Asian countries. Information on the genetic basis of a possible 
multistep process of carcinogenesis is accumulating. Deletions of chromosome 
3p  (Heo et al. 1989; Sacks et al. 1988; Latif et al. 1992) and other nonrandom 
deletions and rearrangements of chromosomes have been identified in patients 
with head and neck cancer (Jin et al. 1988; Carey et al. 1989). Molecular 
changes include amplification and over-expression of the receptor for 
epidermal growth factor (Kamata et al. 1986; Ishitoya et al. 1989; 
Weichselbaum et al. 1989) and amplification of int-2, bcl-1, and other 
oncogenes (Zhou et al. 1988; Somers et al. 1990). In addition, p53 mutations 
have been described, and their occurrence may relate to the prognosis 
(Brachman et al. 1992; Gusterson et al. 1991). The finding of frequent deletions 
of chromosome 18q in patients with head and neck cancers suggests that other 
tumor-suppressor genes may also be affected (Cowan et al. 1992; Kelker et al. 
1992). 
 
1.8.1 Disabling p53 family network in head and neck cancer 
Like other solid tumors, the p53 pathway is disabled by several mechanism in 
Head and neck squamous cell carcinomas (HNSCC). Early studies using 
immunocytochemisty suggested that p53 alterations are an early event in some 
HNSCC. In contrast, analysis of serial oral lesions biopsied from individual 
patients known to have progressed to oral cancer detected mutations in only 
1/12 dysplasias, but in 6/8 carcinomas. These results suggest that mutation is a 
relatively late event in carcinogenesis in the oral cavity, wherein it is associated 
with acquisition of the invasive phenotype (Shahnavas et al. 2000). Another, 
common molecular abnormality observed in these tumors is over-expression of 
the p53 family member p63. Numerous studies have documented increased p63 
expression in up to 80% of primary HNSCC tumors, and its overexpression is 
also commonly observed in other squamous epithelial malignancies, including 
lung and esophagus (Hu et al. 2002; Massion et al. 2003; Sniezek et al. 2004 
and Weber et al. 2002). p63 maps to chromosome 3q, and human squamous 
cell carcinomas (SCCs) frequently exhibit genomic amplification at 3q 
(Bjorkqvist et al. 1998). The relevance of these observations is supported by 
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data showing that increased p63 mRNA levels correlate with increased p63 
gene copy number in squamous cell carcinomas (SCCs) of the lung and head 
and neck (Hibi et al. 2000). In some cases, overexpression of p63 is likely to 
involve mechanisms independent of genomic amplification (Redon et al. 2001). 
In either case, it is apparent that overexpression of p63 is one of the most 
common molecular abnormalities identified in HNSCC. Nevertheless, the 
precise contribution of p63 overexpression to HNSCC remains undefined. The 
essential function of p63 in the epithelium is evidenced by the phenotype of 
p63 null mice, which exhibit profound developmental failure of the epidermis 
and oral epithelium, as well as abnormalities of limb, prostate, and mammary 
development (Mills et al. 1999 and Yang et al. 1999). Expression from two 
distinct p63 promoters produces protein isoforms that either contain or lack the 
N-terminal transactivation domain (TAp63 and Np63, respectively). 
Differential mRNA splicing also gives rise to multiple C-terminal variants 
(Yang et al. 1998). In both normal epithelia and in HNSCC cells, the 
predominant p63 isoform expressed is Np63 (Parsa et al. 1999 and Yang et 
al. 1998). While few bona fide transcriptional target genes of p63 have been 
identified, Np63 is known to function as a transcriptional repressor of 
endogenous cell cycle inhibitors including p21CIP1, implying a contribution by 
p63 to cellular proliferation (Westfall et al. 2003). Other studies have proposed 
roles for p63 in cell survival, cellular differentiation, and morphogenesis (King 
et al. 2003; Mills et al. 1999 and Yang et al. 1999).  In addition to its role in 
normal epithelia, Np63 has been hypothesized to contribute to tumorigenesis 
based on its ability to inhibit p53-dependent transactivation in vitro following 
ectopic expression of these proteins (King et al. 2003 and Yang et al. 1998). 
Such observations supported a model whereby overexpression of p63 might 
inactivate p53, therefore abrogating the requirement for its loss during 
tumorigenesis. Whether these findings reflect an endogenous function of p63 
remains uncertain, since no consistent correlation has been proven between p53 
mutation and p63 overexpression in SCCs (Choi et al. 2002, Hibi et al. 2000, 
Sniezek et al. 2004 and Weber et al. 2002). Similarly, although ectopic 
Np63 expression can block p73-dependent reporter transactivation, and p73 
and p63 associate in cotransfection assays (Chan et al. 2004), it remains to be 
determined whether endogenous p63 exhibits either a physical or functional 
interaction with p73 in tumor cells. Indeed, it has been proposed that p63 
promotes oncogenesis in HNSCC cells by a distinct mechanism-involving 
enhancement of -catenin-dependent transcription (Patturajan et al. 2002). 
Thus, the contribution of any potential interaction between p63 and other p53 
family members in SCC remains to be defined. Other than direct intrinsic 
biological factors disabling p53 net work in HNSCC, extrinsic a cellur viruces 
(eg. Human paipillomavirus, HPV) are well known. 
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1.8.2 Implications of human papillomavirus in head and neck cancers 
Certain mucosal HPV types, termed high risk HPVs, play a role in the 
pathogenesis of head and neck squamous cell carcinomas (HNSCC) (Schwartz 
et al. 1998; Gillison et al. 2000; Andl et al. 1998; Wiest et al. 2002; van Houten 
et al. 2001; Hafkamp et al. 2003;  Mork et al. 2001). High-risk, oncogenic types 
(eg, HPV16, -18, -31, -33, -35) are defined by their strong epidemiologic 
association with cervical cancer (Munoz et al. 2003). The prototypic high-risk 
types -16 and -18 are capable of transforming epithelial cells derived from both 
the genital and upper respiratory tracts (McDougall 1994). The transforming 
potential of high risk HPVs is largely a result of the function of two viral 
oncoproteins, E6 and E7, which functionally inactivate two human tumor-
suppressor proteins, p53 and pRb, respectively (Munger et al. 2002). 
Expression of high-risk HPV E6 and E7 results in cellular proliferation, loss of 
cell cycle regulation, impaired cellular differentiation, increased frequency of 
spontaneous and mutagen-induced mutations, and chromosomal instability 
(Munger et al. 2002). Emerging lines of evidence support the role of another 
group of HPV in human carcinogenesis: the cutaneous HPVs are classified into 
different genera, of which the genus Beta-papillomavirus contains 23 different 
fully characterized HPV types (previously designated “EV” types). Specific 
cutaneous HPV types have been associated with squamous cell carcinoma 
(SCC) of the skin of individuals with the rare hereditary disease 
Epidermodysplasiaverruciformis (EV) (Jablonska et al. 1994), but such 
association has not been reported for SCC in the general population.  
 
1.8.2.1 HPV DNA presence and expression in HNSCC cancers 
Infection by a high-risk HPV type is now known to be associated with the 
development of cervical cancer. In contrast to cervical cancer, in HNSCC, HPV 
appears to play a carcinogenic role for only a subset (Schwartz et al. 1998; 
Gillison et al. 2000; Hafkamp et al. 2003; Balz et al. 2003; Pintos et al. 1999;  
Snijders et al. 1996; Brandwein et al. 1994; Paz et al. 1997; Fouret et al. 1997; 
Ritchie et al. 2003; Haraf et al. 1996). In a recent meta-analysis, HPV genomic 
DNA was detected in approximately 26% of all HNSCC by sensitive 
polymerase chain reaction (PCR) -based methods (Kreimer et al. 2005). 
However, data are most strong and consistent for HPV presence in 
oropharyngeal cancers. In the majority of studies, 50% or more of 
oropharyngeal tumors contained the HPV genome (Ritchie et al. 2003; Haraf et 
al. 1996; Strome et al. 2002). In a recent multinational study conducted by the 
International Agency for Research on Cancer (IARC), only18% of 
oropharyngeal tumors were HPV positive, indicating that this proportion likely 
varies by geography (Herrero et al. 2003). Regardless of the study population, 
high-risk HPV16 accounts for the overwhelming majority (90% to 95%) of 
HPV-positive tumors, whereas other high-risk types -31, -33, and -35 account 
for the minority (Kreimer et al. 2005; Herrero et al. 2003). For oropharyngeal 
tumors, viral HPV DNA has been specifically localized to tumor cell nuclei, 
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(Gillison  et al. 2000; Hafkamp et al. 2003) is frequently integrated (Gillison et 
al. 2000; Wiest et al. 2002; Hafkamp et al. 2003;  Steenbergen et al. 1995) and 
is transcriptionally active (Gillison et al. 2000; Wiest et al. 2002; Ke et al. 
1999). Furthermore, HPV is present in high copy number in tumor cell nuclei 
of in situ, invasive, and metastatic disease and absent in adjacent normal tissue 
(Begum et al. 2003). These data indicate that HPV infection is specific to tumor 
cell nuclei and that infection precedes histopathologic progression of the tumor. 
Equivalent data are not available for non-oropharyngeal tumors. For instance, 
HPV has not been shown to have an etiologic association with oral tongue 
cancers diagnosed at any age. Although HPV can infect the epithelium of the 
upper aerodigestive tract in general, the tonsil appears uniquely susceptible to 
transformation by the virus. As for the transformation zone of the cervix, the 
reason for this anatomic site specificity for transformation is unknown. A role 
for HPV in oropharyngeal tumors is further substantiated by distinct molecular 
genetic alterations in HPV-positive versus HPV negative tumors. As for many 
cancers, inactivation of the p53 and pRb pathways is a common event in the 
molecular progression of HNSCC. However, inactivation occurs by different 
mechanisms in HPV positive and -negative tumors. In HPV-positive HNSCC, 
genetic alterations are reflective of viral oncogene function. For instance, HPV-
positive tumors tend to have wild-type p53, because p53 is functionally 
inactivated by viral E6 oncoprotein (Brachman et al. 1992; Chiba et al. 1996). 
By contrast, HPV-negative tumors have specific p53 mutations demonstrated to 
be induced by carcinogens in tobacco smoke (Gillison et al. 2000; Wiest et al. 
2002; Hafkamp et al. 2003; Brachman et al. 1992; Chiba et al. 1996). As 
another example, pRb function is inactivated by viral E7 protein in the HPV-
positive tumor, but in HPV-negative tumors, the pRb pathway is altered by 
other mechanisms, including amplification of cyclin D and inactivation of 
p16INK4a (Andl et al. 1998; Wiest et al. 2002; Hafkamp et al. 2003; Begum et 
al. 2003). More complex differences in regions of chromosomal loss and gain 
have been demonstrated in HPV-positive versus -negative tumors through 
techniques such as comparative genomic hybridization (Smeets et al. 2005) and 
microsatellite analysis (Braakhuis et al. 2004). 
 
1.9 EGFR and solid tumors 
The Epidermal growth factor receptor (EGFR also known as ErbB1 or HER) 
was the first receptor identified of the ErbB family of receptors (Sato et al. 
1983). Since then, the ErbB family proteins have increased to four, including 
EGFR-1 itself (HER- 1, ErbB1), HER-2 (ErbB2), HER-3 (ErbB3) and human 
HER-4 (ErbB-4) (Carpenter  et al. 1987).  The EGFR, a 170 kDa glycoprotein, 
consisting of an extra-cellular domain, a transmembrane region and an 
intracellular domain with tyrosine kinase function, responds to numerous 
ligands, such as transforming growth factor alpha (TGFa), betacellulin, 
amphiregulin, epiregulin, EGF and heparinbinding EGF (Rogers et al, 2005).  
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In the early 1980s, the discovery that alterations in the EGFR signaling 
pathway contribute to malignant transformation was initially made in studies of 
oncogenic viruses that demonstrated that the EGFR is the cellular homolog of 
the avian erythroblastosis virus v-erbB oncogene. This encodes a truncated 
EGF receptor (or closely related protein) lacking the external EGF binding 
domain but retaining the transmembrane domain and the domain involved in 
stimulating cell proliferation (De Larco et al. 1980; Downward et al. 1984; 
Roskoski et al. 2004). Subsequently, it was discovered that activation of the 
EGFR signaling pathway mediates the malignant transformation of virus-
infected cells (Miller et al. 1995). Furthermore, over-expression of members of 
the ErbB family, EGFR and ErbB2, has been demonstrated to induce malignant 
transformation in NIH-3T3 cells (Di Fiore et al. 1987). Malignant 
transformation as a consequence of EGFR dysregulation can occur in humans 
by different mechanisms, including receptor over-expression, activating 
mutations, alterations in the dimerisation process, activation of autocrine 
growth factor loops, limited or enhanced endocytosis of activated receptor, 
deficiency of specific phosphatases deactivating the phosphorylated EGFR 
tyrosine residues, and limited turnover. EGFR gene over-expression, without 
gene amplification, and EGFR activation, by TGF- in an autocrine loop, are 
two of the main frequent mechanisms implicated in cancer development and 
progression (Athale et al. 2006; El-Obeid et al. 2002). Moreover, it has been 
reported that EGFR is mutated in some cancers and this is particularly 
prevalent in glioblastoma (Collins et al. 1994). While multiple types of 
mutations have been found, one specific mutation is far and away the most 
common. This mutation results in the expression of a truncated EGFR 
designated EGFRvIII (also referred to as del2-7 EGFR or EGFR in the 
literature) (Yamazaki et al. 1990; Wong et al. 1992). In this mutation, the 
information coded for by exons 2 through 7 of the 26-exon EGFR gene is lost. 
Transcription of the mutated gene gives rise to an mRNA with an 801 base pair 
deletion. This deletion is in-frame, and a new glycine codon is formed at the 
fusion junction. Translation of this mRNA in turn gives rise to an EGFR in 
which amino acids 6–273 are replaced by a single glycine residue, resulting in 
a 145-kDa glycoprotein with constitutive, ligand-independent activation of the 
receptor's tyrosine kinase activity (Chu et al. 1997; Moscatello et al. 1998). 
Other than this well known truncated EGFR variant, single nucleotide somatic 
missense mutations, as well as small in-frame deletions and insertions have 
recently been reported in the EGFR tyrosine kinase domain. These somatic 
mutations (L858 and del747–752) also appear to be oncogenic in nature, and 
may provide insights into the potential role of altered EGFR signaling 
pathways in tumorigenesis (Jiang et al. 2005; Greulich et al. 2005). Many cell 
types normally and widely express EGFR, including those of epithelial and 
mesenchymal lineages (Wells 1999). The variability in over-expression or 
dysregulation of EGFR has been also described for human malignancies 
(Nicholson et al. 2001). Epidemiological evidence accumulated over the last 22 
years in human tumors supports the notion that aberrant EGFR expression and 
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signalling contribute to the development of multiple epithelial malignancies in 
humans including squamous carcinomas of the head and neck and breast cancer 
among others (Ibrahim et al. 1997).  
 
1.9.1 Epidermal Growth Factor Receptor Signaling in HNSCC  
In normal cells, the expression of EGFR ranges from 40,000 to 100,000 
receptors per cell (Carpenter et al. 1979). In SCCHN, EGFR and its ligand, 
TGF-α, are over-expressed in 80-90% of cases; the corresponding magnitudes 
of increase are 1.7-fold (P=0.005) and 1.9-fold (P=0.006) respectively, when 
compared to controls (Grandis et al. 1998).The nature of the protein 
overexpression is thought to result from enhanced transcription, with no 
apparent change in mRNA stability; gene amplification has been observed less 
frequently.  EGFR overexpression is an early event in HNSCC carcinogenesis; 
it is already present in “healthy” mucosa (field cancerization) from cancer 
patients, when compared to healthy controls; this overexpression will increase 
steadily in parallel to observed histological abnormalities, from hyperplasia to 
invasive carcinoma, through dysplasia and in situ carcinoma (Rubin Grandis et 
al. 1996).  Dysregulated p53, polymorphisms in dinucleotide repeats in intron 1 
of the EGFR gene and EGFR amplification can all lead to increased EGFR 
mRNA synthesis. However, EGFR gene amplification was only observed in 
seven out of 33 patients with SCCHN and did not correlate with EGFR protein 
overexpression, suggesting that gene amplification is not pathogenetically 
involved in EFGR protein overexpression (Mrhalova et al. 2005). Furthermore, 
overexpression of cortactin may inhibit ligand-induced EGFR downregulation. 
Interestingly, tobaccos smoke increases EGFR ligand levels (e.g. amphiregulin 
and TGF-α) culminating in EGFR activation and increased levels of 
cyclooxygenase 2 and prostaglandin E2, which can transactivate EGFR 
(Kalyankrishna and Grandis 2006). Recently, three identical in-frame deletions 
in exon 19 (E746_A750del) of the EGFR gene were reported in three out of 41 
(7.3%) Korean SCCHN cases (Lee et al. 2005). In contrast, EGFR kinase 
domain mutations were rare among US (zero out of 65) or European (one out 
of 100) SCCHN cases (Cohen et al. 2005; Loeffler-Ragg et al. 2006). 
Interestingly, one gefitinib-responsive SCCHN patient harboured a 
heterozygous mutation within ErbB2 (V773A) (Cohen et al. 2005). ErbB2 
heterodimerises with EGFR and ErbB2 mutations have recently been reported 
within a subset of non-small cell lung cancer (NSCLC). Epidermal growth 
factor receptor vIII, a deletion of exons 2–7 resulting in a truncated 
extracellular domain and constitutive tyrosine kinase activation, has been 
reported in SCCHN (42%); (Sok et al. 2006). Downstream effects of EGFR 
activation after receptor dimerisation, internalisation and autophosphorylation 
are mediated through several signal transduction pathways involving the RAS/ 
MAP kinase, the phosphatidylinositol 3-kinase (PI-3K)/Akt, the PLCg and the 
JAK-STAT pathways (Rogers et al. 2005; Kalyankrishna and Grandis 2006). 
Although the main autophosphorylation sites in ErbB receptors recruit 
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extensively overlapping molecules to the active receptors, preferential 
modulation of signaling pathways seems to occur (e.g. EGFRs with kinase-
domain mutations preferentially activate the pro-survival PI-3K/AKT pathway 
and the STAT pathway). Downstream effectors of EGFR (e.g. ERK-1/2, AKT, 
STAT-3/5) are activated in SCCHN (Kalyankrishna and Grandis 2006). 
Furthermore, EGFR can be activated by other receptor tyrosine kinases 
including insulin-like growth factor-1 receptor, adhesion molecules (e.g. E-
cadherin and integrins) and G-protein-coupled receptors (GPCR).  
 
1.10 Head and Neck Cancer Therapy 
Head and Neck cancer patients with early-stage disease are treated with surgery 
and/or radiotherapy and nearly 80% are cured. Chemotherapy added to 
locoregional treatment provides a demonstrated survival benefit in 
nonmetastatic SCCHN (Pignon et al. 2000). However, despite combined 
treatment approaches (surgery and radiation/chemoradiation therapy) most 
patients with resectable advanced disease develop local or regional recurrences 
(50–60%), metastatic disease (20%) or secondary primaries. Patients with 
unresectable advanced disease have a 5-year survival of 10% and 
recurrent/metastatic cases have a median survival of approximately 6–9 
months, which has not changed significantly for 30 years. Several therapeutic 
options are available for these patients, including irradiation, salvage surgery, 
palliative chemotherapy or best supportive care for patients with low 
performance status. The most commonly used agents are cisplatin or 
carboplatin, often in combination with taxanes or 5-fluorouracil. Response rates 
(RR) to first-line platinum-based chemotherapy are only 30%. In recurrent/ 
metastatic SCCHN, survival benefits of 10 weeks may be expected (Morton et 
al. 1985; Browman and Cronin 1994). Although several combinations of 
classical chemotherapeutics have increased RR, improved survival has not been 
observed. Options and RR of patients refractory to platinum-based therapies are 
generally very poor. Therefore, there is clearly an unmet therapeutic need for 
new active, less toxic agents for SCCHN treatment. In recent years, the field of 
cancer therapy has witnessed the emergence of novel targeted strategies that 
inhibit specific cancer pathways and key molecules in tumor growth and 
progression. Among them, one class of compounds that has shown great 
progress is those targeting tyrosine kinases (TKs), their ligands, and signal 
transducers. Over 20 years ago, Mendelsohn et al proposed that the EGFR was 
a target for cancer therapy (Mendelsohn et al. 2003; Kawamoto et al. 1983; 
Sato et al. 1983). With two classes of anti-EGFR agents with established 
clinical activity in cancer, this hypothesis has now been confirmed. These are 
monoclonal antibodies directed at the extracellular domain of the receptor and 
small molecule, adenosine triphosphate (ATP) -competitive inhibitors of the 
receptor’s TK (Mendelsohn et al. 2003).  
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1.10.1 Targeting EGFR in HNSCC 
Two principal methods to inhibit EGFR have been identified and are being 
used in clinical trials, small molecule inhibitors of EGFR and antibodies to 
EGFR. Two small molecule inhibitors, ZD1839 and erlotinib HCl, OSI-774, 
and one antibody, C225 (IMC-C225) have been evaluated in SCCHN. Each of 
these inhibitors has unique mechanisms of action and pharmacodynamics. The 
small molecule inhibitors can be delivered orally and specifically inhibit the 
enzymatic function of the EGFR. Antibodies can perform diverse functions, 
including blocking of ligand/receptor binding, immune functions, and removal 
of target from the cell surface by ingestion or secretion. C225 prevents binding 
of activating cytokines to the EGFR and causes EGFR movement into the 
cytoplasm, where it is sequestered and unavailable. Inhibition of EGFR, either 
by antibodies or small molecule inhibitors, can cause tumor regression in 
animal models of human tumors; however, slowing or stabilization is a more 
common effect. More robust anti-tumor activity is observed when the inhibitors 
are combined with standard chemotherapy agents and radiotherapy. This is 
because EGFR activation seems to protect malignant cells from chemotherapy- 
and radiotherapy-induced cell death. Blocking EGFR activation enhances 
tumor specific destruction by standard chemotherapy agents and radiotherapy. 
ZD1839 has been shown to inhibit EGFR activation and downstream signaling 
in normal skin at doses acceptable for both primary and combination therapy. 
Phase 1 testing with ZD1839 suggests activity in SCCHN (Albanell et al. 2002; 
Albanell et al. 2001; Ranson et al. 2002). Ultimately, the role of ZD1839 and 
C225 and other inhibitors in the treatment of primary or recurrent SCCHN will 
depend on the outcome of combination trials that explore the potential 
interactions with many different standard treatments, including taxanes, 
anthracyclines, biologics, and radiotherapy techniques. It should be 
remembered that it has taken many years to explore the potential of drugs like 
interferon or 5-fluorouracil, and to understand how to use them optimally in 
patients. We should expect that it would take some time to understand how to 
use this whole new family of TKIs including erlotinib, and newer agents such 
as the ErbB family TKI, CI-1033.  
 
1.10.1.1 EGFR TKIs 
Both ZD1839 (Gefitinib) and OSI-774 (formerly known as CP-358-774, 
Erlotinib) have FDA approval for treatment of locally advanced or metastatic 
NSCLC since May 2003 and November 2004, respectively. Three orally active 
EGFR inhibitors have been tested in clinical trials in recurrent/metastatic 
SCCHN or in combination with radiotherapy in locoregionally advanced 
SCCHN. Gefitinib (IressaR, AstraZeneca Pharmaceuticals, London, UK) 
impeded in vitro and in vivo growth of cell lines that express high, intermediate 
or low levels of EGFR and high levels of HER-2. Furthermore, gefitinib has 
additive or synergistic properties in combination with cisplatin, carboplatin, 
paclitaxel, taxanes, doxorubicin and radiotherapy. A phase II trial of 500 mg 
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gefitinib in 52 patients with recurrent/metastatic HNSCC reported an RR of 
10.6% and a DCR of 53%  (Cohen et al. 2003). Squamous cell carcinomas of 
the head and neck responses to gefitinib or erlotinib seem not to be linked to 
EGFR kinase mutational status, as these mutations are rare in this disease 
(Cohen et al. 2005). Recently, a phase I study in SCCHN reported that gefitinib 
(250/500 mg q.d.) in combination with celecoxib (200/400 mg b.i.d.) is very 
well tolerated in patients with incurable SCCHN (Wirth et al. 2005). 
 
1.10.2 p53 family proteins influence in Head and Neck Cancer Therapy 
Historically, the p53 gene was considered the most important determinant of 
response to radiotherapy or chemotherapy. Many studies conducted during 
1980– 1990 that aimed to correlate the response to treatment with p53 gene 
expression produced conflicting results (Partridge et al. 2005). It is now known 
that apoptosis is a fundamental mechanism of cell death following treatment 
with cytotoxic agents. Wild-type p53 may enhance chemosensitivity by 
promoting apoptosis, and some studies have suggested that the presence of a 
p53 mutation is associated with a lower response to chemotherapy 
(Cabelguenne  et al. 2000; Cutilli et al. 1998 and Fouret et al. 2002). 
Contradictory studies have also been reported, in that tumours that over-
expressed p53 were more responsive to cisplatin than those that did not express 
(Honeycutt et al. 2004). Recent investigations have shown that some of this 
variation in chemosensitivity may be due to a common sequence polymorphism 
of the p53 gene that results in either proline or arginine at amino acid position 
72. This Arg 72 polymorphism is associated with a good response to 
chemotherapy and radiotherapy in clinical trials (Bergamaschi et al. 2003). 
This effect is not due to p53 acting alone, as TA p73 is also induced by many 
chemotherapeutic agents and reinforces the apoptotic response to 
chemotherapy. The accumulating evidence converges on the view that p73 
plays a significant role in curative anti-cancer therapy. Similar to p53, activated 
p73 mediates a cellular response to radio and chemotherapy, including -
irradiation and treatment with cisplatin, doxorubicin, camptothecin, etoposide, 
bleomycin, mitoxantrone, taxol, and the cytosine analogues gemcitabine, Ara-C 
and T-ara-C (Agami et al., 1999; Costanzo et al., 2002; Gong et al., 1999; 
Thottassery et al., 2006; Vayssade et al., 2005). For instance, cisplatin, which 
several groups have found to activate and stabilize the p73 protein, does not 
induce p73 mRNA. Doxorubicin and taxol can induce p73 mRNA and protein 
at the same time. In contrast, -irradiation increases the p73 protein activity 
without affecting the protein or mRNA levels (Agami et al., 1999; Hamer et al., 
2001). However, other studies reported accumulation of p73 following _-
irradiation (Dai et al., 2007; Lin et al., 2004). It is worth noting that p73 protein 
accumulation can be transient and depend on a treatment regiment (Irwin et al., 
2003; Lin et al., 2004). TAp63 isoforms are also induced by various genotoxic 
agents, although their effect appears to be weaker than that of p53 and TAp73. 
Similarly, TAp63 can be a determinant of chemotherapeutic efficacy in some 
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cell types as inhibition of endogenous TAp63 with siRNA leads to a decreased 
chemosensitivity (Gressner et al., 2005). Combined loss of p73 and p63 results 
in the failure of mouse embryonic fibroblasts containing p53 to undergo 
apoptosis in response to DNA damage (Flores et al., 2002). N isoforms of p73 
and p63 as well as mutant p53 are also involved in cross regulation. Upon 
treatment with doxorubicin, Np73 and mutant p53 associate with the Np63 
promoter and induce the Np63 transcription through proximal CCAAT boxes. 
This may have an anti-apoptotic effect and induce chemo-resistance (Lanza et 
al., 2006). In head and neck tumors, high Np63 protein levels correlate with a 
favorable response to platinum-based therapy (Leong et al., 2007; Zangen et 
al., 2005). It suggests that the dominant negative concept cannot explain all 
complexity of interactions attributed to N isoforms. These interactions are 
determined by cellular context and should be analyzed through a prism of 
multiple interactions within and beyond the p53 family. Moreover, how p53 
family network influence to newly developed molecular drugs, e.g. Gefitinib 
yet to be characterized. 
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2. AIMS OF THE STUDY 
 
p53 family protein netwok in cancer biology has atained much importance 
because of its redundant functions in normal versus cancer cells as well as this 
redundancy influences to different modes of anti-cancer therapy. In almost all 
cancers, including HNSCC development, at some stage of signal transduction 
pathway, p53 network has been disabled and that causes the immortalization 
potential of a single cell to advanse to an metastatic carcinoma. Recently, the 
discover of p53 family p63 and p73 proteins similarity with p53 indicates that 
it has some more redundant functions related with p53 as their truncated 
isoforms can act as a dominant negative effect on p53 and their parental 
proteins p63 and p73 itself. Moreover, detailed analysis of p53 functional role 
indicates a positive role in normal cell survival but it is unknown if this cell 
survival function has an over advantage, in cancer cells expressing wild type 
p53 protein. Accordingly, studies from our lab have showed that HPV38 
mediated immortalization of human keratinocytes accumulate wild type p53 
hyperphosphorylated at serine15 and 392 which leads to the overexpression of 
∆Np73 isoform and likely assists cell survival. Therefore, we have tried to 
molecularly characterize accumulated wild type p53 properties and functions in 
HPV positive and negative cancer cell lines as using HNSCC cell lines as a 
study model. Along with our molecular cancer biology studies, we aim to 
identify how p53 family network influences to new molecular based 
therapeutic strategies. One of the more promising is the utilisation of tyrosine 
kinase (TK) inhibitors, targeting epidermal growth factor receptor (EGFR) in 
HNSCC. Therefore: as a prelimenary step, we aim to characterise basic features 
of newly established HNSCC cell lines; including, morphological features, cell 
cycle and ploidy analysis, doubling time and HPV detection. Moreover, we 
have aimed as follows;  
 
 The first aim of this study was to understand in detail of p53 family 
network in these cell lines that includes, p53 mutation analysis, 
expression and its cellular localization. And other p53 family proteins, 
p63 and p73 and their main isoforms expressions and dominant 
negative effects in HNSCC. 
 The second aim was to understand properties and functions of 
accumulated wild type p53 role in HPV positive and negative cancer 
cell lines 
 Characterization of EGFR family receptors and its major down stream 
effectors status in this large panel of cell lines 
 Specific EGFR inhibitor, gefitinib effectiveness and mode of action in 
this large panel of HNSCC cell lines 
 Comparison between the targets analyzed and gefitinib effectiveness 
 Chemoresistance in head and neck cancer cell lines 
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3.  MATERIALS AND METHODS 
 
Reagents 
3.1.a. Chemical reagents 
General laboratory reagents were obtained from a variety of suppliers and were 
of analytical grade or purer. Sources of reagents are always stated whenever 
they are used in the method description. The composition of the various 
solutions used is always stated whenever they are used in the methods 
descriptions. 
 
Acrylamide  (Gibco) 
Agarose  (Gibco) 
Ampicillin  (Sigma) 
BCA Protein assay reagents  (Pierce) 
Calf serum (Sigma) 
ECL detection reagent (Amersham) 
Foetal calf serum (Life Technologies) 
Ligase buffer (Boehringer Mannheim) 
DNA Mass loading dye (Fermentas) 
3MM Gel blotting paper (Schleicher and Schuell) 
Polyscreen PVDF transfer membrane (NEN Life Science Products)  
Powder milk (Sigma) 
Trypsine/EDTA 0.125% (Gibco-Invitrogen) 
PBS – Phosphate Buffered Saline (Cambrex) 
DMSO – Dimethyl sulfoxide (Merck) 
DMEM – Dulbecco’s modified Eagle’s medium (Sigma) 
L-Glutamine (Gibco-Invitrogen) 
Pen-strep (Gibco-Invitrogen) 
3.1.b Compounds 
 
Gefitinib (originally coded ZD1839), N-(3-chloro-4-fluoro-phenyl)-7-
methoxy- 6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine, was kindly 
provided by Astra Zeneca (Pharmaceuticals, Macclesfield, UK).  
 
Figure 5 : Chemical structure of ZD1839 
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Stock solutions were prepared at 20mM in 100% dimethylsulfoxide (DMSO) 
and stored in aliquots at -20°C. From stock solutions, required concentration 
prepaired by diluting with culture media before use.  
 
Cisplatin, cisplatinum or cis-diamminedichloridoplatinum(II) (CDDP), was 
purchased from Sigma Chemical Co. (St Louis, MO) 
 
Figure 6: Chemical structure of Cisplatin 
 
 
Gemcitabine, 4-amino-1-[3,3-difluoro-4-hydroxy-5- (hydroxymethyl) 
tetrahydrofuran-2-yl]- 1H-pyrimidin- 2-one, was purchased from Eli Lilly 
(Indianapolis, IN). 
 
Figure 7: Chemical structure of Gemcitabine 
 
 
PD 098059, was purchased from Cell Signaling Technology, Inc. (Beverly, 
MA). 
 
Figure 8: Chemical structure of PD 098059 
 
 
 
PD 098059 was dissolved in dimethyl sulfoxide (Me2SO) to give a 
concentration of 50 mM, stored in aliquots at -80 °C, and diluted in aqueous 
buffers to <100 µM immediately prior to use. For studies in vitro, PD 098059 
or the equivalent amount of (Me2SO) carried over with the drug was incubated 
with target cells for 48 hours. 
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3.1.c. Biological materials 
 
Kits 
 
Taq DNA Polymerase recombinant (Invitrogen) 
dNTPs set PCR grade (Invitrogen) 
Absolutely RNA miniprep kit (Stratagene) 
First strand cDNA synthesis kit (Fermentas MBI) 
 
Markers 
 
DNA size markers 
DNA/HindIII                             (Fermentas) 
Mass Ruler DNA Ladder Mix     (Fermentas) 
 
Protein size marker 
 
RAINBOW molecular weight standard prestained marker (Amersham) 
 
3.2 DNA constructs 
 
The following retroviral vectors were used: pBabe (described by Caldeira et al, 
2003), and pRetroSuper (Screeninc, Amsterdam, The Netherlands). Np73a 
complementary DNA, kindly provided by Ute Moll (Stony Brook, US), was 
cloned in pBabe. p53 expression was silenced using the oligonucleotides listed 
in Table 1. 
 
 
Table 1 
 
Primer Sequence 
siRNA p53  
5_-CAAUGGUUCACUGAAGACC-3_ 
siRNA scranble  
5_-CAUAGAUUACCGUGAGCAC-3_ 
         
Table 1. Sequences of different primers used for gene silencing. 
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Table 2 
 
Genes/promoters Primer sequence 
Human GAPDH 
(RT PCR) 
F. 5_-AAGGTGGTGAAGCAGGCGT-3_ 
R. 5_-GAGGAGTGGGTGTCGCTGTT-3_ 
Human-∆Np73 F. 5’-AACCATGCTGTACGTCGGTGACCCC-3’ 
R. 5’-GCGACATGGTGTCGAAGGTGG-3’ 
Human-∆N’p73 F. 5’-TCGACCTTCCCCAGTCAAGC-3’ 
R. 5’-TGGGACGAGGCATGGATCTG-3’ 
∆Np63 
 
F. 5’-TGC CCA GAC TCA ATT TAG TGA G-3’ 
R. 5’-AGA GAG AGC ATC GAA GGT GGA G-3’ 
 
 
TAp63 
 
F. 5’-GAC CTG AGT GAC CCC ATG TG-3’ 
R. 5’-CGG GTG ATG GAG AGA GAG CA-3’ 
 
Human-TAp73 F. 5’-AACCAGACAGCACCTACTTCGACC-3’ 
R. 5’-GCGACATGGTGTCGAAGGTGG-3’ 
 
Human SCO2 
 
Forward 5’-GCA GCC TGT CTT CAT CAC TGT GGA 
CC-3’ 
Reverse 5’-CCG CAC ACT GTC TGA GAT CTG CTC-3’ 
 
Human EGFR 
 
EXON 18 
 
 
EXON 19 
 
 
EXON 20 
 
 
EXON 21 
 
EXON27 
 
 
EXON28a 
 
 
EXON28b 
 
Fw 5' CAAATGAGCTGGCAAGTGCCGTGTC 3' 
Rv 5' GAGTTTCCCAAACACTCAGTGAAAC 3' 
 
Fw 5' GCAATATCAGCCTTAGGTGCGGCT 3' 
Rv 5' CATAGAAAGTGAACATTTAGGATGTG 3' 
 
Fw 5' CCATGAGTACGTATTTTGAAACTC 3' 
Rv 5' CATATCCCCATGGCAAACTCTTGC 3' 
 
Fw 5' CTAACGTTCGCCAGCCATAAGTCC 3' 
Rv 5' GCTGCGAGCTCACCCAGAATGTCTGG 3' 
 
27 Fw 5' CAACCTACTAATCAGAACCAGCATC 3' 
Rv 5' CCTTCACTGTGTCTGCAAATCTGC 3' 
 
Fw 5' CCTGTCATAAGTCTCCTTGTTGAG 3' 
Rv 5' GGTAGTCAGGGTTGTCCAGG 3' 
 
Fw 5' CGAGTATCTCAACACTGTCCAGC 3' 
Rv 5' CTAATGCGGGCATGGTG 3' 
 
Table 2. Sequences of the different primers used for PCR and RT- PCR analyses. The 
sequences of forward (F) and reverse (R) primers for gene listed in the table are shown. 
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3.3 Cell culture 
3.3.1. Cultivation conditions 
Used cell lines were cultivated in Dulbecco´s Modified Eagle Medium 
(DMEM). Before using the medium 100 U/ml Penicillin, 0.1 mg/ml 
Streptomycin and 2 mM Glutamine were added. To cultivate NIH/3T3 the 
medium was supplemented with 10 % calf serum (CS), whereas for all other 
cell lines 10 % foetal calf serum (FCS) was used. The serum was inactivated 
before use by a 45 min incubation period at 55°C. The cultivation was done in 
either, flasks, dishes or multi-well plates in an incubator producing a water 
saturated environment of 37°C and 5 % CO2 concentration. To reduce the risk 
of infections and contaminations when handling cells, work was always done 
under a laminar flow. Before adherent cells reached confluency they were 
trypsinised and split. For this, the culture medium was removed and the cells 
were washed twice with 37°C warm PBS and the appropriate amount of 
trypsin/EDTA solution (3 ml for a 175 cm2 flask) was added. The cells were 
incubated at 37°C and monitored under the microscope. As soon as over 80 % 
of the cells were floating, medium was added (10-20 ml for a 175 cm2 flask) 
and the cells were dispersed by pipetting up and down a few times. Counting of 
cells can be done at this stage (see below). The suspension of cells was then 
divided accordingly, pipetted into different culture vessels and filled up with 
medium. Phoenix, was grown in DMEM supplemented with 10% fetal calf 
serum.  
 
Primary human keratinocytes were isolated from skin of adult individuals as 
previously described (Caldeira et al, 2003) and grown together with NIH 3T3 
feeder layers in FAD medium containing 3 parts Ham’s F12, 1 part DMEM, 
5% fetal calf serum, insulin (5 g/ ml), epidermal growth factor (10 ng/ml), 
cholera toxin (8.4 ng/ml), adenine (24 g/ml), and hydrocortisone (0.4 g/ml). 
Feeder layers were prepared by irradiating NIH 3T3 (137Cs; 80 Gy). 
 
3.3.2 Counting of cells 
For the growth rate of cultured cells the initially added cell number is an 
important factor. Thinly seeded cells will grow only very slowly, whereas high 
initial number will mean cells have to be split very often. Hence, counting of 
cells is a good method to get the right cell density at the desired time point. A 
fast and efficient tool is the Neubauer counting chamber. This chamber consists 
of nine big squares, which have an area of 1 mm2. With a depth of 0.1 mm this 
gives a volume of 0.1 µl. The surface of the chamber and the cover slip should 
be cleaned with 70 % ethanol. The cover slip should be moistened slightly and 
pressed onto the counting chamber, until Newton rings appear between the 
chamber and cover slip. 10 µl of a homogenous suspension of cells can be 
applied to the corner of the cover slip. The suspension moves into the chamber 
by capillary force. Counting can subsequently be done under the microscope. 
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At least four big squares should be counted to calculate the average. The actual 
cell number per ml is calculated by multiplying the average of the four squares 
by 10000.  
 
3.3.3 Freezing and thawing of cells 
For freezing, eukaryotic cells were detached from the culture vessel as 
described in point 3.3.1. The cell suspension was transferred into a 15 ml sterile 
tube and centrifuged for 10 min at 1,000 g. The pelleted cells are carefully 
resuspended in 5 ml cold Cell Culture Freezing Medium and then pipetted as 1 
ml aliquots into cryo vials. The vials were placed into a cryobox (Cryo 1°C 
Freezing Container, Nalgene) which was cooled by Isopropyl alcohol and 
stored for 24 h at -70°C. This gentle procedure allows the cells to freeze slowly 
(-1°C/min) leading to higher viability when thawing. After the 24 h period the 
cells were transferred to liquid nitrogen for long term storage. For the thawing 
of cells a cryo vial is placed for 5 min at 37°C and immediately resuspended in 
10 ml pre-warmed medium. To remove the toxic DMSO included in the Cell 
Culture Freezing Medium the cells were centrifuged, resuspended in fresh 
medium and seeded into a culture vessel. After approx. 24 h the condition of 
the cells was checked and the medium was changed.  
 
Cell Culture Freezing Medium: DMEM 
20 % FCS or CS 
7 % DMSO 
3.4 In-vitro growth-inhibition assay 
As our most cell lines are very slow in growth, cells were seeded at a density of 
10,000-12,000 cells per well in 96-well plates and allowed to attach for 24 
hours. Cells were then treated with various concentration of EGFR inhibitor 
(Iressa) (0.001 to 100M) in the presence of 10% serum for 72 hours, at the 
end of which 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) reagent (5mg/ml) was added to each well. After an incubation of 1 hour, 
absorbance was read at 570nmol/L. Values for control cells were considered as 
100% viability. 
 
3.5 Retroviral infections  
Virus production 
Day 0; Plate 2.5 x 106 Phoenix packaging cells in 9 ml medium/10 cm dish in 
the afternoon. It is very important to have good single cells suspensions 
(trypsinize well) and to evenly distribute the cells. Day1; Transfect cells with 
20 µg DNA (±24 hrs after plating), using CaPO4 precipitation. At the moment 
of transfection the cell density should be ± 40-50% such that the cells will be 
about 90% confluent at Day 3 and completely confluent at Day 4. In a 2 ml 
eppendorf tube mix: 50 µl of 2.5 M CaCl2, 20 µg DNA (Qiagen prep purified, 
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pBabe vector) and makes up to total of 500µl with serum free DMEM. While 
vortexing the tube, slowly add 500µl 2x HBS drop by drop. Add the 1 ml mix 
drop by drop to the cells in medium and evenly distribute by swirling the plate. 
Place cells back in incubator. Day 2; Change medium 5-20 hours after 
transfection. Late in the afternoon or in evening replace medium with 9 ml of 
fresh medium. Day3;  Collect first supernatant (this is 48 hrs after transfection 
and not later than 24 hrs after changing medium): Remove virus-containing 
medium and set aside for a moment to supply the packaging cells with 9 mls of 
fresh medium (1-2 plates at a time). 2. Filter the virus-containing medium 
through a 0.45 µm filter and immediately use for infection.  
 
Retroviral Infection 
Day 0 Plate cells at a density such that they are growing well for the entire 
duration of infection and will be confluent at the end of infection (Day 3), 
about 40% confluent. For single round of infection: Day 1; If target cells grow 
in same medium as packaging cells: Add 4µ g/ml Polybrene to virus (from 100 
x stock), remove medium and cover cells with virus + Polybrene: 12-well plate: 
300-500 µl/well 6-well plate: 750-1000 µl/well T25/5 cm dish: 1.5 ml 10 cm 
dish: 4.5 ml. If target cells grow in different medium as packaging cells (not in 
DMEM): Perform the infection using viral supernatant in Phoenix cell medium 
that is only supplemented with polybrene and not with the medium of the target 
cells. This means that the infection efficiency will drop because the cells are 
not growing as optimal as they could be, but this method is better than using 
virus in other medium. Day 1;  6-8 hrs later: Add medium (the type in which 
the target cells grow) to the virus incubations to dilute the Polybrene which is 
toxic at concentrations higher than 2 µg/ml. e.g to: 500 µl of virus, add 750 µl 
of medium 1 ml of virus, add 1.5 ml medium 1.5 ml of virus, add 2 ml medium 
4.5 ml of virus, add 6 ml medium Grow cells like this for 48 hrs after start of 
infection (until Day 3) before splitting or starting antibiotic selection. 
 
Required Solutions 
Polybrene 
Stock is 10,000x in medium stored at 4°C (40 mg/ml) and user stock is 100x. 
Final concentration is 4 g/ml. 
Medium for Phoenix cells: 
DMEM, 10% FBS, 1% Non-essential amino acids, 1% Pen-Strep, 1% 
Glutamate Store medium at 4°C, warm to 37°C before use. 
2.5 M CaCl2, Filter sterilize and store aliquots at -20°C 
2x HBS 
50 mM HEPES pH 7.05 
10 mM KCl 
12 mM Dextrose 
280 mM NaCl 
1.5 mM Na2HPO4 (FW 141.96) 
 53
The final pH of the solution should be 7.05 +/- 0.05. Filter through a 0.2 m 
filter, aliquot, and store at -20°C. Try to avoid multiple freeze/thaw cycles. To 
thaw, warm to room temperature and invert or vortex the tube to achieve 
uniform mixing. Although it is unclear why this occurs, the ability of the 2x 
HBS solution to produce working CaPO4 precipitates deteriorates after 6 
months to one year, even when the 2x HBS solution is stored at -20°C. 
 
3.6 Transfection of cells using Fugine 
One day prior to transfection, 2 x 105 both HPV38 and HNSCC cells cells  
were seeded into sterile 6-well plates and cultured in 2 ml of DMEM 
supplemented with 10% FCS, 1% L-glutamine, and 1% of penicillin and 
streptomycin (FAD medium was used for HPV38 keratinocyts). Following, 
overnight incubation at 37°C/5% CO2, with humidity, 60% confluency resulted 
for each well. Cells were then transfected with siRNA against p53 and 
scrample, using FuGENE® 6 transfection reagents. According to transfection 
protocols for FuGENE® 6 Transfection Reagent, DNA solution containing 10 
µg siRNA was diluted in 100 µl of serum-free Opti-MEM, and various 
transfection reagent:DNA ratios were prepared for each transfection. The 
mixtures were then vortexed and incubated at room temperature for 15 minutes. 
In the meantime, the culture medium in the 6-well plates was removed and 
cells were washed with 1x PBS. 900 µl of fresh serum-free Opti-MEM and 100 
µl of transfection mixture were mixed and added to each well. Fresh medium 
was added following overnight incubation. All cells were then cultured for 
another 2 days. Two days after transfection, cells were washed twice with 1x 
PBS and collected for protein and RNA isolation and  senescence detection 
procedure was followed. 
 
3.7 Immunofluorescence 
To be able to detect antigens in living cells, the cells can be fixed and stained 
with the desired primary antibodies. The secondary antibody, which binds to 
the first, can be labelled with various dyes, which can in turn be detected in the 
microscope, when excited with light of certain wavelengths.  Cells were seeded 
into 6-well plates, each well containing glass cover slips. To reach a confluency 
of approx. 60% before transfection 1x105-1.5x105 cells were seeded 3 days 
before or 2.5x105 cells were seeded the day before transfection. 24-30 h post 
transfection cells were carefully washed 3 times with 37°C warm PBS and 
fixed using 200 µl ice cold 4 % paraformaldehyde (PFA) in PBS for 20 min. 
For permeabilisation the fixed cells were washed and incubated exactly for 2 
minutes with ice cold 0.2 % Triton X-100 in PBS. Cells were washed 
immediately 3 times with 1 % BSA in PBS. Blocking was done by an 
incubation of at least 10 min with 1 % BSA in PBS. The primary antibody 
(dilution as recommended) was incubated by pipetting 20-30 µl drops of 
antibody onto a clean surface and placing cells on cover slips facing down into 
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the drop. After 1 h of incubation at 37°C in a humidified atmosphere, cells 
were washed three times carefully with 1 % BSA in PBS. Before incubation 
with secondary antibody the cells were blocked for 10 min with 1 % BSA in 
PBS. Incubation was done in the dark to avoid bleaching of the fluorescent 
dyes for 45 min. Cells were washed twice with 1 % BSA in PBS and twice 
with PBS. Cover slips were finally embedded in approximately 15 µl 
Fluoromount G (Biozol, Germany) put on slide, cover slip sealed with nail 
varnish and slide was labelled. Samples were viewed by indirect 
immunofluorescence microscopy using the confocal scanning system 
MicroRadiance (Biorad, Great Britain) in combination with a Zeiss Axiophot 
microscope. The following filters were used for FITC- and TRITC-derived 
fluorescence: excitation for FITC at 488 nm and TRITC at 543 nm; emission 
for FITC at 515-530 nm and TRITC at >570 nm. 
 
3.8 FACS analysis 
Flow cytometry is a means of measuring certain physical and chemical 
characteristics of cells or particles as they travel in suspension one by one past 
a sensing point. The fluorescence activated cell sorter (FACS) consists of a 
light source, collection optics, electronics and a computer to translate signals to 
data. In most cytometers the light source of choice is a laser which emits 
coherent light at a specified wavelength. Scattered and emitted fluorescent light 
is collected by two lenses (one set in front of the light source and one set at 
right angles) and by a series of optics, beam splitters and filters, specific bands 
of fluorescence can be measured. Physical characteristics such as cell size, 
shape and internal complexity can be measured and any cell component or 
function that can be detected by a fluorescent compound can also be examined.  
 
3.8.1 Apoptosis assay 
Estimating the amount of apoptotic cells in a population can be done through 
measuring the DNA fragmentation. DNA fragmentation is a late characteristic 
of a cell undergoing apoptosis. Specific endonucleases cleave the DNA in the 
internucleosome linker region, producing single and multiple nucleosomes 
(180-200 bp). To detect the amount of DNA a dye that intercalates into the 
DNA, propidium iodide (PI) is used. The dye is excited with a laser and the 
emitted signal strength corresponds to the DNA content in each cell. The output 
is displayed in a histogram with the amount of counts on the Y-axis and the 
correspondingly emitted signal on a logarithmic scale on the X-axis. Cells that 
have duplicated their DNA (G2-phase) show a signal double as strong as cells 
in G1/G0- phase, revealing two peaks linked by a “valley” corresponding to 
cells increasing their DNA content (S-phase). Cells with reduced DNA content 
correspond to signals left of the G1/G0-peak (sub-G1). The cells were treated 
with different drugs for specifict time points. After treatment of drug of interest 
and incubation period cells were washed with ice cold PBSm the cells were 
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trypsinised and resuspended in fresh medium. After transferring the cell 
suspension into a centrifuge tube, the cells were spun for 10 min at 1,100 g, 
washed twice with cold PBS and finally dissolved in PI-solution. The cells 
were incubated in the dark for 30 min. through this treatment the plasma 
membrane was solubilised leaving the nucleus whole and allowing the dye to 
enter the nucleus. Using laser light with a 620 nm filter the DNA-intercalated 
propidium iodide emits a fluorescence that could be detected in the FACS 
(fluorescence activated cell sorter). 10,000 cells were counted for one data set. 
The data evaluation was done with the computer program CellQuest. PI-
solution: 0.1 % Triton-X-100 0.1 % sodium citrate 50 µg/ml propidium iodide 
in Aqua bidest. Another method we used that, Apoptosis was evaluated using 
the Annexin V-FITC detection kit (BD Transduction) and by propidium iodide 
(PI) following the manufacturer's protocol. 
 
3.9 Immunological detection of proteins (Western blot) 
Protein lysates were prepared according to standard procedures. Briefly, target 
cells were lysed in a buffer containing 50 mM HEPES (pH 7.5), 1% (vol/vol) 
Triton X-100, 150 mM NaCl, 5 mM EGTA, 50 mM NaF, 20 mM sodium 
pyrophosphate, 1 mM sodium vanadate, 2 mM phenylmethylsulfonyl fluoride, 
and aprotinin at 1 µg/mL. Lysates were clarified by centrifugation at 10,000 x g 
for 15 minutes. Equal volumes of lysates containing comparable amounts of 
proteins, as estimated by a modified Bradford assay (Bio-Rad, Munich, 
Germany) (Bradford 1976), were boiled for 5 min in 1X Laemmli sample 
buffer, and resolved on an SDS 10-12% polyacrylamide gel. 
To detect certain proteins transferred to a membrane, polyclonal or monoclonal 
antibodies specifically detecting the proteins were incubated with the 
membranes. The bound antibodies were detected by using secondary antibodies 
binding to the FC part of the primary antibody. These secondary antibodies are 
usually covalently bound to enzymes like horseradish peroxide (HRP) or 
alkaline phosphatase (AP), which in turn reacts with a given substrate allowing 
detection. In the case of HRP, luminol breakdown is catalysed by HRP giving 
off light for detection on filim. To saturate the membrane with protein before 
antibody incubation, the membrane was blocked by 1 h incubation in blocking 
buffer under agitation. The membrane was placed in a plastic foil and the first 
antibody, diluted in blocking buffer, was added. The foil was sealed and 
attached to a tumbling device, ensuring the even distribution of antibody 
solution over the entire membrane during the 1 hour incubation period at room 
temperature or over night depends upon for different primary antibody 
recomendation. After a 15 min wash with blocking buffer and a 15 min wash 
with PBS-T the blot was agitated twice in PBS-M (PBS with milk) for 5 min. 
The membrane was once again inserted in a foil with the secondary antibody 
diluted in blocking buffer and incubated during constant rotation for 1 h at RT. 
The membrane was washed as before, then twice in PBS. Finally, the 
membrane was incubated with a 1:1 mixture of enhanced luminal reagent and 
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oxidising reagent from the Renaissance Chemiluminescence Kit (NEN) for 
approximatly 2 min. Excess solution was removed and the membrane was 
placed in a film cassette and covered with a plastic foil. In the developing 
chamber a film was exposed to the membrane. Through different exposure 
times the intensity of the signals could be optimised. The films were developed, 
fixed and dried. For desitometric analysis the films were scanned and evaluated 
with the program Adobe Photoshop. 
 
Blocking buffer: 
1XPBS  
0.05 % Tween 20 
5 % (w/v) milk powder 
PBS-T: PBS+0.05 % Tween 20 
PBS-M: PBS+5 % (w/v) milk powder 
 
Immunoblot analyses were carried out using the following antibodies: anti-
human p53 (NCL- M1; Novocastra Laboratories Ltd, Newcastle upon Tyne, 
UK), anti-mouse p53 Do-1 from Santa Cruz Biotechnology (USA), anti-mouse 
p53 (NCL-CM5; Novocastra Laboratories), anti-phospho-p53 (Phospho-p53 
Antibody Sampler kit; Cell Signaling, OZYME, Saint Quentin Yvelines, 
France), anti-p73 (Anti-p73 Ab-1; Calbiochem, Fontenay sous Bois Cedex, 
France) and (IMG-259; Imgenex, CliniSciences, Montrouge, France). 
Immunoprecipitation was performed using anti-p53 (NCL-CM1) or anti-p73 
(Ab-1) antibody. The monoclonal antibody anti-EGFR was provided by BD 
Transduction Laboratories (USA); anti-ß-actin antibody was purchased from 
Sigma (Milan, Italy); antiphosphotyrosine PY99, anti-Fhit, anti-PTEN, anti-
VEGFR2, and anti-ß-tubulin antibodies were provided by Santa Cruz 
Biotechnology (USA); anti-AKT, anti-phospho-AKT, anti- ERK1/2 and anti-
phospho-ERK1/2 were provided by Cell Signaling (USA); anti-ABCG2 
(human) MAb (BXP-21) by Alexis Corporation; and p53 polyclonal antibody 
NCL-CM1 and p63 polyclonal antibody were from Novocastra. A mouse and a 
rabbit HRP (Amersham Pharmacia Biotech, Uppsala Sweden) were used as 
secondary antibodies. SCO1 and SCO2 antibody as a gift from Dr. Hwang PM, 
National Institutes of Health, Bethesda, MD 20892, USA. TIGER mouse 
monoclonal antibody as a gift from Dr. Vousden KH, The Beatson Institute for 
Cancer Research, Switchback Road, Glasgow G61 1BD, UK. 
 
3.9.1. Stripping of membranes for reprobing 
To use a different antibody for the same blot the antibodies that bound during 
the first immunological detection must be removed. The proteins are bound 
tightly to the membrane, whereas the antibodies (primary and secondary) can 
be removed by use of detergent (SDS), reducing agent (-mercaptoethanol) and 
heat. The signals obtainable using a reprobed membrane are weaker than for 
“fresh” blots, nevertheless signals are usually very good. The protocol was 
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adapted from (Kaufmann et al., 1987). Antibodies were stripped with Erasure 
buffer by incubating the blot for 30-90 min at 70°C in a water bath. The blot 
was washed twice in TS buffer for 10 min each. Finally, the membrane was 
blocked in blocking buffer for 2.5 h and was ready for primary antibody 
incubation. 
 
Erasure buffer: 2 % (w/v) SDS 
62.5 mM Tris-HCl pH 6.8 
100 mM -mercaptoethanol 
TS buffer: 10 mM Tris-HCl pH 7.4 
150 mM NaCl 
 
3.10 Immunoprecipitation (IP) 
Immunoprecipitation (IP) is a method to use a specific antibody against a 
protein of interest and isolate the protein-antibody complex from the rest of the 
cell lysate. The Fc part of the antibody binds to a Staphylococcus protein A or 
Streptococcus protein G, which is covalently linked to a carrier matrix like 
sepharose. The solid phase matrix brings the antigen-antibody complex out of 
solution. This precipitate can be washed, centrifuged and subsequently 
analysed by Western blot. This method is usually used to analyse protein-
protein interactions, but can also be used to detect proteins. To obtain sufficient 
cell lysate for the IP 8 million adherent cells were used, which corresponds to 
approximatly 1 culture dish of 145 mm diameter. The cells should be roughly 
90 % confluent. After removal of the cell culture medium, the cell layer was 
washed once in PBS. To every culture dish 4 ml ice cold PBS was added, cells 
were scraped off with a rubber policeman and transferred into a 50 ml tube. 
The cells were centrifuged at 4°C for 5 min at 1,000 g. The pellet was 
dissolved in 3 ml IP lysis buffer and transferred to the grinding chamber of a 
Potter-Elvehjem style homogeniser. Using the pestle the tissue was 
homogenised, transferred to a 15 ml tube and the homogeniser rinsed with IP 
lysis buffer. The homogenate was turned on a wheel for 20 min at 4°C. 120 µl 
slurry of protein G agarose (for monoclonal antibodies) or protein A agarose 
(for polyclonal antibodies) was equilibrated in 400 µl IP lysis buffer, later 
added to the lysate and incubated for 1 hour on the wheel at 4°C. This 
procedure of preincubating the lysate removes proteins that bind non-
specifically to protein A or G agarose. Through centrifugation at 10,000 g for 
10 min at 4°C the beads were sedimented, the supernatant was carefully 
removed and used for the IP. This should yield approx. a protein concentration 
of 1-5 µg/µl.  
For an IP, 1 µg of antibody was added per 100 µg protein supernatant. The 
same amount of protein supernatant is used as negative control with an 
unspecific antibody (e.g. -GST). The antibodies were incubated during 
constant rotation for 1 h at 4°C. The formed antibody-protein complexes were 
bound by addition of 30 µl Protein A agarose and could be removed by a 10 
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min centrifugation step at 10,000 g for 4°C. The supernatant was discarded and 
the pellet was washed 4 times with 1 ml IP lysis buffer. After the last washing 
step the pellet was resuspended in 50 µl SDS loading buffer. Probes were 
boiled, run on an SDS-PAGE and analysed by Western blot using an antibody 
directed against the protein interaction partners of the precipitated protein. 
 
IP lysis buffer: 50 mM HEPES pH 7.0 
150 mM NaCl 
0.1 % NP-40 
10 mM -glycerophosphate 
100 µM Na3VO4 
0.2 mM PMSF 
1 mM NaF 
10 µg/ml Aprotinin 
 
3.11 DNA-Sequencing 
Knowledge of the exact sequence of DNA enables detection of mutations, like 
frame-shifts and point mutants, not detectable by restriction digests. The DNA 
sequences were analysed through an improved technique of the dideoxy 
mediated chain termination method (Sanger et al., 1977) by a commercial 
biotech firm. The sequencing could deliver a sequence accuracy of over 99%. 
The DNA used sequencing acts as a template for the enzymatic synthesis of 
new DNA. The sequencing primer defines the starting point of the sequencing 
reaction on the template DNA. In the sequencing reaction, containing DNA 
polymerase I, a certain fraction of the nucleotides are fluorescence-labelled 
dideoxynucleotides, which block further chain elongation, as they do not 
possess a 3´OH. The ratios of deoxy- and dideoxynucleotides are such that a 
finite probability is created for a dideoxynucleotide to be incorporated in place 
of the usual deoxynucleotide at each nucleotide position on the growing chain, 
resulting in a population of truncated fragments. Every dideoxynucleotide 
(ddATP, ddCTP, ddGTP and ddTTP) is coupled to a different dye and can 
hence be distinguished later. The various DNA fragments are then separated 
electrophoretically on a sequencing gel and analysed by exciting the dye with 
laser light. The emitted signals are saved as a diagram, which can be translated 
into the DNA sequence by a special software program. 
 
Mutational analysis of EGFR. Genomic DNA was extracted from each cell 
line, using QIAamp DNA Blood Midi Kit (Qiagen) following the 
manufacturer's instructions. DNA was quantified and mutational analysis was 
performed from EGFR exons 18 to 21 and in exons 27 and 28. EGFR coding 
exon was amplified by PCR using the primers described in Table I. PCR 
amplification was carried out in a total volume of 50 l containing 150 ng of 
genomic DNA as template, 1X reaction buffer, 1.5-3 mM magnesium chloride, 
200 mM dNTP, 20-50 pmol of each PCR primer and 0.25 U AmpliTaq Gold. 
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After PCR amplifications, 5 l of the reaction product was analysed via gel 
electrophoresis and ethidium bromide staining. DNA sequencing was 
performed on both strands of two independent PCR products by cycle 
sequencing on an ABI PRISM 310 automated cycle sequencer, using the 
Terminator Cycle Sequencing Kit according to the manufacturer's protocol 
(Applied Biosystems, CA). Whenever an alteration was identified, a new DNA 
aliquot from the same cell line was sequenced to confirm the result. The 
variants found in the sequence were characterized and compared to those in the 
online databases, EntrezSNP (http://www.ncbi.nlm.nih.gov) and Ensembl 
(www.ensembl.org). 
 
3.12 Reverse-Transcription PCR 
Each cell line was collected, the RNA was extracted with Absolutely RNA 
miniprep kit (Stratagene) and Five micrograms of RNA were converted to 
cDNA using the First strand cDNA synthesis kit (Fermentas MBI). The primers 
used for the PCR were as follows: ∆Np73, 5’-ACC ATG CTG TAC GTC GGT 
GAC CCC-3’ (forward) and 5’-GCG ACA TGG TGT CGA AGG TGG AGC-
3’ (reverse); ∆Np63, 5’-TGC CCA GAC TCA ATT TAG TGA G-3’ (forward) 
and 5’-AGA GAG AGC ATC GAA GGT GGA G-3’ (reverse); TAp63, 5’-
GAC CTG AGT GAC CCC ATG TG-3’ (forward) and 5’-CGG GTG ATG 
GAG AGA GAG CA-3’ (reverse). As a control, the following human GAP-DH 
was used: 5’-AAG GTG GTG AAG CAG GCG T-3’ and 5’-GAG GAG TGG 
GTG TCG CTG TT-3’. Annealing temperatures (Ta) and number of cycles are 
specific for each isoform: Np63, 25 cycles and Ta 64°C; TAp63, 35 cycles 
and Ta 58°C; Np73, 40 cycles Ta at 62°C; TAp73, 35 cycles and Ta at 61°C 
and rest of the PCR amplification consisted of (94°C for 30 seconds, Ta for 30 
seconds, and 72°C for 30 seconds) followed by incubation at 72°C for 7 
minutes. The bands were visualized by ethidium bromide staining. 
 
3.13 Determinations of human papilloma virus (HPV) infection by reverse 
line blot hybridization. 
 The presence of human papilloma virus HPV (type 4, 5, 8, 9, 12, 14, 15, 17,19, 
20, 21, 22, 23, 24, 26, 36, 37, 38, 47, 48, 49, 50, 60 and 65) DNA was 
determined by reverse line blot hybridization previously described by Kleter et 
al. (Kleter et al., 1999; Melchers et al., 1999; Quint et al., 2001) 
Oligonucleotide probes specific for 24 different Human Papillomavirus types 
are covalently attached to a membrane in parallel lines using a miniblotter. The 
templates to analyze are DNA extracts previously labeled with Biotin using 
PCR. The labeled-PCR products are then loaded on the membrane in slots 
perpendicular to the oligo lines in order to allow all the samples to interact with 
the HPV probes. Hybridization takes place in the miniblotter and is visualized 
using a peroxidase labeled streptavidine, which interacts with the biotin of the 
PCR products, followed by chemiluminescence’s detection.  
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3.14 Statistical Analysis 
All the experiments were performed in triplicates and the average results of 
three independent assays ± standard deviation are indicated. Student’s t test 
was used to assess if null hypothesis is true. All P values were two-sided, and 
differences were statistically significant at P <. 02. To evaluate the effect of a 
drugs induced IC50 values, CalcuSyn (Version 1.1.1 1996, Biosoft, Cambridge, 
UK) was used, a program based on the method of Chou and Talalay (Chou and 
Talalay, 1984). 

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4. RESULTS AND DISCUSSION 
 
4.1 In-vitro Model of Head and Neck Squamous Cell Carcinoma 
(HNSCC); Twelve Novel Cell Lines (manuscript C) 
Establishment of cancer cell lines is very important in cancer research to 
understand several molecular pathways and perform different drug screening 
analyzis which cannot be performed invivo for any cancers including head and 
neck cancer (Lin et al. 2007). As an in-vitro model of Head and Neck 
Squamous Cell Carcinoma (HNSCC), we have selected a large panel of cell 
lines derived from different anatomical regions (Figure 9 and 10) of Head and 
Neck Cancer. Twelve cell lines consisted of larynx (one case, HNC-150), oral 
cavity (six cases, HNC-91, -97, -124, -160, -199, -212), tonsil (three cases, 
HNC-41, -206, -211), hypopharynx (one case, HNC- 180) and paranasal sinus 
(one case, HNC-136) (dramatic representation in Figure 9). HNC-136 is 
sometimes not really considered as Head and Neck cancer cell line due to its 
origin from paranasal sinus. 
 
Figure 9 

 
Figure 9. Dramatic representation of Human Head and Neck Anatomy.  Head and Neck cancer 
is the term given to a variety of malignant tumors that develop in different regions of Head and 
Neck area as shown in figure. In this study twelve novel head and neck squamous carcinoma 
(HNSCC) cell lines were selected from different regions of head and neck cancers and they  
highlited in the figure. 
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Our cell lines were undergone several passage numbers as indicated in Figure 
10 before utilization in experimental analyisis.   
 
Figure 10 
 
 
 
Figure. 10. Different Head and Neck tissues, from which cell lines were derived and their 
minimum passage numbers are undergone before utilization of different experimental 
procedures are drawn. 
  
These cell lines are now available for a variety of studies designed to broaden 
our understanding of the biology of the head and neck cancer. Survival rates for 
patients with cancers of the head and neck have not been improving recently, 
and there is a need for new and innovative therapeutic approaches in addition to 
surgery, radiation, and chemotherapy. These can only be developed on the 
basis of an improved knowledge of the tumor properties and its behaviour in 
vivo and in vitro. Clearly, well-characterized cell lines are a valuable resource 
for such studies. 
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4.2 General Characterization of Head and Neck Cancer Cell Lines 
4.2.1 Phenotypic features of head and neck cancer cell lines 
Most cell lines have shown their own phenotypic characteristics and growth 
properties, for example HNC-136 cells are round-shaped ones grown in a 
clustered way but HNC-180, long-shaped cells with a homogeneous 
distribution (Figure. 11).  
 
Figure 11 
 
 
Fig.11. a-, b- Cell line 180, different magnifications. c-, d-, e-, f- Cell line 136, different 
magnifications. Cell lines derive from different tissues in the head and neck region (larynx, 
hypopharinyx, paranasal sinus, oral cavity, etc.) and this is the reason why the phenotypes of 
the cells are extremely various. In the two examples above, it is possible to see long-shaped 
cells with a homogeneous distribution (fig. a-, b-) and round-shaped ones grown in a clustered 
way (fig. c-, d-, e-, f-) 
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This diffrence in cell phenotype  is maily due to its origin deriving from 
different anatomical regions of head and neck cancer. Figure 11 shows cell 
lines HNC-180 and HNC-136 derived from hypopharinyx and paranasal sinus, 
respectively. 
4.2.2 Doubling time population and DNA ploidy analysis 
Another general characteristic was that all cell lines grew as monolayer but 
they have shown significant difference in doubling time population, ranging 
from 18 to 72 hours (Table 3). For example, HNC-212 was very slow in growth 
and its doubling time was around more than 72 hours. In contrast, HNC-136 
was very fast growing cell line and its doubling time was around 18-24 hours. 
Since all cell lines were established with the same culture conditions, these data 
generally indicate that different cellular pathways are altered in different cell 
lines. Cell cycle analysis reported in table 3 shows that each cell line has 
peculiar distribution in the G0/G1-, S- and G2/M-phase and, as respect to 
lymphocytes all of them are aneuploid with a DNA index ranging in-between 
1.13 and 1.75. 
 
Table 3 
 
 
Cell Lines 
 
DNA 
Index 
Cell Cycle Analysis 
(% of cell at different phase of cell 
cycle) 
 
 
Ploidy 
 
Doubling 
Time in 
Hours G0/G1 S G2/M 
HNC-41 1.54 65.45 22.05 17.50 Aneuploid 18-24 
HNC-91 1.76 73.48 6.63 19.89 Aneuploid 24-48 
HNC-97 1.48 73.95 4.81 21.24 Aneuploid 24-48 
HNC-124 1.41 54.95 19.77 25.28 Aneuploid >48 
HNC-136 1.48 63.01 6.93 30.06 Aneuploid 18-24 
HNC-150 1.43 74.60 5.99 19.41 Aneuploid 24-48 
HNC-160 1.13 66.62 13.81 19.56 Aneuploid 24-48 
HNC-180 1.75 47.64 33.63 18.73 Aneuploid >48 
HNC-199 1.37 60.70 16.21 23.08 Aneuploid 18-24 
HNC-206 1.36 51.77 30.07 18.17 Aneuploid 24-48 
HNC-211 1.58 63.63 19.26 17.08 Aneuploid 24-48 
HNC-212 1.67 60.65 4.06 16.29 Aneuploid >72 
 
Table. 3. General Cell cycle analyses and DNA index of each cell lines were determined by 
FACS analysis. Exponentially growing each cell lines were collected and stained with 
propedium iodide and DNA index was determined with respect to normal lymphocytes.  Each 
cell lines doubling time population was determined by direct cell counting. 
 
Aneuploidy, an abnormal nuclear DNA content, is considered almost positive 
evidence of any malignancy including HNSCC (Rubio Bueno et al. 1998). As 
our all cell lines analyzed were aneuploid indicating that during tumour 
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progression there must be an acquisition and accumulation of chromosomal 
aberrations in Head and Neck Cancer. 
4.3 HPV Detection  
High-risk human papillomaviruses (HPVs) have been proposed to be associated 
with a subset of head and neck cancers (HNSCCs). All cell lines were 
previously tested for the presence of these HPV types. No DNA of the high-
risk HPV was detected in all cell lines. Recent epidemiologic studies have 
reported associations between markers of ß-HPV infection (presence of viral 
antibodies in serum and presence of viral DNA in plucked eyebrow hairs) and 
actinic keratosis (AK) and Cutaneous squamous cell carcinoma (SCC) 
independently (de Villiers et al. 1997). Therefore, we examined whether 
HNSCC cell lines were positive for cutaneaus HPV types DNA (type 4, 5, 8, 9, 
12, 14, 15, 17,19, 20, 21, 22, 23, 24, 26, 36, 37, 38, 47, 48, 49, 50, 60 and 65) 
by reverse line blot hybridization (Figure 12). In order to check for HPV 
presence, reverse line blot hybridization was performed on DNA extracts from 
the twelve cancer cell lines. The membrane was already prepared with HPV 
probes loaded vertically; DNA extracts from the twelve cell lines were loaded 
horizontally on the membrane in order to cross-interact with the HPV DNA 
probe (Figure 12). Our analysis revealed that all cell lines used for this study 
were negative for most prevalent mucosal and cutaneous HPV types. 
 
Figure 12 
 
Figure 12. HPV typing. Dramatic representation of reverse line blots hybridization for HPV 
typing. The blotting didn’t give any positive results indicating that there is no evidence of HPV 
infection in the cell lines under study. On the membrane the DNA extracts from the 12 cell 
lines have been loaded horizontally in order to cross with the specific HPV probes loaded 
vertically. The light blue lanes are the blanks and the negative controls, while the HPV38 was 
used as positive control (the black spot).   
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HPV negativity in our HNSCC cell lines analysed for prevalent mucosal and 
cutaneus HPVs inderectly suggest that HPV infection is an early event in 
HNSCC development and virus DNA integration may not be strictly necessary 
for HNSCC progression when compared with cervical cancer, where viral 
DNA integration to host genome is most prevalent. 
 
 
Part I 
4.4 Characterization of “p53 family net work” in twelve novel HNSCC cell 
lines 
We analyzed the expression profiles of p53 family members in our squamous 
cell carcinomas of the head and neck (HNSCC) derived cell lines. Each cell 
line was collected, the RNA was extracted with Absolutely RNA miniprep kit 
(Stratagene) and reverse transcription was carried out using the First strand 
cDNA synthesis kit (Fermentas MBI). In order to evaluate the expression levels 
of the p53 homologous and isoforms, polymerase chain reactions (PCR) were 
performed using isoform-specific primers. In particular the levels of TAp63, 
Np63, TAp73, Np73 were analysed. A PCR for the housekeeping gene 
GAPDH was performed on all the samples in order to normalize the quantity of 
the cDNA. For comparing our RT data with protein levels, western blot 
analysis were performed for all p53 homologous and isoforms. In the majority 
of HNSCC cells different p63/p73 isoforms were expressed with cell-line-
specific patterns for composition and intensity of transcript expression and 
these results are descriped separately in the following sections. 
 
4.4.1 TAp63 expression and over-expression of Np63 in HNSCC cell lines 
The human p63 gene encodes a series of proteins that differ in their N- and/or 
C-terminal sequences and have widely differing properties in promoting or 
repressing p53-related functions such as growth arrest and apoptosis. In 
addition, p63 has important roles in the maintenance and differentiation of 
epithelial cell populations. In our study noticeably Np63 was found over-
expressed already in the first PCR in almost all the cell lines (Figure 13-a). 
After the NESTED PCR two other cell lines appeared to be positive except 
HNC-91 and HNC-136 (Figure 13-b). 
 
The expression levels of TAp63 were also analysed and it was found that HNC-
41 and HNC-206 highly expressed Tap63 at RNA level (Figure 14) and its 
increased mRNA expression correlated with protein in HNC-41 but HNC-206 
has shown comparatively less amount of protein. (Figure 15).
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Figure 13 
 
 
Figure 13. PCR on Np63. The first PCR gave several positive results, which have been 
confirmed in the NESTED PCR with the addition of two other positive bands in the cell lines 
97 and 212. 
 
Figure 14 
 
 
Figure 14. PCR on TAp63. Even in this case the increase in the number of positives and the 
enhancement of the intensity of the signals is evident between the first PCR and the NESTED. 
Only in the 211-cell line there is a regression of positivity, which may be an artefact due to the 
excess of template for that specific sample. 
 
4.4.1.1 TAp63 and Np63 protein analysis by immunoblotting 
Protein extract were prepared from each cell line and analyzed by 
immunoblotting with a polyclonal antibody against p63 (Figure 15). Our 
immunoblot results confirmed that TAp63 and Np63 are not expressed in 
HNC-91 and HNC-136 at RNA and protein levels.   
 
Figure 15 
 
 
Figure 15. Westernblot for p63. 100 g of each protein extract were loaded on a 12% 
polyacrilamide gel, transfered to a PVDF membrane and immunostained overnight by a 
polyclonal antibody against p63 used at the dilution 1:1000.  An immunostaining for -tubulin 
was performed on the same membrane as a loading control. 
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Our invitro results supports the previous finding that Squamous cell carcinomas 
of the head and neck (SCCHN), express high levels of Np63 isoform 
compared to normal tissue from the same patients, suggesting a role for these 
isoforms in the pathogenesis of this common human malignancy. 
4.4.2 p53 homologue Tap73 and its isoform Np73 expression in HNSCC 
cell lines 
High levels of Np73 mRNA were found expressed in only two cell lines, the 
150 and the 211 (Figure 16-a). In order to amplify the signal, a NESTED PCR 
was performed on the products from the previous PCR and the enhancement 
was significant since the 75% of all the cell lines appeared to be positive for 
Np73 (Figure 16-b). The first PCR on TAp73 detected only two positive cell 
lines as well, the HNC 41 and the 136 (Figure 17-a). Also in this case we 
performed NESTED PCR, but the analylsis did not show p73 expression in 
additional cell lines (Figure 17-b). 
 
Figure 16 
 
Figure 16. PCR on Np73. The first PCR gave 2 positive bands, while in the NESTED PCR 
the outcome of positive signals is significantly enhanced. In total, 9 cell lines out of 12 appear 
to express Np73. 
 
Figure 17 
 
Figure 17. PCR on TAp73. In the first PCR is possible to see two positive bands, a stronger one 
on the 136 cell line and a weaker one on the 41 cell line. The NESTED PCR didn’t give any 
results despite the several tests performed in different conditions. 
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4.4.2.1 TAp73 and Np73 protein analysis by immunoblotting 
To correlate with our RT-PCR data we have preformed western blotting for 
p73 and it revealed that HNC-206, -180 and HNC-41 accumulated both Tap73 
and Np73 while others were positive for only Np73 (Figure 18). We 
couldn’t perfom protein analysis of p73 in HNC-91 and 160 cell lines. 
 
Figure 18 
 
 
Figure 18. Western Blot analysis shows Tap73 and Np73 expression in Head and Neck 
Cancer Cell lines. 
 
The results from the RT-PCR and the western blots of p63 and p73 are 
compared in the table 4 
 
Table 4 
 
 
Cell 
Lines 
 
p63 RT- PCR p63 Western p73 RT-PCR p73 Western 
 
∆N 
 
TA 
 
∆N 
 
TA 
 
∆N 
 
TA 
 
∆N 
 
TA 
41 +++ + +++ +++ + + ++ +++ 
91 - - - - ++ - Nd Nd 
97 + - + + ++ - + - 
124 +++ - +++ +++ +++ - ++ - 
136 - + - - ++ ++ +++ - 
150 +++ + ++ +++ ++ - ++ - 
160 +++ + + ++ ++ - Nd Nd 
180 +++ ++ Nd Nd - - + ++ 
199 +++ - - - ++ - + - 
206 +++ ++ + ++ - - + ++ 
211 +++ + +++ +++ ++ - ++ - 
212 + - - - - - ++ - 
 
Table 4. Results from the western blot and RT-PCR for Np63, Np73, TAp63 and Tap73 are 
compared  
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We have found strong expression of p73 and p63 short-variants in 75% and 
83% respectively of all cell lines in contrast with the very low expression of the 
related full-length isoforms. This result is consistent with other data on head 
and neck and related tumors, where it is also very often showed strong 
expression of N-variants of p53 homologous. In according with these results,  
Np73 and Np63 overexpression has been found in several different tissue-
related cancers but not in its normal counterpart.  
 
High levels of expression of these N-variants of p53 isoforms in most of the 
twelve cancer cell lines suggest the possible role of these isoforms in 
tumorigenesis, for example through inhibition of wild type p53 functions. 
Surprisingly the major finding of this study was the detection of the higher 
expression of Np63, which shows a similar pattern of expression to the one of 
Np73. These results could suggest a more important role of Np63 in 
tumorigenesis than what assumed in the past.  
 
4.5 p53 status and protein levels in head and neck cancer cell lines 
4.5.1 p53 mutation predispose to HNSCC 
Since in more than 50% of tumors p53 is mutated, next we checked p53 status 
in our head and neck cancer cell lines under study. Furthermore, HNSCC with 
mutated TP53, may have a higher proliferative potential caused by a lack of 
control in G1 checkpoint. We collected the cells and performed DNA 
extraction. Exon 4-10 were amplified by PCR using specific primers annealing 
in the introns. The DNA was sequenced and screened for p53 mutations. The 
mutations and their location in the gene are listed in Table 5.  
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Table 5 
 
Cell Lines EXON CODON BASE AA CHANGE 
41 WT (4-9) 
 
  
91 WT (4-9) 
 
  
97 Exon 5 
Exon 7 
 
180        GAG-AAG 
248        CGG-TGG 
 
Glu-Lys 
Arg-Trp 
 
124 WT (4-9) 
 
  
136 WT (4-9) 
 
  
150 Exon 5 
 
135         TGC-TAC 
 
Cys-Tyr 
 
160 Exon 6 
 
213        CGA-CGG 
 
Arg-Arg 
 
180 Exon 6 
 
220         TAT-TGT 
 
Tyr-Cys 
 
199 Exon 5 
 
135         TGC-TTC 
 
Cys-Phe 
 
206 Exon 5 
 
134          TTT-TCT 
 
Phe-Ser 
 
211 Exon 6 
 
177-183  Del 5 
codons 
 
In frame 
 
212 Exon 6 
Exon 9 
 
196        CGA-CCA 
331         CAG-.AG 
 
Arg-Pro 
Frameshift 
 
 
Table 5.  p53 status: mutations and wild types. 
 
Sequence analysis revealed that 8 cells lines out of 12 harbour a mutated state 
of p53. Our results also support the common fact that p53 mutations are more 
common to DNA binding domains in HNSCC (Poeta et al. 2007). For any wild 
type and/or mutated genes to induce its positive or negative function  it has to 
express at protein level and this is more stringent to p53 protein because its 
protein level and cellular localization determine its negative or positive roles in 
human cells especially the fate of immortalized cancer cells. Therefore, we 
have decided to determine p53 protein level in our all cell lines and their 
cellular localization in some selected cell lines. 
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4.5.2 p53 protein levels in head and neck cancer cell lines  
The expression of p53 protein has been reported to be in the range of 35% to 
67% in head and neck squamous cell carcinoma (HNSCC). Mutation of the p53 
gene often results in over-expression of p53 protein. However, it is possible 
that p53 protein accumulation may be a result of alternative mechanisms 
leading to p53 protein stabilization. For understanding p53 protein 
accumulation and localization in our cell lines we have checked p53 levels by 
western blot analysis and to localize p53 protein we performed 
immunoflurescence in  some selected cell lines. Our westernblot analysis 
showed that seven cell lines out of twelve exhibited detectable levels of p53 
(HNC 97, 124, 136, 150, 199, 211, 212) and they included both mutated and 
wild type p53 (Figure 19). The results from the western blot analysis are listed 
in table 6. 
 
Figure 19 
 
Figure19. Westernblott for p53. 50 g of each protein extract were loaded on a 12% 
polyacrilamide gel, transfered to a PVDF membrane and immunostained overnight by a 
monoclonal antibody (DO-1) against p53  used at the dilution 1:1000.  An immunostaining for 
-actin  was performed on the same membrane as a loading control. 
 
Table 6 
Cell Lines p53 Levels p53 Status 
41 - WT 
91 - WT 
97 + Mutant 
124 ++ WT 
136 +++ WT 
150 + Mutant 
160 - Mutant 
180 + Mutant 
199 + Mutant 
206 + Mutant 
211 + Mutant 
212 ++ Mutant 
                                 
Table 6. p53 protein expression levels in different HNSCC cell lines, WT: Wild type 
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p53 protein accumulation in some HNSCC cells line was interesting. Because 
of transdominant inhibiting isoforms, Np73 and Np63 would be then the 
truly important gene products, overexpressed and inhibiting the tumor 
suppressive function of p53 and its phenotypically neutral isoforms, TAp73 and 
TAp63. These inhibitors would antagonize the apoptotic function of p53 and of 
its own p53-like isoforms, either by direct competitive binding to the same 
cognate p53 DNA binding sites or by engaging in heterocomplexes that are 
defective for specific DNA binding. Therefore,  it was reasonable to find high 
levels of  Np73 particularly in those cell lines that exhibit wild type p53. Of 
nine cell lines with a noticeable Np73 expression, only three also showed 
expression of p53 (HNC 124, 136, 211) and only two of them harbored a wild 
type p53 (HNC 124, 136), whereas all the remaining have no high levels of p53 
expression. We didn’t find any correlation of Np63 and p53 level in these cell 
lines because two cell lines which didn’t express Np63 are HNC-91 and 136, 
without and with accumulation wild type p53, respectevily.    
 
4.5.3 Analysis of cellular localization of p53 protein 
 
Cellular localization of p53 protein determines its functional activity and also 
to correlate with our immunoblot results, we performed immunoflorescence for 
p53 in some of our selected HNSCC cell lines expressing wild and mutant p53 
protein. Our immunofluroscence results of HNC-41, HNC-97, HNC-136 and 
HNC-206 are shown in Figure 20. 
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Figure 20 
 
 
Figure 20. Immunofluroscence staining for p53. HNC-41, 97, 136, and –206 cell lines were 
monolayer-cultured, formaldehyde-fixed and stained with antibodies against p53 and/or 
Cytokeratin with or without DAPI. It is more evident that HNC136 cell line is more 
predominantly accumulating wild type p53 in nucleus compared with other cell lines.   
 
Our analysis revealed that HNC-136 is highly positive for p53 protein 
expression and localized in the nucleus. In regards with another cell line, which 
harbour wild type p53 but not detected by western-blot analysis was HNC-41. 
Immunofluroscence staining for p53 showed slight expression but diffused 
throughout the cell. The observation that p53 is frequently detected in the cell 
nucleus suggests that nuclear localization of this protein is most likely 
important for p53 activity. Our results evidence that both  p53 wild type and 
mutant cells accumulate p53 protein predominantly present in the nucleus. 
Negative role of mutant p53 protein in cancer is well documented; that it can 
co-operate with other oncogenes like ras to assist cancer cell survival and 
proliferation. This may be the role of nuclear p53 in HNC-97. But what the 
functions of wild p53 protein accumulated in the nucleus are not known in the 
case of HNC-136. Therefore, we have expanded our study to understand 
accumulated wild type p53 properties and functions in Head and Neck Cancer 
cells by using HPV38 mediated immortalized human keratinocytes as a 
prototype model. 
 
4.6 Characterization of novel mechanisms of alteration of wild-type p53 
tumor supressor function in HPV positive and negative cancer cells 
p53 was initially identified as a protein associated with viral oncoproteins and 
later its involvement in several cell fate determining pathways was most found. 
 75
And in notion to this evident support that more than 50% of human tumors 
contain a mutated or deleted p53 gene. Accordingly it has also been noted that 
in absence of p53 mutation, viral mediated tumorogenesis, viral oncoproteins 
reported to inactivate p53 tumor suppressor function. High Risk Human 
Papilloma Virus (HPV) HPV-16 and 18 have been reported as main etiological 
factors, almost 90% of cervical cancers and 20 to 30% of Head and Neck 
cancers world-wide. Moreover, High-risk HPV early oncoprotiens E6 and E7 
reported to immortalize primary human keratinocytes in-vitro. HPV 16 E6 
mediated immortalization process, E6 protein reported to degrade wild type 
p53 by E6AP mediated ubiquitination process while E7 protein slightly 
accumulates p53 (Figure 21) and an unknown pathway compromises its tumor 
suppressor activity. Recently, it has been reported from our lab that beta type 
human papillomavirus (HPV38) E6/E7 mediated immortalization process leads 
to accumulation of wild type p53 (Figure 21). However, what is the 
significance of this accumulated wild type p53 in HPV38 E6 and E7 (hereafter 
referred to as HPV38-keratinocytes) keratinocytes is going to be revealed. One 
mechanism could be the selective activation of the transcription of Np73, an 
isoform of the p53-related protein p73, which in turn inhibits the capacity of 
p53 to induce the transcription of genes involved in growth suppression and 
apoptosis (Figure 21) (Accardi et al. 2006). Moreover, its more important to 
understand existance of this molecular mechanism in  other HPV negative 
cancer cell lines. Our Head and Neck Cancer cell lines characterization 
revealed four cell lines harboring wild type p53 and two of them were 
accumulating wild type p53 and Np73 proteins (HNC-124 and HNC-136) 
(Figure 21).   
 
Figure 21 
 
Figure 21. P53 protein levels in HPV positive and negative cancer cell lines. Human freskin 
keratinocytes (HFKs) expressing HPV38 E6 and E7 accumulates high levels of p53 protein 
(38i and 38I). HPV 16 E6 or E7 alone and E6/7 together expressing keratinocytes are also 
shown. Head and Neck cancer cell lines established from head and neck squamous carcinoma 
which are devoid of any HPV DNA (HNC-136 and-124) also showed accumulation of wild 
type p53. 
 
In this regards it’s very important to understand how these cancer cell lines are 
continuously proliferating without showing any sign of apoptosis or senescence 
in presence of huge amount of wild type p53 protein. Therefore, we have 
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focused on molecularly characterize the properties (different post translational 
modifications of accumulated wild type p53) and functions (down-stream 
events) of accumulated wild type p53 in HPV positive (HPV38) and negative 
cancer (HNSCC) cells. 
 
4.6.1 Molecular properties of accumulated wild-type p53 in HPV38 and 
head and neck cancer cells 
The well-studied post-translational modification of a single protein to date is 
human p53 protein. It includes p53 phosphorylations at different amino acid 
residues and p53 C-terminal lysines are modification by ubiquitylation, 
acetylation, sumoylation, neddylation and methylation. As, p53 each post-
translational modification can influence its stability and functional properties, 
we have tried to over look on feasible post-translational modifications involved 
in accumulation of wild type p53 in HPV38 and HNSCC cells.   
4.6.1.1 p53 ubiquitination 
MDM2 is an E3 ubiquitin ligase that targets p53 for proteasomal degradation. 
We have tried to analyze wild type p53 accumulation in our cancer cell lines 
due to altered p53 ubiquitination and deregulation by MDM2. MDM2 
ubiquitinates p53 prior to proteasome degradation. For understanding MDM2 
and p53 cross talk in our cancer cell lines, we have analyzed basic 
ubiquitinated p53 status in our cell lines and its interaction with MDM2. Basic 
p53 ubiquitination analysis showed that according to p53 protein levels, it 
ubiquitinated and degraded because normal keratinocytes express low-levels of 
p53 is less ubiuquitinated compared with 38i and HNC-136 cells have more 
p53 and more ubiquitination (Figure 22). Our analysis indicates that there are 
basal level of p53 ubiquitination and degradation in all cell lines with respect to 
p53 protein levels (Figure 22).  
 
Figure 22 
Figure 22. Basal ubiquitinated p53 status in HPV38 E6/E7 immortalized keratinocytes and 
selected head and neck cancer cell lines. 
 
Next, we have analysed that these consequences are due to the altered 
interaction of p53 and MDM2. For understanding functional interaction 
between p53 and MDM2 we have immunopricipitated p53 and performed 
western blot for MDM2. The results revield that p53 accumulated cell lines are 
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less interacting with MDM2 in comparison with Normal Keratinocytes and 
HNC-41 cell lines which have less amount of wild type p53 protein (Figure 
23). 
 
Figure 23 
 
Figure 23. p53 accumulated HPV38 immortalized keratinocytes (38i and 38I) and Head and 
Neck cancer cell lines (HNC-136 and 124) were less interacting with MDM2. 
 
For understanding in detail whether MDM2 protein level may be down 
regulated in those p53 accumulated HPV positive and negative cell lines, we 
have performed immunoblot for MDM2 in total cell lysate and revealed that 
MDM2 protein expression is less in those cells which are accumulating wild 
type p53 in comparison with cells (normal keratinocytes and HNC-41) 
containing less wild type p53 protein (data not shown). It indicates that p53 
feedback loop is altered in these cell lines. Meantime, p14ARF1 has been 
reported to prohibit MDM2 mediated ubiquitination of p53, therefore we have 
analyzed p14ARF1 in the cells of our study. 
 
4.6.1.1.1 p14ARF1 protein accumulated in HPV38 and HNC-136 
Oncogenic signalling activates p53 though ARF, which, in turn, interacts with 
MDM2 inhibiting its p53-ubiquitin ligase activity. In this manner, ARF-
dependent stabilization of p53 results in a dramatic increase in p53 activity. In 
our cell lines both HPV38 keratinocytes and HNC-136 are accumulating huge 
amount of wild type p53 and p14ARF too (Figure 24).  
 
Figure 24 
 
 
Figure 24. Western blot analysis shows p14ARF protein accumulated in HPV38 keratinocytes 
and HNC-136, which are accumulating huge amount of wild type p53 protein. 
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In our cells under study (HPV38keratinocytes and HNC-136), MDM2 protein 
level was very less and it’s makes less significance of p14ARF interaction with 
MDM2 leads to p53 accumulation. It idicates that accumulated p14ARF has 
some assisting role in cell survival in co-operation with accumulated wild type 
p53 protein. 
4.6.1.2 p53 sumoylation 
The tumour suppressor p53 has been shown to be modified at its C-terminus 
with the ubiquitin-like proteins SUMO1 and NEDD8. Recently, p53 
sumoylation has been proposed to induce senescence in normal human 
fibroblasts but apoptosis in RB (retinoblastoma)-deficient cells. Moreover, p53 
sumoylation reported to influence in p53 mediated transcription activity. For 
understanding p53 sumoylation role in p53 protein accumulation and its 
functional impairement in p53 mediated tumor suppressor functions, we have 
analyzed sumoylated p53 status in our immortalized cell lines. Figure 31 shows 
that accumulated wild type p53 in HPV38 and Head and Neck cancer cells 
have no difference in sumoylation pattern in comparison with normal 
keratinocytes because none of them showed significantly sumoylated p53 
(Figure 25). 
 
Figure 25 
 
 
Figure 25. Basal sumoylated p53 in HPV38 immortalized keratinocytes (38ii, 38i and 38I) and 
other head and neck cancer cell lines. Total cell lysated from each cell lines were 
immunopricipitated with p53 monoclonal antibody and immunobloted with anti-sumo-1 
antibody.  
 
In addition, for understanding UV treatment enhance p53 sumoylation, we have 
treated our selected HPV positive and negative cancer cells for UV-B 
treatment. Our result shows there wasn’t a significant role of p53 sumoylation 
leading to protein accumulation because in comparison with normal 
keratinocytes and p53 mutated HNC-211, wild type p53 accumulated cells 
didn’t show any difference in sumoylation pattern with or without UVB 
treatment (Figure 26). 
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Figure 26 
 
 
 
Figure 26. Analysis of p53 sumoylation with and without UVB treatment Cells were exposed 
with and without UVB for 10 minutes. Then, total cell lysates were prepared and 
immunopresipitated with p53 monoclonal antibody and immunobloted for sumo-1 with anti-
sumo-1 antibody. The same blot was stripped and immunobloted for p53 with polyclonal 
antibody for checking p53 input. 
 
Our data support the finding of Kwek et al. 2001  that SUMO-1 modification of 
p53 at lysine 386 may not be essential for p53's cellular localization, 
transcriptional activation, or growth regulation, at least in HNSCC. 
Interestingly, we have noticed that some proteins, which are interacting with 
p53, have 90KD size accumulated in cancer cell lines in comparison with 
normal keratinocytes. Moreover, this unspecific p53 interacting protein level is 
increased after UVB treatment (Figure 26). Further analysis is required to 
understand sumoylation of p53 with sumo2 and 3 involved in wild type p53 
accumulation and if it exists lead to rise a 90kD size of p53, which we have 
noticed in our exprements. 
 
4.6.1.3 HPV positive and negative cancer cell lines accumulated wild p53 is 
hyper-phosphorylated at serine15 and 392 residues 
Stabilization of wild type p53 is normally associated with phosphorylation 
(Bode and Dong, 2004). To evaluate the phosphorylation status of p53 in 
human keratinocytes immortalized by HPV38 and other head and Neck cancer 
harbouring wild type p53, we first determined its protein levels by 
immunoblotting. p53 is strongly accumulated in HPV38-keratinocytes and 
HNC-136 and HNC-124 in comparison with primary keratinocytes (Figure 
27a). Immunoblot analysis using antibodies specific for various phosphorylated 
forms of p53 showed a marked increase in phosphorylation of p53 at serines 
15, 46 and 392 in HPV38-keratinocytes, HNC-136, and HNC-124, compared 
with normal keratinocytes (Fig 27a and b). 
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Figure 27a 
 
 
Figure 27a. Status of phosphorylation of p53 in HPV Negative Head and Neck Cancer Cells. 
Protein extracts of the indicated cells were analyzed by immunoblotting using the indicated 
antibodies. 
 
In contrast, serine 9 was less phosphorylated in the HPV38, HNC-136 and 
HNC-124 cells accumulating wild type p53 in comparison with control cells 
(normal keratinocytes) (Figure 27 a and b).  
 
Figure 27b 
 
Figure 27b.  Characterization of p53 phosphorylation pattern.  After normalization of the levels 
of the different phosphorylated forms of p53 to the signal for total p53, the relative level of p53 
phosphorylation in HFK, HPV38 E6/E7(38i and 38I), and other cancer cell lines (HNSCC) 
were evaluated in comparison with primary keratinocytes. 
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To exclude the possibility that p53 stabilization might also result from an 
accidental mutation in the TP53 gene, we sequenced exons 2-10 (plus flanking 
splice junctions) in the HPV38-keratinocytes, HNC-136 and 124 (these two cell 
lines were already checked for p53 sequence, see before)  and confirmed a 
wild-type sequence. Moreover, it represents that hyperphosphorylated form of 
p53 is unable to accumulate MDM2 protein (results 4.6.1.1). 
 
4.6.1.4 Wild-type p53 is accumulated in the nucleus of  HPV positive and 
negative cancer cells 
Immunofluorescence staining showed that p53 was distributed in both the 
cytoplasm and nucleus in control cells (normal human keratinocytes), whereas 
it was exclusively localized in the nucleus in HPV38-keratinocytes (Figure 28), 
HNC-124 and -136 accumulating wild type p53 (Figure 29).  
 
Figure 28 
 
 
 
Figure 28. Imunofluorescence showing p53 localization in Primary keratinocytes and in 
HPV38 keratinocytes. 
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Figure 29 
 
Figure 29. Imunofluorescence showing p53 localisation in HNC136. Monolayer-cultured cell 
formaldehyde-fixed and stained with antibodies against p53 and/or Cytokeratin with or without 
DAPI. 
 
Taken together, these data indicates that HPV positive and negative cancer cell 
lines induce the hyper-phosphorylation of p53 at specific serine residues, 
resulting in the stabilization and nuclear accumulation of wild type p53 with 
impaired tumour suppressor functions. Despite the presence of high levels of 
p53 in the nucleus, HPV38-keratinocyte, HNC-136 and HNC-124 actively 
proliferate and do not show any sign of apoptosis, indicating that wild type p53 
tumor supressor function has been impaired in these cells. Results from 
molecular characterization of accumulated wild type p53 properties indicate 
that p53 hypersphosporylation (especially at serine15, 46 and 392) plays a 
crucial role in wild type p53 accumulation and impairement of tumor supressor 
functions of p53. Based on these finding, we have further studied the down 
stream effectors of hyperphosphorylated form of wild type p53 in HPV38 and 
HNSCC cells. 
 
4.6.2 Accumulated wild type p53 down stream effectors in HPV positive 
and negative cancer cells 
As our HPV positive and negative cancer cell lines were accumulating wild 
type p53 didn’t show any sign of apoptosis and senescence, we were most 
interested to study its role in cell survival and proliferation pathways. One of 
the mechanism by which accumulated wild type p53 assist cell survival and 
proliferation is by specifically activating Np73, already published from our 
laboratory (Accardi  et al. 2006) in HPV38 model. Other than Np73, recent 
reports suggest that p53 can be involved in different cell survival pathways. 
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Therefore, we have further analysed those recently indentified p53 regulated 
cell survival and proliferative protein levels in both HPV38 and HNSCC cells. 
 
4.6.2.1 ∆Np73 protein is up-regulated in HPV positive and negative cancer 
cell lines accumulate wild-type p53 hyper-phosphorylated at serine15 and 
392 
It has been shown that isoforms of the p53-related protein, p73, lacking the 
amino-terminal transcriptional activation ∆(TA) domain, collectively called 
(delta) isoforms, antagonize the transactivation functions of p53 and p73 
(Melino et al. 2002). The isoforms ∆Np73’, p73∆Exon2/3 and p73∆Exon2 are 
generated by alternative splicing at the 5’ region of the p73 messenger RNA, 
whereas the ∆Np73 isoform is expressed by the internal promoter located in 
intron 3 that contains a p53-responsive element (p53-RE; Levrero et al, 2000; 
Melino et al, 2002). RT-PCR analysis showed that HPV38-keratinocytes 
express high levels of the ∆Np73 isofrom (Figure 30). Immunoblot analysis 
with an anti-p73 antibody detected a protein band with an approximate 
molecular mass of 60kDa that co-migrated with the ectopically expressed 
∆Np73 isoform (Figure 30), confirming the RT-PCR data.  
 
Figure 30 
 
 
Figure 30. HPV38 E6 and E7 expression promotes ∆Np73 accumulation. (A). Reverse 
transcription-PCR (RT-PCR) was performed using specific primers for the ∆Np73. (B) 
∆Np73α protein is present at high levels in HPV38-keratnocytes. 
 
 
For understanding this scenario in HPV negative and wild type p53 
accumulated HNSCC cancer cell lines, we have analyzed ∆Np73 isofrom in 
HNC-136 and HNC-124 and found that in these cell lines high levels of  
∆Np73 are expressed  at protein level (Figure 31) 
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Figure 31 
 
 
 
Figure 31. Western blot analysis showed that HNC-136 and HNC-124 express high levels of 
∆Np73 isofrom at protein level. 
 
 
Our data shows that both HPV positive and negative cancer cells modulate 
stabilization of wild-type p53 by hyper-phosphorylation at serine 15 and 392, 
which in turn preferentially activate transcription of ∆Np73. We also observed 
that TAp73 is down-regulated in HPV38-keratinocytes and Head and Neck 
cancer cell lines (HNC-136 and -124). As ∆Np73 is able to antagonize p53 and 
p73 transcriptional function, the TAp73 down regulation is probably less 
relevant than ∆Np73 accumulation. Interestingly, it has been shown that 
∆Np73a shows in vitro transforming activities (Petrenko et al, 2003) and is up 
regulated in many human cancers (Zaika et al, 2002; Concin et al, 2004). 
 
4.6.2.1.1 Inhibition of MEK1 cause down regulation of ∆Np73 in HPV38 
and HNC-136 
Human p53 has 23 different phosphorylation and dephosphorylation sites and 
p53 serine residue phosphorylations are correlating with p53 activation 
scenario. Moreover, our cancer cell lines are proliferating with accumulated 
wild type p53 hyperphosphorylated at serine15 and serine392, we have decided 
to analyse possible kinases, which are involved in these phosphorylation. 
Several serine-thrionine kinases are reported to phosphorylate p53 at several 
residues and some kinases are redundant in phophorylation of different p53 
serine residues. Using specific protein kinase inhibitors, we examined the 
involvement of protein kinases in p53 phosphorylation and also tried to analyse 
p53 serine15 and serine 392 phoporylation, important for ∆Np73α protein 
accumulation. PD98059, a MEK1 kinase inhibitor treatment in our HPV38 
keratinocytes and HNC-136 significantly inhibited p53 serine15 and 46 
phosphorylation and it led to the down regulation of ∆Np73 (Figure 32). 
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Figure 32 
 
Figure 32. HFK38E6E7 and HNC-136 were treated with the MEK1 inhibitor PD, after 24 
hours the cells were collected and analyzed for  the indicated proteins  by Immunoblot analysis. 
 
Our analysis showed that p53 ser15 and ser46 phosphorylation have been 
mediated my MEK/MAPK cascade of kinases and these signal trasduction 
pathway is activated constituently in HPV positive and negative cancer cell 
lines where wild type p53 is hyperphosphorylated at serine15 residue. 
Moreover, these phoshorylation influences p53 mediated accumulation of 
∆Np73 protein.  
 
4.6.2.2 TIGAR protein status in HPV positive and negative cancer cell 
lines 
Many p53 regulated cell survival genes have recently been reported and among 
them one is p53-inducible gene named TIGAR (TP53-induced glycolysis and 
apoptosis regulator). TIGAR expression lowered fructose-2,6-bisphosphate 
levels in cells, resulting in an inhibition of glycolysis and an overall decrease in 
intracellular reactive oxygen species (ROS) levels. These functions of TIGAR 
correlated with an ability to protect cells from ROS-associated apoptosis, and 
consequently, knockdown of endogenous TIGAR expression sensitized cells to 
p53-induced death. Expression of TIGAR may therefore modulate the 
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apoptotic response to p53, allowing survival in the face of mild or transient 
stress signals that may be reversed or repaired. The decrease of intracellular 
ROS levels in response to TIGAR may also play a role in the ability of p53 to 
protect from the accumulation of genomic damage. As our interest was to 
analyse the role of accumulated wild type p53 in HPV38 and other Head and 
Neck Cancer cell lines, we checked TIGAR protein level by western blot 
experiment and found that level of TIGAR protein is higher in Keratinocytes 
and comparatively less expressed in Head and Squamous cell carcinoma cell 
lines (Figure 33).  
 
Figure 33 
 
 
 
Figure 33. Western blot analysis shows TIGAR protein level is high in Keratinocyte origin in 
comparison with Head and Neck squamous carcinoma cell lines. Among head and Neck cancer 
cell lines HNC-136 showed very less level of TIGAR protein. 
 
 
We didn’t  find any definite correlation between p53 status and TIGAR 
expression. Because, among different head and neck cancer cell lines were 
analyzed HNC-136 was the one accumulated more wild type p53 and very less 
TIGAR protein level in combarison with other HNC-cell lines. In our study, 
keratinocytes showed more TIGER protein level indicating that this protein has 
major cell protection function in keratinocytes from reactive oxygen species 
(ROS) induced by UV-B radiation. 
 
4.6.2.3 SCO2 expression levels in HPV positive and negative cancer cell 
lines accumulating wild-type p53 
p53 has been shown to induce the expression of the copper transporter SCO2, 
which is required for the assembly of cytochrome c oxidase (Matoba, S. et al. 
2006). This allows p53 to enhance oxidative phosphorylation. Conversely, the 
loss of p53 activity in cells results in a reduction in oxygen consumption. As 
our cell lines were accumulating wild type p53, we were more interested to 
analyze whether these cell lines are more depends upon oxidative 
phosphorylation pathway for high energy demanded for continues cell 
proliferation. Our analysis found that HPV38 keratinocytes are over expressing 
SCO2mRNA with respect to control keratinocytes but we found less expression 
of SCO2mRNA in HNC-136 (Figure 34).  
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Figure 34 
 
 
Figure 34. p53-regulated SCO2 gene is unregulated in HPV38-HFKs but we found lower level 
of SCO2 mRNA in HNC-136  
 
 
For further conforming our RT-PCR data, we have analyzed SCO2 protein 
level in our cell lines and found that p53 accumulated HPV38 keratinocytes 
and Head and Neck cancer cell lines over-express SCO2 at protein levels in 
comparison with Normal Keratinocytes (Figure 35).  
 
Figure 35 
 
Fig 35. SCO2 protein is over-expressed in HPV38 and Head and Neck cancer cell lines 
accumulated wild type p53. 
 
In our analysis, we found that HNC-136 expresses comparatively less amount 
of SCO2mRNA  but its protein level is high with respect to other cancer cell 
lines analyzed. Cells can obtain energy through the oxygen-dependent pathway 
of oxidative phosphorylation (OXPHOS) and through the oxygen-independent 
pathway of glycolysis. Since OXPHOS is more efficient in generating ATP 
than glycolysis, it is recognized that the presence of oxygen results in the 
activation of OXPHOS and the inhibition of glycolysis (Pasteur effect). The 
finding that p53 was inactivated in the majority of cancers and that the majority 
of tumors also exhibit the Warburg effect has stimulated to consider whether 
p53 may regulate glycolysis. Our results supports the possibility that wild type 
p53 accumulated cells depend upon oxidative phosphorylation for cell 
proliferation. 
 
4.6.2.4 p21WAF-1 protein level in HPV positive and negative cells 
Next we have analyzed p21waf1 level in our cells accumulating wild type p53. 
p21waf1 has been shown to mediate the p53-dependent growth arrest induced 
by DNA-damaging agents. Our analysis showed that p21waf1 is slightly 
accumulated in HPV38 keratinocytes in comparison with control cells (Figure 
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36). HNC-136 showed relatively less p21 protein and it may correlate with its 
hyper proliferative characteristics indicated in Table 3. 
 
Figure 36 
 
Figure 36. Western blot analysis shows that p21waf1 protein is slightly accumulated in HPV38 
keratinocytes but HNC-136 shows comparatively less protein than other cell lines analyzed. 
 
Several functions have been ascribed to p21waf1 that could be involved in this 
growth arrest. For one, p21waf1 is an efficient inhibitor of cyclin-dependent 
kinases (CDKs). Moreover, p21waf1 can interact with proliferating cell nuclear 
antigen (PCNA), and as such inhibit in vitro DNA-replication. Finally, 
p21waf1 has been reported to inhibit stress-activated protein kinases (SAPKs). 
In our system p21 level is indespensible to the p53 status. These results 
revealed a p53-independent role in p21 induction in HNSCC. 
4.7 Loss of p53 leads to growth arrest in both HPV38 immortalized 
keratinocyte and Head and Neck cancer cell lines (HNC-124 and HNC-
136) 
Our study revealed that wild type p53 hyper-phosphorylated at serine15 and 
392 is accumulated in some cancers, both HPV38 positive and negative cells 
and  favouring for ∆Np73 accumulation and cell survival. For confirming these 
aspects and understanding in more detail the functions of accumulated p53 role 
in cell survival, we have knockdown p53 by retroviral vector expressing p53-
shRNA and performed colony formation assay. We have produced retrovirus 
contain shRNA against p53 in phoenix cells and infected HPV38, HNC-124 
and HNC-136 cells. After one-day infection cells were tripsinised, counted and 
equally plated for colony formation in a selection medium containing 
puromycin. As a control we have used (scramble agamy) retrovirus vector 
alone, which doesn’t contain shRNA for p53. After several days of selection 
visible colonies were formed, and stained with crystal violet and found that p53 
shRNA infected plates contain less colonies in comparison with control plates 
(Figure 37). We have counted the colonies and found around 50% of reduction 
in cell colonies by plates, which are infected with shp53 scramble agamy in 
comparison with control scramble agamy (Figure 37a and 37b). 
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Figure 37a 
 
 
Figure 37a. Both HPV38 and HNC136 were equally plated and infected with scramble 
(control) and shRNA against p53 by retroviral infection. After complete selection colonies 
were stained with crystal violet.  
 
Figure 37b 
Figure 37b. Inhibition of colony formation in shp53 infected plate in comparison with control 
plates in percentage.
In colony formation assay, we have used retroviral vector expressing shRNA 
against p53 and selection with peuromycin. Peuromycin selection made 
difficult to analyze p53 knock down effects in these cells, other than colony 
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formation assay. Therefore, we used siRNA against p53 to down regulate p53 
expression to analyze its down stream effectors. 
 
4.7.1 p53 knockdown by siRNA induces morphological changes in HPV 
positive and negative cancer cells 
We have performed p53 knockdown by transfection of siRNA against p53 
(indicated in material and methods) by fugine reagent. As a control scrable 
siRNA was used. After 48 hours of tranfection cells were analyzed and 
collected for RNA and protein analysis. After 48 hours of transfection analysis 
shown significant difference in cellular phenotypes in p53 siRNA transfected 
cells in comparison with control (scramble) and shown in Figure 38. 
 
Figure 38 
 
Figure 38. HPV38, HNC-136 and HNC-124 were treated with siRNA against p53. After 48 
hours of siRNA treatment against p53, cells show different morphological features in 
comparison with control (scramble). 
 
After 48 hours of p53 siRNA treatment inhibited cell proliferation and induced 
contractile cell phenotypes in comparison with scramble. Among the cell lines 
analyzed, HNC-124 shwed very prominent phenotypic changes after p53 knock 
down. Figure 39 shows difference in phenotypes after 48 hours of p53 siRNA 
treatment at different magnifications (Figure 39). 
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Figure 39 
 
 
 
Figure 39. HNC-124 showed more prominent morphological changes after p53 knockdown. 
After 48 hours of siRNA treatment against p53, HNC-124 cells are shown with different 
magnifications. 
 
4.7.2 p53 knock-down inhibited cell proliferation in HPV38 and HNSCC 
cells 
 
We have also performed cell proliferation assay after p53siRNA treatment. 
After 48 hours of transfection plates were stained with cristal violet and 
showed that p53 siRNA treated plates present very less cell density in 
comparison with control plates, where plates became 95% confluent (Figure 
40). 
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Figure 40 
 
 
 
Figure 40. p53 knock down by siRNA inhibited cell proliferation in HFK38, HNC-136 and 
HNC-124. Cells were plated in a six well plate at different cell numbers and treated with 
siRNA against p53 and as a control scramble siRNA. After 48 hours of treatment wells were 
stained with crystal violet and showed that siRNA treatment reduced cell growth in HFK38, 
HNC-136 and HNC-124 in comparison with control (scramble). 
 
 
In Figure 41, we show that silencing of p53 by siRNA down-regulate p53 
levels in all cancer cell lines understudy. HFK38 shown more down regulation 
of p53 protein (around 80%) than HNC-136 and HNC-124 (Figure 41). Next, 
we determined p53 short interfering RNA (siRNA) mediated inhibition of cell 
proliferation due to apoptosis by checking PARP cleavage (Figure 41). 
 
Figure 41 
 
 
 
 
Figure 41. Characterization of p53 knock down induced apoptosis. After 48 hours of post-
transfection of HPV38- keratinocytes and Head and Neck Cancer cell lines (HNC-136 and 
HNC-124) with indicated short interfering RNAs (siRNAs) protein extracts were analyzed by 
immunoblotting using the indicated antibodies. 
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We have found cleaved PARP in p53 siRNA treated HFK38 cells but not in 
head and neck cancer cells. This may due to the high p53 down regulation in 
this cells after p53 siRNA treatment in comparison with HNSCC cells. 
 
4.7.3 p53 Knock-down induced senescence-associated -galactosidase 
activity  
p53 knockdown inhibited cell proleferation in all cell lines analyzed and slight 
apoptosis induction only in HFK38. But we have found significant cell 
morphology pattern like scenescence in all cell lines, therefore we have 
analyzed for senescence induction in these cell lines after 48 hours of p53 
siRNA treatment (Figure 42a).  
 
Figure 42a 
 
 
Figure 42a. p53 knock down induced senescence in HPV positive and negative cancer cells. 
Cells were plated in a six well plate at different cell numbers and treated with siRNA against 
p53 and as a control scramble siRNA. After 48 hours of treatment wells were stained for beta 
galactosidase activity (senescence detection) and showed that siRNA treatment induced 
senescence in HFK38, HNC-136 and HNC-124 in comparison with controls (scramble). 
 
Our senescence analysis revealed that p53 knowck down induced slight 
increase in beta galatosidase activity in HFK38, HNC-136 and more in HNC-
124 (Figure 42b). 
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Figure 42b 
 
 
 
Figure 42b. HNC-124 has shown prominant senesence induction after p53 knock down. After 
48 hours of siRNA treatment against p53, senescence detection was performed with senescence 
detection kit from cell signalling by manufactures protocol. HNC-124 cells have shown 
prominant senescence associated beta galatosidase activity and shown with different 
magnifications. 
 
 
Our results are novel, in the sense that in some cancers, where wild type p53 is 
not mutated instead wild type p53 is accumulated and favors cell proliferation. 
Moreover, p53 knock down inhibited cell proliferation and induced senescence. 
Cellular senescence has been theorized to oppose neoplastic transformation 
triggered by activation of oncogenic pathways in vitro (Lowe and  Cepero, 
2004; Serrano and Blasco, 2001). Here, we propose that accumulated wild type 
p53 protein in some cancers suppresses oncogenes induced senescence, insted 
of assisting cell proliferation, at least in some cancers. This may be the 
consequence of wild type p53 knock down induced senesece in our HPV 
positive and negative cancer cells. Future experiments are called for to 
understand how wild type p53 by passes senesence and assists cell 
proliferation.  
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4.7.4 p53 knock-down in HPV38 and Head and Neck Cancer cell lines 
down-regulate ∆Np73 expression 
 
Next, we determined whether down-regulation of p53 by short interfering RNA 
(siRNA) decreases ∆Np73 levels in our HPV positive and negative cancer cell 
lines. Figure 43 shows that silencing of p53 expression correlated with down 
regulation of ∆Np73. 
 
Figure 43 
 
 
 
Figure 43. ∆Np73 expression is mediated by p53. After transfection of HPV38- keratinocytes 
and Head and Neck Cancer cell lines (HNC-136 and HNC-124) with indicated short interfering 
RNAs (siRNAs), ∆Np73 expression levels were determined by reverse transcription–PCR 
(RT–PCR; right panel), respectively. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
HFK, human foreskin keratinocyte. 
 
Our study identifies the preferential role of hyper-phosphorylation mediated 
accumulation of wild type p53 in ∆Np73 up-regulation. But ∆Np73 up-
regulation alone assist cell survival and cell proliferation of HPV positive and 
negative cancer cells by inhibiting senescence; this aspect has to be further 
analyzed. For further understand molecular signalling pathways involved in 
cellular senescence after p53 knockdown, we have analysed several targets 
shown in Figure 44. 
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Figure 44 
 
 
Figure 44. Characterization of p53 knock down induced downstream effects. After 48 hours of 
post- transfection of HPV38- keratinocytes and Head and Neck Cancer cell lines (HNC-136 
and HNC-124) with indicated short interfering RNAs (siRNAs) protein extracts of the 
indicated cells were analyzed by immunoblotting using the indicated antibodies. 
 
Other than ∆Np73 down regulation some cell survival and proleferative 
regulatores like pRB, CyclinA, TIGAR and SCO2 also altered after p53 
knockdown. p53 down-regulation inhibited pRB phosphorylation at 
serine807/811 and it may corresponds to slight pRB accumulation in HFK38 
and HNC-136. TIGAR has shown down regulated in HFK38 and 136 but at 
higher level in HFK38 and it may be the reason of slight apoptosis induction in 
HFK38 after p53 knock down.  Cyclin-A has down regulated only in HFK38 
after p53 knockdown but p21 levels remained constant in all cell lines 
analysed. In this experiment p53 down regulation is more prominent in HFK38 
but very less in HNSCC cells. We need futher obtimization for p53 knock 
down in HNSCC cells to analyze in detail the down stream effectors and this 
can be done only by using stable siRNAs. Due to time constraint, we could not 
perform those experiments and include in this thesis. 
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4.8 Literally known Breast and Colon Cancer cell lines also accumulate 
wild type p53 protein hyperphosphorylated at serine15 and 392 
 
For expanding our study, we have analysed literally known breast (breast 
cancer cell lines with wild type p53 were HCC-1937, Cal-51, and MCF-7) and 
colon (colon cancer cell lines with wild type p53 were HCT-116, LS-174T, Co-
115, and TC-7) cancer cell lines harbouring wild type p53 and find that some of 
them show accumulated wild type p53 hyperphosphorylated at serine15 and 
392 (Figure 45). Moreover, p53 accumulated cells contain very less amount of 
MDM2 protein (Figure 45)  
 
Figure 45 
 
 
 
Figure 45.  Western blot shows that wild type p53 is accumulated and hyperphosphorylated at 
serine15 and 392 in some of the breast and colon cancer cell lines. Serine15 and 392 
hyperphosphorylated and accumulated cell lines were less expressing MDM2 at protein level. 
 
Our data show that in absence of p53 mutation, some percentage of cancer cells 
accumulate wild type p53 hyperphosphorylated at serine15 and 392 and it may 
be significant for cancer cell survival. Due to time constraint we couldn’t 
perform same p53 knockdown experiments to analyse this accumulated p53 
role in cell proliferation and whether p53 knowck down induces senescence in 
these cell lines. For detailed understanding further p53 cell survival pathways 
have to be characterised in these cell lines. 
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Part II 
 
4.9 Anti-EGFR Therapy In Head and Neck Cancer In-vitro Model 
Head and neck cancer (HNC) accounts for about 5% of all cancers world-wide, 
and the overall survival period is very short as the cancer often metastasises in 
the lymph nodes of the throat. The failure of conventional chemotherapy, 
which does not increase the overall survival rate of patients, and the goal of 
identifying new biological targets for anticancer therapy have stimulated the 
study of the molecular mechanisms of HNSCC progression. Among the 
promising new cellular targets, epidermal growth factor receptor (EGFR) 
seems to have a prominent role since it has been recognized as a prognostic 
factor in head and neck cancer. One of the most promising is the utilisation of 
tyrosine kinase (TK) inhibitors, targeting epidermal growth factor receptor 
(EGFR) in HNSCC. It has recently been suggested that gefitinib (ZD1839; 
Iressa), an orally active, selective EGFR tyrosine kinase (TK) inhibitor can 
being utilized in head and neck cancer therapy (www.clinicaltrials.gov). As an 
in-vitro model of Head and Neck cancer, we aimed to molecularly characterize 
our large panel of HNSCC cell lines for EGFR and its related receptors 
expression and down stream effectors to use gefitinib as an anti-cancer therapy. 
Moreover, we have compared the targets analyzed, “p53 family network” and 
gefitinib effectiveness. 
 
4.9.1 Major TK receptors EGFR (ErbB1), ErbB2, and VEGFR2 status in 
head and neck cancer cell lines 
The expression level of TK receptors, EGFR, ErbB2, and VEGFR-2 protein 
status, determined in our newly established HNSCC cell lines are shown in 
Figure 46.  
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Figure 46 
 
Figure 46. Major TK receptors (EGFR, ERB2 and VGFR-2) status in Head and Neck Cancer 
Cell Lines 
 
Higher levels of EGFR were observed in HNC-211, -199, and -206 cells 
whereas it was undetectable in HNC-91 and -136. Conversely, only HNC-206 
and -212 showed detectable levels of p-EGFR. The other two TK receptors, 
ErbB2 and VEGFR-2 were ubiquitously expressed in all cell lines (Figure 46). 
Moreover, activated Akt has been reported to stabilize MDM2 and lead to p53 
protein checkup (Feng et al. 2004). We choose to analyse TK receptors, 
especially EGFR pathway downstream effectors, as total and phosphorylated 
form, trying the possibility to suggest a biological therapy with EGFR 
inhibitors. 
 
4.9.2 Status of major EGFR down stream effectors in HNSCC cell lines 
Once EGF receptor is activated it lead to the activation of its down stream 
effectors, mainly Akt and Erk1/2 phosphorylation. In our all cell lines we found 
comparatively similar expression pattern of Akt and Erk1/2, conversely, p-Akt 
and p-Erk1/2 varied among cell lines characterised (Figure 47).  

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Figure 47 
 
 
Figure 47. EGFR down stream effectors in Head and Neck Cancer Cell lines. 
 
Very low or undetectable amount of p-Akt was observed in HNC-97, -150, -
136 mean times HNC-211 showed high level of this phosphorylated protein 
(Figure 47). Undetectable amount of p-Erk1/2 was observed in HNC-41 and –
124, mean time HNC-91 and 212 showed high level of this phosphorylated 
protein (Figure 47). Interestingly the tumour suppressor, PTEN which acts 
upstream Akt activation, was expressed ubiquitously in all lines (Figure 48). 
 
Figure 48 
 
 
Figure 48. The tumor suppressor gene PTEN protein level in head and neck cancer cell lines 
and it’s ubiquitously expressed and not correlated with EGFR down stream effector activator p-
AKT. 
 
 
PTEN was reported as epigenetically silent in many tumours but our analysis 
showed it is ubiquitously expressed in head and neck cancer cell lines and not 
correlated with p-Akt activation (Fig.48). Our results supports findings by 
Henderson (Henderson et al. 1998), who reported a low percentage of 
inactivated form of PTEN in head and neck cancer.  
 
4.9.3 Influence of p53 family network on EGFR signal transduction 
pathway  
Wild type and mutated p53 can differentially transactivate the EGFR promoter 
by binding to a response element present in the EGFR promoter. However, 
EGFR promoter sequence requirements for transactivation by wild type p53 
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and mutated p53 are different (Ludes-Meyers et al. 2006). In addition to p53, 
its closely related homologue p63 has also been shown to regulate the EGFR 
promoter, through multiple encoded proteins (TAp63, ∆Np63). In specific, the 
p63 isoform, TAp63gamma, represses EGFR expression by directly interacting 
with Sp1 and impairing Sp1 binding to the target DNA (Nishi et al. 2001). In 
this perspective it was worthy to analyse p53 family tumor suppressors 
influence in EGFR signal transduction pathway. We found the existance of 
correlation only between ∆Np63 and EGFR expression, both reported as 
oncogenes in the progression of Head and Neck cancer. Infact among twelve 
cell lines analysed, only two were devoid of both EGFR and ∆Np63 (HNC-91 
and 136) while in the others both proteins were co-expressed.  
 
4.10  Anti-EGFR drug, gefitinib effects on head and neck cancer cell lines 
In this study, we tested gefitinib effectiveness in a broad panel of 12 newly 
established HNSCC cell lines, investigating its ability to reduce cell growth, to 
induce apoptosis and to modulate cell cycle and various EGFR pathway-related 
targets. Moreover, p53 family proteins influence on the efficacy of EGFR 
inhibitor, gefitinib, was investigated.   
4.10.1 Gefitinib IC50 values in HNSCC cell lines 
The capability of gefitinib to inhibit cell growth was determined by incubating 
each HNSCC cell line with various drug concentrations for 3 days, and the 
results are reported as IC50 values in Table 7.  
 
Table 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. IC50 value for Gefitinib in each Head and Neck Cancer Cell lines. 
 
Cell Lines IC-50 (µM) 
± S.D. 
HNC-211 0.064±0.01 
HNC-180 0.71±0.12 
HNC-97 1.9±0.9 
HNC-124 1.9±1.2 
HNC-160 2.2±1.1 
HNC-212 4.22±1.8 
HNC-91 5.3±2.0 
HNC-41 5.4±1.6 
HNC-206 8.3±2.4 
HNC-136 9.3±1.9 
HNC-199 25±3.3 
HNC-150 33±2.7 
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Out of all cell lines, HNC-211 was the most sensitive of the drug, with IC50 of 
64 nM, and the most resistant ones were HNC-150 and -199 (IC50 of 25 and 33 
M, respectively). The other cell lines showed 10- to 300-fold greater 
resistance to the drug than HNC-211. The validity of our in vitro model for a 
complete analysis of gefitinib activity in HNSCC, was warranted by such a 
significant cell line-specific drug variability. 
 
4.10.2 Gefitinib-dependent cell cycle Inhibition 
The high variability of gefitinib IC50 values among cell lines suggested to 
investigate drug activity in each cell line. In particular, the ability of gefitinib to 
modulate cell cycle progression was determined. A three-days drug exposure 
induced a slight blockage at G0/G1 phase in the cell cycle, with a maximum 
effect on HNC-206 inducing G0/G1 phase accumulated cells around ~22% 
(Table 8). 
 
Table 8 
 
 
Table 8. Gefitinib induced cell cycle inhibition. After 3 days Gefitinib treatment cells were 
stained with propedium iodide and analyzed by FACS. 
 
Our analysis revealed that gefitinib induced cell cycle inhibition and that is not 
the main mechanism of its antiproliferative effects because in such large panel 
of head and neck cancer cell lines, HNC-206 and HNC-180 only showed 
significant cell cycle arrest at G0/G1 phase of cell cycle.  
 No gefitinib + gefitinib 3 days 
Cell lines DNA index G0/G1 
phase 
S 
phase 
G2/M 
phase 
increase in G0/GI 
phase % 
HNC-211 1.58 63.63 19.26 17.08 9 
HNC-180 1.75 47.64 33.63 18.73 17 
HNC-97 1.48 73.95 4.81 21.24 1 
HNC-124 1.41 54.95 19.77 25.28 7 
HNC-160 1.13 66.62 13.81 19.56 1 
HNC-212 1.67       60.65         4.06        16.29 9 
HNC-91 1.76 73.48 6.63 19.89 4 
HNC-41 1.54 65.45 22.05 17.50 0 
HNC-206 1.36 51.77 30.07 18.17 22 
HNC-136 1.48 63.01 6.93 30.06 5 
HNC-199 1.37 60.70 16.21 23.08 7 
HNC-150 1.43 74.60 5.99 19.41 0 
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4.10.3 Gefitinib induced apoptosis in HNSCC cells 
Gefitinib effectiveness to induce apoptosis in Head and Neck cancer cell lines 
has also been determined by annexinV-FITC and propidium iodide using the 
Apo-Target kit (BD transduction). All cell lines were treated with Gefitinib at 
IC50 concentrations for 1 to 3-days and apoptosis induction was analysed by 
flow cytometry analysis. Only in five cell lines (HNC-211; -124; -136; -199 
and -150) we found an increase (10-20%) of the Annexin V positive cells. 
These results indicate that there was not a direct correlation between apoptosis 
induction and drug sensitivity because our most sensitive and resistant cell 
lines, HNC-211 and -150, respectively showed apoptosis at IC-50 
concentrations of Gefitinib treatment. In our twelve cell lines analysed, HNC-
211 and HNC-180 showed comparatively more apoptotic cells during 
increasing time interval of drug exposure and shown in Figure 49. 
 
Figure 49               
 
 
 
Figure 49. HNC-211 and HNC-180 cell lines were treated with Gefitinib at IC-50 
concentrations for different time periods and analysed for apoptosis detection by Anexin-V 
method. Figure shows that percentage of apoptosis increases with increasing time intervals. 
 
Gefitinib was able to induce apoptosis after 3 days of exposure mainly in the 
most resistant cell lines. This was probably due to the high drug concentration 
rather than specificity of action. Notably, this TK inhibitor also induced 
apoptosis in two sensitive cell lines, suggesting that its ability to initiate the 
apoptotic process could be cell line-specific. This idea is supported by the 
evidence that in the resistant cells, apoptosis increased in a time-dependent 
manner leading to the hypothesis that the mechanism of drug saturation could 
be involved. 
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4.10.4 Gefitinib inhibits phosphorylation of p-EGFR, p-Akt and p-Erk1/2 
in HNSCC cells 
The drug-dependent modulation of EGFR and its downstream effectors, Akt 
and Erk1/2, has also been investigated. Each cell line was treated with gefitinib 
at IC50 concentration for three days and the modulation of total and 
phosphorylated forms of EGFR, Erk1/2 and Akt was analysed. Gefitinib did 
not modulate the expression of EGFR, Akt and Erk1/2 (data not shown). Only 
HNC-212 and -206 cells showed detectable levels of p-EGFR expression and a 
3-day gefitinib treatment showed 80% of residual EGFR in the phosphorylated 
form (Figure 50b and c). p-Akt was completely abolished by gefitinib in four 
cell lines, HNC-41,-124, -97 and -212, and variously reduced in the remainder, 
conversely p-Erk1/2 was reduced to a lesser extent with the exception of HCN-
180 and -160, as reported in Figure 50 a, b and c, and summarised in Table 9. 
 
Figure 50a 
 
 
 
Figure 50b 
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Figure 50c 
 
 
Figure 50 a, b and c.  EGFR pathway modulation by gefitinib. HNSCC cells were incubated 
with gefitinib at IC50 concentration and the protein extracts were analysed by 
immunoprecipitation and/or Western blotting. In Western blot analysis, the amount of the 
different targets was determined using monoclonal- or polyclonal- specific antibodies and ß-
actin was used to normalise the values. p-EGFR was clearly detectable only in HCN-212 and 
HCN-206. 
 
 
Table 9 
 
 
Table 9. Gefitinib effectiveness in HNSCC cell lines 
Cell Lines IC-50 (µM) 
± S.D. 
Increase 
in G0/G1 
phase 
% 
Apoptosis p-EGFR 
expression 
% 
p-Akt 
expression 
% 
p-Erk1/2 
expression 
% 
HNC-211 0.064±0.01 9 + ND 20 40 
HNC-180 0.71±0.12 17 - ND 10 0 
HNC-97 1.9±0.9 1 - ND 0 50 
HNC-124 1.9±1.2 7 + ND 0 ND 
HNC-160 2.2±1.1 1 - ND 10 0 
HNC-212 4.22±1.8 9 - 80 0 10 
HNC-91 5.3±2.0 4 - ND 100 100 
HNC-41 5.4±1.6 0 - ND 0 ND 
HNC-206 8.3±2.4 22 - 80 30 100 
HNC-136 9.3±1.9 5 + ND ND ND 
HNC-199 25±3.3 7 + ND 100 100 
HNC-150 33±2.7 0 + ND 30 100 
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Analysis of the modulation of EGFR signal transduction pathways by gefitinib 
showed that this drug, after three days of exposure, did not seem to inhibit 
EGFR phosphorylation completely. However, based on our previous evidence 
(Giannelli et al. 2004), we hypothesised that gefitinib inhibited EGFR 
activation early on, while after a prolonged exposure (3 days), the 
phosphorylated form of the receptor recovered its baseline level. Analysis of 
the ability of gefitinib to reduce the activation of two main signal transduction 
pathways, PI3K/Akt/mTor and Ras/MAPK, evidenced a selective action on the 
first of these two signaling pathways. 
 
4.10.5 EGFR mutation analysis in HNSCC cell lines 
Recently, EGFR mutations have been reported to determine gefitinib sensitivity 
and resistance, we have sequenced EGFR kinase domain coding exons (exons 
18 to 21) and carboxyl terminal exons 27 and 28. Mutational analysis, 
performed in the region of the EGFR gene coding for the tyrosine kinase 
domain and in the ATPase domain showed that all HNSCC cell lines were wild 
type. However, this characterisation, utilising primers designed about 150 
nucleotides downstream and upstream exonic region, evidenced intronic 
variants (IVS) (Table 10). Our sequencing analysis found some missense 
mutations in HNC-180, -199, -211 and -136 along with intron variant 
sequences listed in Table 10. 
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Table 10 
 
Cell Lines Ex 18 Ex 19 Ex 20 Ex 21 Ex 27 Ex 28 
HCN 180 wt WT 
G787A 
G>A 
Gln>Gln 
WT WT WT 
HCN 199 wt WT 
G787A 
G>A 
Gln>Gln 
WT WT WT 
HCN 206 wt WT WT WT WT WT 
HCN 211 
IVS 
163924 
C>A; 
IVS 
164250 
C>T 
IVS 
164996 
G>A 
G787A 
G>A 
Gln>Gln; 
IVS 
171340 
T>C 
WT WT WT 
HCN 41 
IVS 
159715 
C>A 
omoz 
WT 
IVS 
167131 
T>C; 
 
WT 
WT 
Intron delA  
pos 188573 
WT 
HCN 91 wt IVS A>G 
rs2017000 
IVS 
167131 
T>C; 
 
WT WT WT 
HCN 97 wt WT WT WT WT WT 
HCN 124 wt WT WT WT WT WT 
HCN 136 wt WT 
G787A 
G>A 
Gln>Gln 
WT WT WT 
HCN 150 wt WT WT WT WT WT 
HCN 160 wt wt WT WT WT WT 
HCN 212 wt wt WT WT WT WT 
 
Table 10. EGFR kinase domain and carboxyl terminal exon and flanking intron sequence 
alterations. Table legends IVS: intron variants, WT: wild type. 
 
HCN-211 presented IVS17-104 C>A and IVS18+103 C>T intronic variants 
while HCN-41 cell lines only IVS17-104 C>A. The intron 19 presented two 
different types of intronic variants: IVS19+96 A>G in HCN-91 and HCN-211 
and IVS 19-60  in HCN-41, -91, -199 and -211. However, these intronic 
variants seeme not interfere in EGFR expression. Based on evidence that in 
lung cancer, certain mutations in the region of the EGFR gene coding for the 
ATPase and tyrosine kinase domains are related to drug sensitivity, we 
analysed our 12 cell lines for EGFR mutation status, confirming the data of 
Puhringer-Oppermann, suggesting that these mutations are not relevant in 
determining gefitinib response in oral cancer (Puhringer-Oppermann et al. 
2007). 
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4.10.6 Correlation of p53 family proteins influence in gefitinib sensitivity  
Cellular sensitivity to the growth inhibitory effects of gefitinib remained 
unchanged, irrespective of p53 and its family proteins status. In fact our 
molecular characterisation results concerning the mutations and protein level of 
p53, the mRNA and protein level of p73 (isoforms Np73 and TAp73) and p63 
(isoforms Np63 and TA p63) among twelve HNSCC cell lines were not 
correlated to gefitinib sensitivity. Moreover, p53 protein levels did not 
influence gefitinib sensitivity in our panel of head and neck cancer cell lines. 
Table11 summarises the results of p53 and its homologous correlation with 
Gefitinib drug sensitivity. 
 
Table 11 
 
Cell 
Line
s 
 
IC-50 
(µ M) ± 
S.D. 
p53 Status p63 RT- 
PCR 
p63 
Western 
p73 RT-
PCR 
p73 
Western 
 
Exon 
Codon base Amino 
acid 
change 
Prot
ein 
expr
essi
on 
 
∆
N 
 
T
A 
 
∆N 
 
TA 
 
∆N 
 
T
A 
 
∆N 
 
TA 
41 5.4±1.6 WT (4-9) 
 
  - -
++
+ 
+ ++
+ 
++
+ 
+ + ++ ++
+ 
91 5.3±2.0 WT (4-9) 
 
  - - - - - ++ - Nd Nd 
97 1.9±0.9 Exon 5 
Exon 7 
 
180        
GAG-AAG 
248        
CGG-TGG 
 
Glu-
Lys 
Arg-
Trp 
 
+ + - + + ++ - + - 
124 1.9±1.2 WT (4-9) 
 
  ++ ++
+ 
- ++
+ 
++
+ 
++
+ 
- ++ - 
136 9.3±1.9 WT (4-9) 
 
  +++ - + - - ++ ++ ++
+ 
- 
150 33±2.7 Exon 5 
 
135         
TGC-TAC 
 
Cys-
Tyr 
 
+ ++
+ 
+ ++ ++
+ 
++ - ++ - 
160 2.2±1.8 Exon 6 
 
213        
CGA-CGG 
 
Arg-
Arg 
 
- ++
+ 
+ + ++ ++ - Nd Nd 
180 0.71±0.
12 
Exon 6 
 
220         
TAT-TGT 
 
Tyr-
Cys 
 
+ ++
+ 
++ Nd Nd - - + ++ 
199 25±3.3 Exon 5 
 
135         
TGC-TTC 
 
Cys-
Phe 
 
+ ++
+ 
- - - ++ - + - 
206 8.3±2.4 Exon 5 
 
134          
TTT-TCT 
 
Phe-
Ser 
 
+ ++
+ 
++ + ++ - - + ++ 
211 0.064±0
.01 
Exon 6 
 
177-183  Del 
5 codons 
 
In 
frame 
 
+ ++
+ 
+ ++
+ 
++
+ 
++ - ++ - 
212 4.22±1.
8 
Exon 6 
Exon 9 
 
196        
CGA-CCA 
331         
CAG-.AG 
 
Arg-
Pro 
Frames
hift 
 
++ + - - - - - ++ - 
Table 11. Summary, p53 and its homologous are not directly influencing gefitinib drug 
sensitivity in a large panel of Head and Neck cancer cell lines. 
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Although our cell characterisation did not identify any valid predictive factor 
for gefitinib effectiveness, the comparison between p53 family and EGFR 
expression suggested, for the first time, a correlation between the Np63 
isoform and EGFR expression level. Transcription factors of the p53 family are 
mainly considered to be tumour suppressors, even though recent evidence 
demonstrated opposite functions for the p63 isoforms, Np63 and TAp63, 
promoting cell proliferation and mimicking tumour suppressor p53, 
respectively (Foschini et al. 2004). In our study, two of the HNSCC cell lines 
did not express either Np63 or EGFR, while the remainder co-expressed both 
proteins, suggesting a direct correlation between EGFR and Np63 expression 
in the development of head and neck squamous cell carcinomas. 
 
4.11 Chemoresistance tests to head and neck cancer cell lines 
Resistance to chemoterapy remains a major obstacle to the successful 
management of many human cancers, especially in HNSCC. More specifically, 
the cellular resistance to anti-cancer agents arises through failure of p53 family 
member signalling. Chemoresistance tests were performed to investigate 
whether different levels of p53, p63, p73 and their isoforms differently affect 
resistance to chemotherapy. All the twelve cell lines were analysed for 
chemoresistance and the drugs chosen for the test were gembitabine and 
cisplatin. Cell lines reacted in various different ways to the administration of 
the two drugs. Most of the cancer cells showed a high resistance to the 
treatment with gemcitabine, in particular the HNC 136; while only four cell 
lines appeared  to be sensitive, with highest level of mortality found in the 124. 
For cisplatin test, the cell lines presenting a high resistance were the 212 and 
even in this case the 136, while the most sensitive were the 206 and again the 
124. The results obtained were contradictory, for example, the two cell lines 
with the highest (HNC 136) and the lowest (HNC 124) resistance to 
gemcitabine both harbour a wild type p53 (Table 12).  
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Table 12 
 
 
Cell 
Line
s 
 
p63 RT- PCR p63 Western p73 RT-
PCR 
p73 Western  
p53 
Status 
 
∆N 
 
TA 
 
∆N 
 
TA 
 
∆N 
 
TA 
 
∆N 
 
TA 
41 +++ + +++ +++ + + ++ +++ -       WT 
91 - - - - ++ - Nd Nd -       WT 
97 + - + + ++ - + - + 
124 +++ - +++ +++ +++ - ++ - ++    WT S 
136 - + - - ++ ++ +++ - +++  WT R 
150 +++ + ++ +++ ++ - ++ - + 
160 +++ + + ++ ++ - Nd Nd - 
180 +++ ++ Nd Nd - - + ++ + 
199 +++ - - - ++ - + - + 
206 +++ ++ + ++ - - + ++ + S 
211 +++ + +++ +++ ++ - ++ - + 
212 + - - - - - ++ - ++ R 
 
Table 12. Summary of the results. The results obtained by RT on p73 and Np73, p63 and 
Np63, by western blot analysis on p53 and the data from the chemoresistance tests are listed 
and compared in the above table.  
 
Again we didn’t see correlation between resistance to chemotherapeutic drugs 
and the state of p53, neither with the level of expression of the other p53 
homologues. We assumed that other p53 indipendent pathways may be 
involved in chemioresistance and apoptotic prevention in head and neck cancer 
cell lines. Further work is necessary to understand the complex regulatory 
network generated by multiple p73 and p63 isoforms, their expression profiles, 
the interactions among themselves and the resulting differentials in their 
activities. In addition, such large spectrum of malignant cells needs to be 
surveyed to determine whether consistent protein expression pattern could be 
identify when drug sensitivity or resistance would be predicted. 
 
4.11.1 Elevated expression of ABCG2 protien in HNSCC cell lines 
To justify the high resistance of Head and Neck cancer to some 
chemotherapeutic drugs during treatment, we determined the expression level 
of one drug efflux pump protein ABCG2 in our in vitro panel (Figure 51).  
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Figure 51 
 
 
Figure 51. Western blot analysis shows ABCG2 protein level in the twelve head and neck 
cancer cell lines. 
 
Interestingly, ABCG2 was expressed in all our HNSCC cell lines with very 
high expression in HNC-180, -199 and 136 in comparison with other cell lines 
were analysed and these may be one of the reasons of high drug resistance of 
HNC-136 to cisplatin and gemcitabine. Furthermore our study revealed that 
cell sensitivity to growth inhibitory effects of ZD 1839 remained unchanged 
irrespective of ABCG2 status. 
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5. CONCLUSIONS 
 
Molecular characterization of newly established cancer cell lines are very 
valuable source for understanding molecular mechanism of cancerogenesis and 
demonstrating the efficacy of various anti-cancer therapy in Head and Neck 
Squamous Cell Carcinoma (HNSCC). In this study, we have molecularly 
characterized 12 novel HNSCC cell lines for understanding p53 family netwok, 
efficacy of anti-EGFR therapy and p53 family network influence in gefitinib 
effectivness. p53 family network is considered the skeleton of cellular 
signalling pathway to co-ordinate both internal and external signals received by 
a single cell to determine its ultimate fate. Generaly, p53 has been considerd as 
a tumor suppresson due to its ability to induce cell cycle inhibition and/or 
apoptosis depends upon the interrupted signal received by a cell. Majority of 
cancers arises in presence of an inactive p53 (mainly by mutation) and 
consequently introduction of wild type p53 in those cells can induce apoptosis 
and/or senescence, it depends upon the cellular system. Here, we found out a 
new scenario where there are some cells acquiring immortalization in presence 
of wild type p53 protein and in those cells p53 has been modified in such a way 
to assit cell survival and proliferation. This hypothesis is confermed by HPV38 
mediated immortalization process, where wild type p53 protein is accumulated 
in favor of cell survival and proliferation. For extending this phenomenon in 
other cancers, we have molecularly characterized a large panel of head and 
neck cancer cell lines and revealed that this mechanism is not restricted to 
HPV38 mediated immortalization process but also exists in other sporadic 
cancers. Our detailed analysis in both HPV positive and negative cancer cells 
for p53 showed that accumulation of wild type p53 is correlated with its 
hyperphosphorylation at serine15 and 392 residues. Moreover, this led to the 
over-expression of DNp73 in these cells. Using specific protein kinase 
inhibitors, we examined the involvement of protein kinases in p53 
phosphorylation at serine 15 and 392 residues. PD98059, a MEK1 kinase 
inhibitor treatment in our HPV38 keratinocytes and HNC-136 cells 
significantly inhibited p53 serine15 phosphorylation and it led to the down 
regulation of DNp73. Our analysis for other p53 post-translational 
modifications showed less influence in wild type p53 accumulation in the 
nucleus and activation of cell survival and/or proliferative genes like DNp73. 
To further understand functions of hyperphosphorylated and accumulated wild 
type p53 in HPV38 and HNSCC cells, we have knocked down p53 by siRNA. 
Interestingly p53 knock down inhibited cell proliferation and induced 
senescence in these cells. This was associated with down regulation of p53 
mediated cell survival and/or proliferative genes, examples are deltaNp73 and 
TIGER. Other cell survival and/or proliferative genes, specifically under 
control of this hyperphosphorylated and accumulated wilde type p53 in cancer 
cells, have yet to be characterized. 
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As part of a translational cancer research work, we have analyzed feasibility of 
using target oriented drug like gefitinib in head and neck cancer. We have 
characterized our Head and Neck in vitro panel extensively, with the aim of 
identifying predictive factors for gefitinib effectiveness. Recently improved 
understanding of the pathogenesis of human head and neck squamous cell 
carcinoma (HNSCC) have led to the development of new molecular based 
therapeutic strategies; one of the most promising is the utilization of tyrosine 
kinase (TK) inhibitors, targeting epidermal growth factor receptor (EGFR). Our 
molecular analysis revealed that all cell lines were free of human papilloma 
virus infection, four harbored wild-type p53, with two of them accumulating 
wild type p53, and all of them variously expressed other two p53 family 
members, p63, p73 and its isoforms. The comparison between the targets 
analyzed and gefitinib effectiveness evidenced the absence of a clear 
relationship, allowing to exclude them as predictive factors for gefitinib 
effectiveness. Our results confirmed the in vitro efficacy of an anti-EGFR 
approach, but other targets than those analyzed in my thesis should be 
characterized in order to identify valid predictive factors for gefitinib utilization 
in HNSCC 
 
Resistance to chemoterapy remains a major obstacle to the successful 
management of many human cancers and p53 and p73 seem to have an 
important role in mediating the activity of anti-cancer drugs. More specifically, 
the cellular resistance to anti-cancer agents arise through failure of p53 family 
signalling network. Chemoresistance tests were performed to investigate 
whether different levels of p53, p63, p73 and their isoforms differently affect 
resistance to chemotherapy. All twelve cell lines were analysed for 
chemoresistance and the drugs chosen for the test were gembitabine and 
cisplatin. The cell lines reacted in various different ways to the administration 
of drugs. Most of the cancer cells showed a high resistance to the treatment 
with gemcitabine, in particular the HNC 136; while only four appeared to be 
sensitive, with highest level of mortality found in the 124. For the cisplatin test, 
the cell lines presenting a high resistance were the 212 and even in this case the 
136, while the most sensitive were the 206 and again the 124. The results 
obtained were contradictory, for example, the two cell lines with the highest 
(HNC 136) and the lowest (HNC 124) resistance to gemcitabine both harbour a 
wild type p53. Again we didn’t see any correlation between resistance to 
chemotherapic and the state of p53, neither with the level of expression of other 
p53 homologues. We assume that other p53 indipendent pathways may be 
involved in chemoresistance and apoptotic prevention in head and neck cancer 
cell lines. It may include ABCG2 because ABCG2 was expressed in all our 
HNSCC cell lines with very high expression in HNC-180, -199 and 136 in 
comparison with other cell lines analysed and these may be one of the reason of 
HNC-136 high drug resistance to cisplatin and gemcitabine. 
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